[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdEieS00MaYDmbNVmZ15Yv_gXr95g9zPCK9nPjp4iHAw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Mahidol University",[4],721,false,83,69,184018,32,435,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Septic Shock",13,{"name":18,"count":19},"Stroke",10,{"name":21,"count":22},"Postoperative Pain",9,{"name":24,"count":22},"Pain",{"name":26,"count":22},"Pain, Postoperative",{"name":28,"count":29},"Critical Illness",8,{"name":31,"count":32},"Asthma",7,{"name":34,"count":35},"Cesarean Section Complications",6,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05895955","Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","2024-03-25","TetraFluvac TF vaccine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06484530","Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis","2024-09-18","N acetyl cysteine",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06543940","Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane","2025-08-01","Vancomycin",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06498323","Intravenous TNK vs TPA for AIS Treatment on MSU,a Prospective Multicenter RCT","2025-08-31","tenecteplase",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06121479","Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients","2025-09-23","Branched-chain amino acid",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06432127","Role of Ultrasound Guide Greater Occipital Nerve Block at Second Cervical Vertebra in Migraine Headache Prophylaxis","2026-01","Bupivacaine",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06850454","Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy","2026-01-10","olanzapine",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06517199","Olanzapine for Cancer Related Anorexia-cachexia Syndrome","2026-01-21","Olanzapine 2.5 MG",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07080996","Effect of Biofeedback Tongue Strengthening Program on Tongue Pressure and Swallowing Performance","2026-02-24","Strengthening training with biofeedback",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06803524","10-year Follow-up After a Single Dose Acellular Pertussis Vaccination","2026-03","Pertagen® vaccine",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,142,170,188,215,242,260,286,309,331,349,408,456,493,515,539,557,583,609,627,651,676,705,729,747,772,799,817,854,913,933,958,984,1047,1104,1139,1161,1195,1224,1265,1304,1340,1370,1405,1430,1454,1481,1509,1527,1545,1572,1600,1618,1645,1667,1693,1711,1735,1760,1778,1804,1822,1847,1865,1892,1915,1933,1958,1981,2005,2023,2046,2064,2093,2118,2136,2161,2185,2213,2231,2255,2273,2299,2325,2343,2369,2387,2409,2435,2460,2478,2507,2525,2548,2572,2601,2624,2642,2667,2692,2710,2736,2754,2781,2799,2817,2840,2865,2890,2908,2934,2952,2976,3001,3019,3042,3065,3092,3110,3128,3152,3170,3194,3217,3240,3264,3282,3306,3332,3358,3383,3406,3433,3451,3477,3495,3513,3537,3555,3577,3600,3622,3647,3665,3688,3706,3731,3749,3773,3791,3815,3833,3860,3878,3922,3957,3979,4012,4044,4066,4092,4110,4134,4152,4175,4199,4222,4246,4264,4290,4316,4339,4362,4387,4408,4426,4448,4469,4493,4511,4533,4557,4575,4601,4619,4644,4667,4685,4703,4729,4747,4773,4791,4809,4834,4859,4882,4900,4918,4944,4962,4987,5005,5032,5058,5076,5100,5123,5147,5165,5189,5213,5231,5257,5275,5297,5321,5352,5387,5412,5430,5454,5477,5495,5520,5538,5567,5591,5616,5639,5666,5684,5702,5726,5752,5770,5792,5816,5841,5865,5891,5909,5931,5954,5976,5999,6024,6046,6064,6087,6111,6136,6154,6177,6199,6228,6246,6264,6282,6300,6324,6350,6368,6393,6456,6502,6544,6579,6611,6642,6664,6700,6722,6744,6771,6812,6844,6872,6897,6925,6943,6961,6979,7003,7026,7044,7062,7085,7103,7127,7150,7176,7201,7219,7243,7265,7283,7307,7325,7348,7373,7397,7419,7441,7459,7477,7495,7513,7537,7555,7580,7598,7625,7643,7661,7684,7708,7730,7748,7769,7795,7819,7843,7867,7899,7917,7942,7967,7989,8013,8038,8056,8080,8098,8120,8145,8168,8193,8217,8235,8260,8278,8305,8323,8347,8369,8395,8418,8436,8461,8489,8507,8525,8549,8567,8585,8607,8625,8643,8666,8696,8714,8742,8760,8785],{"intervention":46,"totalTrials":96,"cells":97},2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":121,"NA":140},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":120},"NCT05738681","Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial","UNKNOWN",[90,91],"2023-03-31","2023-05-31","2022-09-09",82,[117,118,119],"Tuberculosis","Drug Induced Liver Injury","Hepatitis",[46],{"trials":122,"activeCount":139,"soonestReadout":45},[123],{"nctId":43,"briefTitle":44,"status":124,"phases":125,"primaryCompletion":45,"completion":45,"start":126,"enrollment":127,"conditions":128,"interventions":138},"RECRUITING",[92],"2024-03-12",116,[129,130,131,132,133,134,135,136,137],"Tuberculosis (TB)","Isoniazid Toxicity","Rifampicin Toxicity","Pyrazinamide Adverse Reaction","Ethambutol Toxicity","NAT2 Slow Acetylator Status","NAT2 Rapid Acetylator Status","NAT2 Polymorphism","N-Acetylcysteine",[46],1,{"trials":141,"activeCount":100},[],{"intervention":143,"totalTrials":139,"cells":144},"Nitrofurantoin",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":168},{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":139,"soonestReadout":159},[155],{"nctId":156,"briefTitle":157,"status":124,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":166},"NCT07186465","Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis",[92],"2026-06-30","2026-08-30","2025-09-11",100,[164,165],"Cystitis, Recurrent","Urinary Tract Infections",[143,167],"Gynoflor",{"trials":169,"activeCount":100},[],{"intervention":167,"totalTrials":139,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":186},{"trials":173,"activeCount":100},[],{"trials":175,"activeCount":100},[],{"trials":177,"activeCount":100},[],{"trials":179,"activeCount":100},[],{"trials":181,"activeCount":139,"soonestReadout":159},[182],{"nctId":156,"briefTitle":157,"status":124,"phases":183,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":184,"interventions":185},[92],[164,165],[143,167],{"trials":187,"activeCount":100},[],{"intervention":189,"totalTrials":139,"cells":190},"Lemborexant",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":213},{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":100},[],{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":139,"soonestReadout":206},[201],{"nctId":202,"briefTitle":203,"status":204,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":162,"conditions":209,"interventions":212},"NCT07407400","Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients","NOT_YET_RECRUITING",[92],"2027-07-31","2027-12-31","2026-04-01",[210,211,28],"Sleep Disturbance","Delirium",[189],{"trials":214,"activeCount":100},[],{"intervention":216,"totalTrials":139,"cells":217},"Beta-lactam monotherapy",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":240},{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":100},[],{"trials":223,"activeCount":100},[],{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":139,"soonestReadout":207},[228],{"nctId":229,"briefTitle":230,"status":204,"phases":231,"primaryCompletion":207,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":238},"NCT07240077","Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia",[92],"2028-12-31","2026-01-01",165,[236,237],"Bacteremia","Streptococcus Infection",[216,239],"Beta-lactam plus levofloxacin combination therapy",{"trials":241,"activeCount":100},[],{"intervention":239,"totalTrials":139,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":258},{"trials":245,"activeCount":100},[],{"trials":247,"activeCount":100},[],{"trials":249,"activeCount":100},[],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":139,"soonestReadout":207},[254],{"nctId":229,"briefTitle":230,"status":204,"phases":255,"primaryCompletion":207,"completion":232,"start":233,"enrollment":234,"conditions":256,"interventions":257},[92],[236,237],[216,239],{"trials":259,"activeCount":100},[],{"intervention":261,"totalTrials":139,"cells":262},"PRP",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":284},{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":100},[],{"trials":272,"activeCount":139,"soonestReadout":277},[273],{"nctId":274,"briefTitle":275,"status":204,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT06384859","Effectiveness of Extracorporeal Shockwave Therapy Combined With Platelet-rich Plasma in the Treatment of Chronic Insertional Achilles Tendinopathy",[92],"2026-05-01","2027-05-01","2024-05-01",94,[282],"Insertional Achilles Tendinopathy",[261],{"trials":285,"activeCount":100},[],{"intervention":56,"totalTrials":139,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":307},{"trials":289,"activeCount":100},[],{"trials":291,"activeCount":100},[],{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":139,"soonestReadout":55},[298],{"nctId":53,"briefTitle":54,"status":124,"phases":299,"primaryCompletion":55,"completion":55,"start":300,"enrollment":301,"conditions":302,"interventions":306},[92],"2022-08-03",160,[303,304,305],"Intravenous","Thrombosis","Acute Ischemic Stroke",[56],{"trials":308,"activeCount":100},[],{"intervention":86,"totalTrials":139,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":329},{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":139,"soonestReadout":85},[321],{"nctId":83,"briefTitle":84,"status":124,"phases":322,"primaryCompletion":85,"completion":85,"start":323,"enrollment":324,"conditions":325,"interventions":327},[92],"2025-05-13",126,[326],"Pertussis",[86,328],"Adacel® vaccine",{"trials":330,"activeCount":100},[],{"intervention":328,"totalTrials":139,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":347},{"trials":334,"activeCount":100},[],{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":139,"soonestReadout":85},[343],{"nctId":83,"briefTitle":84,"status":124,"phases":344,"primaryCompletion":85,"completion":85,"start":323,"enrollment":324,"conditions":345,"interventions":346},[92],[326],[86,328],{"trials":348,"activeCount":100},[],{"intervention":66,"totalTrials":350,"cells":351},4,{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":394},{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"trials":357,"activeCount":100},[],{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":139,"soonestReadout":65},[362,373,386],{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":19,"conditions":369,"interventions":371},"NCT01219062","Postoperative Pain Control After Hip Hemiarthroplasty: Intrathecal Morphine vs Periarticular Infiltration of Bupivacaine","TERMINATED",[92],"2011-04","2010-09",[370],"Femoral Neck Fracture",[372,66],"morphine",{"nctId":374,"briefTitle":375,"status":376,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":385},"NCT01636869","Plasma Concentrations of Bupivacaine After Peri-articular Injection in Total Knee Arthroplasty","COMPLETED",[92],"2014-07","2012-07",43,[382,383,384],"Serum Bupivacaine Level","Periarticular Block","Total Knee Arthroplasty",[66],{"nctId":63,"briefTitle":64,"status":204,"phases":387,"primaryCompletion":65,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},[92],"2027-01","2024-05-30",108,[392],"Migraine Disorders",[66],{"trials":395,"activeCount":100},[396],{"nctId":397,"briefTitle":398,"status":376,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":406},"NCT03232957","Intrathecal Morphine for Unilateral Total Knee Arthroplasty",[93],"2019-02-01","2019-07-31","2017-08-01",131,[405],"Primary Osteoarthritis of Knee Nos",[407,66],"Morphine",{"intervention":61,"totalTrials":409,"cells":410},3,{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":438,"NA":454},{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":100},[],{"trials":416,"activeCount":100},[],{"trials":418,"activeCount":96,"soonestReadout":60},[419,430],{"nctId":420,"briefTitle":421,"status":422,"phases":423,"primaryCompletion":159,"completion":159,"start":424,"enrollment":425,"conditions":426,"interventions":429},"NCT06121492","Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia","ENROLLING_BY_INVITATION",[91],"2023-11-15",86,[427,428],"Sarcopenia","Cirrhosis of the Liver",[61],{"nctId":58,"briefTitle":59,"status":422,"phases":431,"primaryCompletion":60,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},[91],"2025-12-31","2023-11-13",30,[436],"Decompensated Cirrhosis and Ascites",[61],{"trials":439,"activeCount":100},[440],{"nctId":441,"briefTitle":442,"status":376,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":452},"NCT05724485","Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis",[92],"2023-10-31","2023-12-31","2023-04-01",48,[449,450,451],"Muscle Cramp","Cirrhosis","Quality of Life",[453],"Branched-chain Amino Acid",{"trials":455,"activeCount":100},[],{"intervention":457,"totalTrials":96,"cells":458},"olanzapine 5 mg",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":489,"NA":491},{"trials":460,"activeCount":100},[],{"trials":462,"activeCount":100},[],{"trials":464,"activeCount":100},[],{"trials":466,"activeCount":139,"soonestReadout":75},[467,480],{"nctId":468,"briefTitle":469,"status":110,"phases":470,"primaryCompletion":471,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":477},"NCT03876938","Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy",[91],"2020-08","2020-12","2019-03-01",147,[476],"Antiemetic for Highly Emetogenic Chemotherapy",[478,479,457],"aprepitant","olanzapine 10 mg",{"nctId":73,"briefTitle":74,"status":124,"phases":481,"primaryCompletion":75,"completion":75,"start":482,"enrollment":483,"conditions":484,"interventions":487},[91],"2024-01-22",138,[485,486],"Anorexia","Cachexia",[76,488],"Olanzapine 5 MG",{"trials":490,"activeCount":100},[],{"trials":492,"activeCount":100},[],{"intervention":71,"totalTrials":139,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":511,"NA":513},{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":100},[],{"trials":500,"activeCount":100},[],{"trials":502,"activeCount":139,"soonestReadout":70},[503],{"nctId":68,"briefTitle":69,"status":124,"phases":504,"primaryCompletion":70,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":510},[91],"2026-01-31","2025-01-10",140,[509],"Chemotherapy Induced Nausea and Vomiting",[71],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":100},[],{"intervention":81,"totalTrials":139,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":535,"NA":537},{"trials":518,"activeCount":100},[],{"trials":520,"activeCount":100},[],{"trials":522,"activeCount":100},[],{"trials":524,"activeCount":139,"soonestReadout":80},[525],{"nctId":78,"briefTitle":79,"status":422,"phases":526,"primaryCompletion":80,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":533},[91],"2026-03-24","2025-03-25",52,[531,532],"Presbyphagia","Abnormal Tongue Pressure",[81,534],"Endurance training with biofeedback",{"trials":536,"activeCount":100},[],{"trials":538,"activeCount":100},[],{"intervention":534,"totalTrials":139,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":553,"NA":555},{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":139,"soonestReadout":80},[549],{"nctId":78,"briefTitle":79,"status":422,"phases":550,"primaryCompletion":80,"completion":527,"start":528,"enrollment":529,"conditions":551,"interventions":552},[91],[531,532],[81,534],{"trials":554,"activeCount":100},[],{"trials":556,"activeCount":100},[],{"intervention":558,"totalTrials":139,"cells":559},"Trelegy or Anoro",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":579,"NA":581},{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":139,"soonestReadout":572},[568],{"nctId":569,"briefTitle":570,"status":124,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":578},"NCT06474039","The Efficacy of Fluticasone Furoate\u002FVilanterol\u002FUmeclidinium Compared With Vilanterol\u002FUmeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD",[91],"2026-06","2026-12","2024-10-01",50,[577],"COPD",[558],{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[],{"intervention":584,"totalTrials":139,"cells":585},"Aminophylline",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":605,"NA":607},{"trials":587,"activeCount":100},[],{"trials":589,"activeCount":100},[],{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":139,"soonestReadout":598},[594],{"nctId":595,"briefTitle":596,"status":204,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":604},"NCT06196853","Prevention of Cisplatin-induced Nephrotoxicity",[90,91],"2026-09-30","2025-12-01",24,[602,603],"Acute Kidney Injury","Renal Tubulopathy",[584],{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":100},[],{"intervention":76,"totalTrials":139,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":623,"NA":625},{"trials":612,"activeCount":100},[],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":139,"soonestReadout":75},[619],{"nctId":73,"briefTitle":74,"status":124,"phases":620,"primaryCompletion":75,"completion":75,"start":482,"enrollment":483,"conditions":621,"interventions":622},[91],[485,486],[76,488],{"trials":624,"activeCount":100},[],{"trials":626,"activeCount":100},[],{"intervention":628,"totalTrials":139,"cells":629},"Human Albumin 20% Solution",{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":647,"NA":649},{"trials":631,"activeCount":100},[],{"trials":633,"activeCount":100},[],{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":139,"soonestReadout":642},[638],{"nctId":639,"briefTitle":640,"status":204,"phases":641,"primaryCompletion":642,"completion":643,"start":599,"enrollment":644,"conditions":645,"interventions":646},"NCT07212582","Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)",[91],"2029-12-31","2030-12-31",304,[28,15],[628],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[],{"intervention":652,"totalTrials":139,"cells":653},"Holy basil extract",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":672,"NA":674},{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":139,"soonestReadout":666},[662],{"nctId":663,"briefTitle":664,"status":124,"phases":665,"primaryCompletion":666,"completion":573,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT07175272","Holy Basil in The Treatment of Dyspepsia",[90,91],"2026-10","2026-02-13",27,[670],"Dyspepsia and Other Specified Disorders of Function of Stomach",[652],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"intervention":677,"totalTrials":139,"cells":678},"Rifaximin",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":701,"NA":703},{"trials":680,"activeCount":100},[],{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":139,"soonestReadout":691},[687],{"nctId":688,"briefTitle":689,"status":204,"phases":690,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":695,"interventions":700},"NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders",[91],"2027-10","2027-12","2026-04",78,[696,677,697,698,699],"Bloating","Functional Bowel Disorder","Irritable Bowel Syndrome","Constipation",[677],{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":100},[],{"intervention":41,"totalTrials":139,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":708,"activeCount":100},[],{"trials":710,"activeCount":100},[],{"trials":712,"activeCount":139,"soonestReadout":40},[713],{"nctId":38,"briefTitle":39,"status":714,"phases":715,"primaryCompletion":40,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"ACTIVE_NOT_RECRUITING",[89,90],"2025-07-31","2023-11-04",290,[720],"Influenza",[41,722],"Vaxigrip vaccine",{"trials":724,"activeCount":100},[],{"trials":726,"activeCount":100},[],{"trials":728,"activeCount":100},[],{"intervention":722,"totalTrials":139,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":139,"soonestReadout":40},[737],{"nctId":38,"briefTitle":39,"status":714,"phases":738,"primaryCompletion":40,"completion":716,"start":717,"enrollment":718,"conditions":739,"interventions":740},[89,90],[720],[41,722],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":100},[],{"intervention":748,"totalTrials":139,"cells":749},"GMP compliant-BM-MSC derived sEVs",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":100},[],{"trials":755,"activeCount":139,"soonestReadout":760},[756],{"nctId":757,"briefTitle":758,"status":124,"phases":759,"primaryCompletion":760,"completion":207,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT06242379","Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa",[89,90],"2026-12-31","2024-05-23",15,[764],"Retinitis Pigmentosa",[748],{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"trials":771,"activeCount":100},[],{"intervention":773,"totalTrials":139,"cells":774},"Wharton's jelly-derived mesenchymal stem cells",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":139,"soonestReadout":785},[781],{"nctId":782,"briefTitle":783,"status":204,"phases":784,"primaryCompletion":785,"completion":786,"start":572,"enrollment":787,"conditions":788,"interventions":791},"NCT07018739","Mesenchymal Stem Cells With Cooling Therapy for Infants With Hypoxic-Ischemic Encephalopathy",[89,90],"2032-12","2033-12",40,[789,790],"Hypoxic-Ischemic Encephalopathy, Neonatal","Brain Injuries, Hypoxic-Ischemic",[773,792],"0.9 % Normal Saline",{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"intervention":792,"totalTrials":139,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":139,"soonestReadout":785},[807],{"nctId":782,"briefTitle":783,"status":204,"phases":808,"primaryCompletion":785,"completion":786,"start":572,"enrollment":787,"conditions":809,"interventions":810},[89,90],[789,790],[773,792],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"trials":816,"activeCount":100},[],{"intervention":818,"totalTrials":96,"cells":819},"rDEN2Δ30-7169",{"EARLY_PHASE1":820,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":821,"activeCount":139,"soonestReadout":572},[822,832],{"nctId":823,"briefTitle":824,"status":110,"phases":825,"primaryCompletion":826,"completion":85,"start":827,"enrollment":828,"conditions":829,"interventions":831},"NCT05476757","Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.",[88],"2023-01","2022-08",5,[830],"Dengue",[818],{"nctId":833,"briefTitle":834,"status":204,"phases":835,"primaryCompletion":572,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":843},"NCT06908018","Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)",[88],"2028-09","2025-09",12,[840,830,841,842],"Safety Issues","Viremia","Immune-related Adverse Event",[818],{"trials":845,"activeCount":100},[],{"trials":847,"activeCount":100},[],{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"intervention":855,"totalTrials":350,"cells":856},"Tranexamic acid",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":878},{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":100},[],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":100},[],{"trials":866,"activeCount":100},[867],{"nctId":868,"briefTitle":869,"status":376,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":694,"conditions":873,"interventions":875},"NCT01643135","Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid",[92],"2013-12","2012-06",[874],"Bleeding",[876,877],"tranexamic acid","0.9% NaCl",{"trials":879,"activeCount":139,"soonestReadout":884},[880,891,901],{"nctId":881,"briefTitle":882,"status":124,"phases":883,"primaryCompletion":884,"completion":598,"start":599,"enrollment":885,"conditions":886,"interventions":890},"NCT07278037","Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage",[],"2026-03-31",648,[887,888,34,889],"Postpartum Hemorrhage","Delivery Complication","Perinatal Problems",[855],{"nctId":892,"briefTitle":893,"status":376,"phases":894,"primaryCompletion":895,"completion":896,"start":895,"enrollment":897,"conditions":898,"interventions":900},"NCT01449552","Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT",[93],"2008-06","2008-11",240,[899],"Osteoarthritis of Knee",[855],{"nctId":902,"briefTitle":903,"status":376,"phases":904,"primaryCompletion":905,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT01850394","Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement",[93],"2011-01","2012-01","2010-01",152,[405],[911,912],"Tranexamic Acid","Physiologic saline",{"intervention":51,"totalTrials":139,"cells":914},{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":916,"activeCount":100},[],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"trials":922,"activeCount":100},[],{"trials":924,"activeCount":100},[],{"trials":926,"activeCount":139,"soonestReadout":50},[927],{"nctId":48,"briefTitle":49,"status":124,"phases":928,"primaryCompletion":50,"completion":432,"start":929,"enrollment":29,"conditions":930,"interventions":932},[93],"2024-09-01",[931],"AKI - Acute Kidney Injury",[51],{"intervention":934,"totalTrials":139,"cells":935},"Lidocaine 2% and Methylprednisolone 80 mg",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":139,"soonestReadout":952},[948],{"nctId":949,"briefTitle":950,"status":204,"phases":951,"primaryCompletion":952,"completion":952,"start":277,"enrollment":953,"conditions":954,"interventions":957},"NCT07568496","Greater Occipital Nerve Block for Migraine With Medication Overuse Headache",[93],"2028-11-01",130,[392,955,956],"Medication Overuse Headache","Greater Occipital Nerve Block",[934],{"intervention":959,"totalTrials":139,"cells":960},"Standard systemic treatment for advanced lung cancer",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[],{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":139,"soonestReadout":693},[973],{"nctId":974,"briefTitle":975,"status":124,"phases":976,"primaryCompletion":693,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":983},"NCT06786468","Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients",[93],"2027-04","2024-04-02",104,[981,982],"Lung Cancer - Non Small Cell","Lung Cancer (NSCLC)",[959],{"intervention":985,"totalTrials":828,"cells":986},"Colistin",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":1032,"NA":1045},{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[995,1004,1014,1023],{"nctId":996,"briefTitle":997,"status":110,"phases":998,"primaryCompletion":871,"completion":871,"start":906,"enrollment":999,"conditions":1000,"interventions":1002},"NCT01501968","Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity",[91],54,[1001],"Drug Safety",[985,1003],"Colistin + Ascorbic acid",{"nctId":1005,"briefTitle":1006,"status":110,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":953,"conditions":1011,"interventions":1012},"NCT01297855","Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii",[91],"2012-05","2012-08","2010-06",[1001],[985,1013],"Colistin plus Rifampicin",{"nctId":1015,"briefTitle":1016,"status":110,"phases":1017,"primaryCompletion":1008,"completion":1008,"start":1010,"enrollment":1018,"conditions":1019,"interventions":1020},"NCT01297894","Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii",[91],92,[1001],[1021,1022],"colistin","colistin plus fosfomycin",{"nctId":1024,"briefTitle":1025,"status":110,"phases":1026,"completion":1027,"start":1028,"enrollment":908,"conditions":1029,"interventions":1031},"NCT00300560","Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli",[91],"2006-12","2006-02",[1030],"Infections",[985],{"trials":1033,"activeCount":100},[1034],{"nctId":1035,"briefTitle":1036,"status":110,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":280,"conditions":1041,"interventions":1043},"NCT05586815","Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection",[92],"2024-01-31","2024-06-30","2023-01-10",[1042],"Acinetobacter Infections",[985,1044],"Minocycline",{"trials":1046,"activeCount":100},[],{"intervention":1048,"totalTrials":350,"cells":1049},"Ketamine",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1102},{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[],{"trials":1057,"activeCount":100},[],{"trials":1059,"activeCount":100},[1060,1072,1084,1094],{"nctId":1061,"briefTitle":1062,"status":376,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":11,"conditions":1066,"interventions":1070},"NCT03280017","Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain",[92],"2018-12-31","2017-09-25",[1067,1068,1069],"Pain, Acute","Pain, Chronic","Pain, Neuropathic",[1048,1071],"Normal saline",{"nctId":1073,"briefTitle":1074,"status":376,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1082},"NCT04524130","Intraoperative Lidocaine and Combined With Ketamine on Opioid After Bariatric Surgery",[92],"2024-10-30","2025-01-31","2021-04-01",87,[1081],"Laparoscopic Bariatric Surgery",[1083,1048],"Lidocaine Hydrochloride",{"nctId":1085,"briefTitle":1086,"status":376,"phases":1087,"primaryCompletion":1088,"completion":1039,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1093},"NCT03879564","Ketamine-fentanyl VS Fentanyl for Analgosedation in SICU",[92],"2021-12-30","2019-04-05",118,[1092,26],"Critically Ill",[1048,1071],{"nctId":1095,"briefTitle":1096,"status":376,"phases":1097,"primaryCompletion":1064,"completion":1064,"start":1098,"enrollment":11,"conditions":1099,"interventions":1101},"NCT02570230","Ketamine Combination With Spinal Morphine for Post Thoracic Surgery Pain : A Randomized Control Study",[92],"2017-10-01",[24,1100],"Postoperative Period",[1048],{"trials":1103,"activeCount":100},[],{"intervention":1105,"totalTrials":96,"cells":1106},"Chorhexidine scrub",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1115,"NA":1137},{"trials":1108,"activeCount":100},[],{"trials":1110,"activeCount":100},[],{"trials":1112,"activeCount":100},[],{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[1117,1128],{"nctId":1118,"briefTitle":1119,"status":1120,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":100,"conditions":1124,"interventions":1126},"NCT04337749","Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination for Prevention of Pitted Keratolysis","WITHDRAWN",[92],"2022-12-01","2022-11-05",[1125],"Foot Dermatoses",[1105,1127],"Combination of chorhexidine scrub and ZnO-NPs socks",{"nctId":1129,"briefTitle":1130,"status":376,"phases":1131,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT04332796","Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination for Treatment of Pitted Keratolysis",[92],"2022-11-01","2022-03-15",60,[1125],[1105,1127],{"trials":1138,"activeCount":100},[],{"intervention":1127,"totalTrials":96,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1159},{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[1151,1155],{"nctId":1118,"briefTitle":1119,"status":1120,"phases":1152,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":100,"conditions":1153,"interventions":1154},[92],[1125],[1105,1127],{"nctId":1129,"briefTitle":1130,"status":376,"phases":1156,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1157,"interventions":1158},[92],[1125],[1105,1127],{"trials":1160,"activeCount":100},[],{"intervention":1162,"totalTrials":96,"cells":1163},"0.25% Bupivacaine",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1193},{"trials":1165,"activeCount":100},[],{"trials":1167,"activeCount":100},[],{"trials":1169,"activeCount":100},[],{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[1174,1183],{"nctId":1175,"briefTitle":1176,"status":376,"phases":1177,"primaryCompletion":368,"completion":368,"start":1178,"enrollment":1134,"conditions":1179,"interventions":1181},"NCT01364194","Local Infiltration With Bupivacaine to Increase Quality of Post-operative Pain Control in Total Knee Replacement",[92],"2010-03",[26,1180],"Arthropathy of Knee Joint",[1162,1182],"0.9% normal saline",{"nctId":1184,"briefTitle":1185,"status":376,"phases":1186,"primaryCompletion":1187,"completion":1188,"start":367,"enrollment":162,"conditions":1189,"interventions":1191},"NCT01593566","Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction",[92],"2013-04","2013-06",[1190],"Analgesia After ACL Reconstruction",[1162,1192],"0.5% Bupivacaine",{"trials":1194,"activeCount":100},[],{"intervention":1182,"totalTrials":96,"cells":1196},{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1222},{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":100},[],{"trials":1202,"activeCount":100},[],{"trials":1204,"activeCount":100},[],{"trials":1206,"activeCount":100},[1207,1211],{"nctId":1175,"briefTitle":1176,"status":376,"phases":1208,"primaryCompletion":368,"completion":368,"start":1178,"enrollment":1134,"conditions":1209,"interventions":1210},[92],[26,1180],[1162,1182],{"nctId":1212,"briefTitle":1213,"status":376,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":787,"conditions":1217,"interventions":1219},"NCT03583567","Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine",[92],"2019-03-31","2018-09-05",[1218],"Protamine Adverse Reaction",[1220,1221],"Chlorpheniramine and ranitidine","0.9% Normal Saline",{"trials":1223,"activeCount":100},[],{"intervention":1225,"totalTrials":96,"cells":1226},"Diltiazem",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1245,"PHASE4":1247,"NA":1263},{"trials":1228,"activeCount":100},[],{"trials":1230,"activeCount":100},[],{"trials":1232,"activeCount":100},[1233],{"nctId":1234,"briefTitle":1235,"status":376,"phases":1236,"primaryCompletion":1237,"completion":871,"start":1238,"enrollment":1239,"conditions":1240,"interventions":1243},"NCT01408524","Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem",[89,90],"2012-11","2010-02",184,[1241,1242],"Hypertension","Craniotomy",[1225,1244],"Labetalol",{"trials":1246,"activeCount":100},[],{"trials":1248,"activeCount":100},[1249],{"nctId":1250,"briefTitle":1251,"status":110,"phases":1252,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1260},"NCT05261464","Heart Rate Controller in Computed Tomography Coronary Angiography",[92],"2022-06-20","2022-06-30","2021-01-30",246,[1258,1259],"Heart Rate","Coronary Computed Tomography Angiography",[1261,1262,1225],"Metoprolol tartrate","Ivabradine",{"trials":1264,"activeCount":100},[],{"intervention":1266,"totalTrials":96,"cells":1267},"Lidocaine Spray",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1302},{"trials":1269,"activeCount":100},[],{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[1278,1290],{"nctId":1279,"briefTitle":1280,"status":110,"phases":1281,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT02317770","Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy",[92],"2016-03","2016-04","2013-11",110,[1287],"Anesthesia of Mucous Membrane",[1266,1289],"Nebulized Lidocaine",{"nctId":1291,"briefTitle":1292,"status":376,"phases":1293,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1300},"NCT03870711","10% Lidocaine Spray for Intrauterine Device Insertion",[92],"2019-12-17","2018-08-01",124,[1298,1299],"Contraception","Intrauterine Device",[1301],"lidocaine spray",{"trials":1303,"activeCount":100},[],{"intervention":1305,"totalTrials":96,"cells":1306},"Ertapenem",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1325,"PHASE4":1327,"NA":1338},{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":100},[],{"trials":1312,"activeCount":100},[1313],{"nctId":1314,"briefTitle":1315,"status":110,"phases":1316,"primaryCompletion":1317,"completion":1318,"start":1237,"enrollment":1319,"conditions":1320,"interventions":1323},"NCT02537847","Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli",[90],"2015-09","2016-05",96,[1321,1322],"Infection Due to Escherichia Coli","Acute Pyelonephritis",[1324,1305],"Sitafloxacin",{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":100},[1329],{"nctId":1330,"briefTitle":1331,"status":110,"phases":1332,"primaryCompletion":1187,"completion":1333,"start":1334,"enrollment":162,"conditions":1335,"interventions":1336},"NCT01297842","Ertapenem Versus Meropenem\u002FImipenem for ESBL+ Gram-negative Infections",[92],"2013-08","2011-05",[1001],[1305,1337],"Meropenem or Imipenem",{"trials":1339,"activeCount":100},[],{"intervention":1044,"totalTrials":96,"cells":1341},{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1348,"PHASE4":1350,"NA":1368},{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[],{"trials":1351,"activeCount":100},[1352,1364],{"nctId":1353,"briefTitle":1354,"status":110,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":1359,"conditions":1360,"interventions":1362},"NCT05575427","Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections",[92],"2024-07-01","2024-11-01","2022-11-24",112,[1361],"Hospital Infections",[1044,1363],"Levofloxacin or Cotrimoxazole",{"nctId":1035,"briefTitle":1036,"status":110,"phases":1365,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":280,"conditions":1366,"interventions":1367},[92],[1042],[985,1044],{"trials":1369,"activeCount":100},[],{"intervention":1371,"totalTrials":139,"cells":1372},"vaginal 17 beta-estradiol",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1403},{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[1383],{"nctId":1384,"briefTitle":1385,"status":376,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":425,"conditions":1390,"interventions":1402},"NCT06508944","Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women",[92],"2024-10-22","2024-10-31","2024-04-08",[1391,1392,1393,1394,1395,451,1396,1397,1398,1399,1400,1401],"Lower Urinary Tract Symptoms","Female Genitourinary Disease","Urinary Stress Incontinence","Urinary Urge Incontinence","Nocturia","Voiding Disorders","Vagina Atrophy","Urethral Atrophy","Overactive Bladder","Overactive Bladder Syndrome","Bladder, Overactive",[1371],{"trials":1404,"activeCount":100},[],{"intervention":1406,"totalTrials":139,"cells":1407},"alfacalcidol and calcitriol",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1428},{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"trials":1415,"activeCount":100},[],{"trials":1417,"activeCount":100},[1418],{"nctId":1419,"briefTitle":1420,"status":376,"phases":1421,"primaryCompletion":1422,"completion":1422,"start":1423,"enrollment":11,"conditions":1424,"interventions":1427},"NCT01115543","Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism",[92],"2009-08","2008-08",[1425,1426],"Secondary Hyperparathyroidism","End Stage Renal Disease",[1406],{"trials":1429,"activeCount":100},[],{"intervention":1431,"totalTrials":139,"cells":1432},"Colistin Sulfomethate",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1452},{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[1443],{"nctId":1444,"briefTitle":1445,"status":376,"phases":1446,"primaryCompletion":1447,"completion":1447,"start":1448,"enrollment":16,"conditions":1449,"interventions":1451},"NCT05586438","Pharmacokinetics of Colistin in Critically-ill Patients With AKI Who Receive SLED",[92],"2022-10-31","2021-10-18",[1450],"Bacterial Infections",[1431],{"trials":1453,"activeCount":100},[],{"intervention":1455,"totalTrials":139,"cells":1456},"lansoprazole, clarithromycin, amoxycillin",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1479},{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[],{"trials":1466,"activeCount":100},[1467],{"nctId":1468,"briefTitle":1469,"status":376,"phases":1470,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1478},"NCT00467571","Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura",[92],"2008-09","2008-12","2006-03",26,[1476,1477],"Chronic Idiopathic Thrombocytopenic Purpura","Helicobacter Pylori Infection",[1455],{"trials":1480,"activeCount":100},[],{"intervention":1482,"totalTrials":139,"cells":1483},"cisatracurium",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1507},{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[],{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[1494],{"nctId":1495,"briefTitle":1496,"status":376,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":19,"conditions":1500,"interventions":1506},"NCT03337373","The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium",[92],"2018-08-31","2017-12-15",[28,1501,1502,1503,1504,1505],"Respiratory Distress Syndrome, Adult","Neuromuscular Blockade","Respiratory Failure","Paralysis","ARDS, Human",[1482],{"trials":1508,"activeCount":100},[],{"intervention":1261,"totalTrials":139,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1525},{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[1521],{"nctId":1250,"briefTitle":1251,"status":110,"phases":1522,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":1523,"interventions":1524},[92],[1258,1259],[1261,1262,1225],{"trials":1526,"activeCount":100},[],{"intervention":1262,"totalTrials":139,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1543},{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[1539],{"nctId":1250,"briefTitle":1251,"status":110,"phases":1540,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":1541,"interventions":1542},[92],[1258,1259],[1261,1262,1225],{"trials":1544,"activeCount":100},[],{"intervention":1546,"totalTrials":139,"cells":1547},"Oxycodone",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1570},{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[1558],{"nctId":1559,"briefTitle":1560,"status":110,"phases":1561,"primaryCompletion":1562,"completion":1563,"start":1564,"enrollment":1565,"conditions":1566,"interventions":1569},"NCT03145272","Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Thai Pediatric Surgical Patients",[92],"2020-08-01","2023-12-01","2018-10-08",20,[1567,1568,1546],"Pharmacokinetics","Pharmacogenomics",[1546],{"trials":1571,"activeCount":100},[],{"intervention":1573,"totalTrials":139,"cells":1574},"Thiamine 1",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1581,"PHASE4":1583,"NA":1598},{"trials":1576,"activeCount":100},[],{"trials":1578,"activeCount":100},[],{"trials":1580,"activeCount":100},[],{"trials":1582,"activeCount":100},[],{"trials":1584,"activeCount":100},[1585],{"nctId":1586,"briefTitle":1587,"status":376,"phases":1588,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":1296,"conditions":1592,"interventions":1596},"NCT02464865","Thiamin Deficiency in Obese Thai Children",[92],"2018-07","2018-08","2015-08",[1593,1594,1595],"Obesity","Child","Thiamine Deficiency",[1573,1597],"Thiamine 2",{"trials":1599,"activeCount":100},[],{"intervention":1597,"totalTrials":139,"cells":1601},{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1608,"PHASE4":1610,"NA":1616},{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[1612],{"nctId":1586,"briefTitle":1587,"status":376,"phases":1613,"primaryCompletion":1589,"completion":1590,"start":1591,"enrollment":1296,"conditions":1614,"interventions":1615},[92],[1593,1594,1595],[1573,1597],{"trials":1617,"activeCount":100},[],{"intervention":1619,"totalTrials":139,"cells":1620},"hydroxyzine",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1627,"PHASE4":1629,"NA":1643},{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"trials":1630,"activeCount":100},[1631],{"nctId":1632,"briefTitle":1633,"status":376,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1642},"NCT01055236","Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients",[92],"2008-10","2007-08",80,[1639,1640,1641],"Pruritus","Nausea","Vomiting",[1619],{"trials":1644,"activeCount":100},[],{"intervention":1646,"totalTrials":139,"cells":1647},"Magnesium",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1654,"PHASE4":1656,"NA":1665},{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":100},[],{"trials":1657,"activeCount":100},[1658],{"nctId":1659,"briefTitle":1660,"status":376,"phases":1661,"primaryCompletion":1282,"completion":1282,"start":1662,"enrollment":434,"conditions":1663,"interventions":1664},"NCT02481518","Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity",[92],"2015-03",[602],[1646],{"trials":1666,"activeCount":100},[],{"intervention":1668,"totalTrials":139,"cells":1669},"bupivacaine and dexamethasone",{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1691},{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":100},[1680],{"nctId":1681,"briefTitle":1682,"status":110,"phases":1683,"primaryCompletion":1684,"completion":1684,"start":1685,"enrollment":575,"conditions":1686,"interventions":1689},"NCT03486548","Analgesic Efficacy of Adding SCB With Low Concentration Bupivacaine Combined With Dexamethasone on Pain After TKA",[92],"2019-02","2018-04",[384,1687,1688],"Adductor Canal Block","Sciatic Nerve Block",[1668,1690],"bupivacaine and lidocaine",{"trials":1692,"activeCount":100},[],{"intervention":1690,"totalTrials":139,"cells":1694},{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1701,"PHASE4":1703,"NA":1709},{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":100},[],{"trials":1702,"activeCount":100},[],{"trials":1704,"activeCount":100},[1705],{"nctId":1681,"briefTitle":1682,"status":110,"phases":1706,"primaryCompletion":1684,"completion":1684,"start":1685,"enrollment":575,"conditions":1707,"interventions":1708},[92],[384,1687,1688],[1668,1690],{"trials":1710,"activeCount":100},[],{"intervention":1712,"totalTrials":139,"cells":1713},"nitroglycerine",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1720,"PHASE4":1722,"NA":1733},{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[1724],{"nctId":1725,"briefTitle":1726,"status":376,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":162,"conditions":1730,"interventions":1732},"NCT00707928","Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study",[92],"2010-12","2008-02",[1731],"Retained Placenta",[1712],{"trials":1734,"activeCount":100},[],{"intervention":1736,"totalTrials":139,"cells":1737},"Gentamicin nasal irrigation",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1758},{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[1748],{"nctId":1749,"briefTitle":1750,"status":110,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":787,"conditions":1754,"interventions":1756},"NCT02582099","The Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis",[92],"2019-06-30","2017-01-01",[1755],"Rhinosinusitis",[1736,1757],"Normal saline nasal irrigation",{"trials":1759,"activeCount":100},[],{"intervention":1757,"totalTrials":139,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1776},{"trials":1763,"activeCount":100},[],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[1772],{"nctId":1749,"briefTitle":1750,"status":110,"phases":1773,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":787,"conditions":1774,"interventions":1775},[92],[1755],[1736,1757],{"trials":1777,"activeCount":100},[],{"intervention":1779,"totalTrials":139,"cells":1780},"0.05% Clobetasol propionate",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1802},{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[1791],{"nctId":1792,"briefTitle":1793,"status":376,"phases":1794,"primaryCompletion":1795,"completion":1796,"start":1797,"enrollment":600,"conditions":1798,"interventions":1800},"NCT02487212","Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery",[92],"2015-04","2015-05","2014-04",[1799],"Hypertrophic Scars",[1779,1801],"Petrolatum gel",{"trials":1803,"activeCount":100},[],{"intervention":1801,"totalTrials":139,"cells":1805},{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1812,"PHASE4":1814,"NA":1820},{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":100},[],{"trials":1815,"activeCount":100},[1816],{"nctId":1792,"briefTitle":1793,"status":376,"phases":1817,"primaryCompletion":1795,"completion":1796,"start":1797,"enrollment":600,"conditions":1818,"interventions":1819},[92],[1799],[1779,1801],{"trials":1821,"activeCount":100},[],{"intervention":1823,"totalTrials":139,"cells":1824},"2.5% benzoyl peroxide gel",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1833,"NA":1845},{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[1835],{"nctId":1836,"briefTitle":1837,"status":1120,"phases":1838,"primaryCompletion":1839,"completion":1839,"start":1840,"enrollment":100,"conditions":1841,"interventions":1843},"NCT04000347","A Study of Efficacy of Benzoyl Peroxide Regimens in Treatment of Unpleasant Foot Odor",[92],"2022-04-01","2019-06-26",[1842,1125],"Benzoyl Peroxide",[1823,1844],"5% benzoyl peroxide gel",{"trials":1846,"activeCount":100},[],{"intervention":1844,"totalTrials":139,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1857,"NA":1863},{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"trials":1856,"activeCount":100},[],{"trials":1858,"activeCount":100},[1859],{"nctId":1836,"briefTitle":1837,"status":1120,"phases":1860,"primaryCompletion":1839,"completion":1839,"start":1840,"enrollment":100,"conditions":1861,"interventions":1862},[92],[1842,1125],[1823,1844],{"trials":1864,"activeCount":100},[],{"intervention":1866,"totalTrials":139,"cells":1867},"17β-estradiol 10 mcg",{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1874,"PHASE4":1876,"NA":1890},{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[1878],{"nctId":1879,"briefTitle":1880,"status":376,"phases":1881,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":434,"conditions":1885,"interventions":1889},"NCT06780163","Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder",[92],"2025-11-10","2025-11-11","2025-06-27",[1886,1887,1888],"Overactive Bladder (OAB)","Menopause","Microbiome",[1866],{"trials":1891,"activeCount":100},[],{"intervention":1893,"totalTrials":139,"cells":1894},"oxymetazoline",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1903,"NA":1913},{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":100},[],{"trials":1900,"activeCount":100},[],{"trials":1902,"activeCount":100},[],{"trials":1904,"activeCount":100},[1905],{"nctId":1906,"briefTitle":1907,"status":376,"phases":1908,"primaryCompletion":1909,"completion":1909,"start":1187,"enrollment":575,"conditions":1910,"interventions":1912},"NCT01847131","Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction",[92],"2014-12",[1911],"Nasal Obstruction Present Finding",[1893],{"trials":1914,"activeCount":100},[],{"intervention":1289,"totalTrials":139,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1923,"PHASE4":1925,"NA":1931},{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":100},[],{"trials":1924,"activeCount":100},[],{"trials":1926,"activeCount":100},[1927],{"nctId":1279,"briefTitle":1280,"status":110,"phases":1928,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1929,"interventions":1930},[92],[1287],[1266,1289],{"trials":1932,"activeCount":100},[],{"intervention":1934,"totalTrials":139,"cells":1935},"0.1% triamcinolone , 0.05% clobetasol propionate ointment",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1956},{"trials":1937,"activeCount":100},[],{"trials":1939,"activeCount":100},[],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":100},[1946],{"nctId":1947,"briefTitle":1948,"status":376,"phases":1949,"primaryCompletion":1950,"completion":872,"start":1951,"enrollment":1952,"conditions":1953,"interventions":1955},"NCT01703325","Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails",[92],"2012-03","2010-11",16,[1954],"Psoriatic Nails",[1934],{"trials":1957,"activeCount":100},[],{"intervention":1959,"totalTrials":139,"cells":1960},"Polymyxin B",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1967,"PHASE4":1969,"NA":1979},{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"trials":1966,"activeCount":100},[],{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[1971],{"nctId":1972,"briefTitle":1973,"status":110,"phases":1974,"primaryCompletion":1975,"completion":1975,"start":1909,"enrollment":162,"conditions":1976,"interventions":1978},"NCT02328183","Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria",[92],"2015-11",[1977],"Hospital Infection",[1959],{"trials":1980,"activeCount":100},[],{"intervention":1982,"totalTrials":139,"cells":1983},"spinal morphine 0.3 mg",{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1990,"PHASE4":1992,"NA":2003},{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":100},[],{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[1994],{"nctId":1995,"briefTitle":1996,"status":376,"phases":1997,"primaryCompletion":1950,"completion":1950,"start":1951,"enrollment":787,"conditions":1998,"interventions":2001},"NCT01236495","Comparison for Pethidine Requirement in Patients Received Spinal Morphine 0.2 and 0.3 mg for Post Lobectomy Analgesia",[92],[1999,2000],"Solitary Mass","Lung Diseases",[1982,2002],"spinal morphine 0.2 mg",{"trials":2004,"activeCount":100},[],{"intervention":2002,"totalTrials":139,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2015,"NA":2021},{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"trials":2012,"activeCount":100},[],{"trials":2014,"activeCount":100},[],{"trials":2016,"activeCount":100},[2017],{"nctId":1995,"briefTitle":1996,"status":376,"phases":2018,"primaryCompletion":1950,"completion":1950,"start":1951,"enrollment":787,"conditions":2019,"interventions":2020},[92],[1999,2000],[1982,2002],{"trials":2022,"activeCount":100},[],{"intervention":2024,"totalTrials":139,"cells":2025},"Methadone",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2044},{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[2036],{"nctId":2037,"briefTitle":2038,"status":376,"phases":2039,"primaryCompletion":871,"completion":871,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2043},"NCT02335398","Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management",[92],"2011-07",34,[1068],[2024],{"trials":2045,"activeCount":100},[],{"intervention":1192,"totalTrials":139,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2054,"PHASE4":2056,"NA":2062},{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":100},[],{"trials":2053,"activeCount":100},[],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[2058],{"nctId":1184,"briefTitle":1185,"status":376,"phases":2059,"primaryCompletion":1187,"completion":1188,"start":367,"enrollment":162,"conditions":2060,"interventions":2061},[92],[1190],[1162,1192],{"trials":2063,"activeCount":100},[],{"intervention":2065,"totalTrials":139,"cells":2066},"APP",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2091},{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[2077],{"nctId":2078,"briefTitle":2079,"status":376,"phases":2080,"primaryCompletion":2081,"completion":2082,"start":2083,"enrollment":2084,"conditions":2085,"interventions":2090},"NCT06444724","The Effect of Smartphone Application on the Quality of Bowel Preparation for Colonoscopy",[92],"2024-12-31","2025-02-28","2022-07-01",488,[2086,2087,2088,2089],"Colonoscopy","Bowel Preparation","Quality","Smartphone Application",[2065],{"trials":2092,"activeCount":100},[],{"intervention":2094,"totalTrials":139,"cells":2095},"morphine and bupivacaine",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2102,"PHASE4":2104,"NA":2116},{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[2106],{"nctId":2107,"briefTitle":2108,"status":376,"phases":2109,"primaryCompletion":2110,"completion":2110,"start":1635,"enrollment":301,"conditions":2111,"interventions":2114},"NCT00795223","Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA",[92],"2009-05",[2112,2113],"Post Operative Pain","Total Knee Replacement",[2094,2115,2094,2094],"spinal morphine and marcaine",{"trials":2117,"activeCount":100},[],{"intervention":2115,"totalTrials":139,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2134},{"trials":2121,"activeCount":100},[],{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[2130],{"nctId":2107,"briefTitle":2108,"status":376,"phases":2131,"primaryCompletion":2110,"completion":2110,"start":1635,"enrollment":301,"conditions":2132,"interventions":2133},[92],[2112,2113],[2094,2115,2094,2094],{"trials":2135,"activeCount":100},[],{"intervention":2137,"totalTrials":139,"cells":2138},"0.05% cyclosporin eye drop",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2159},{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[2149],{"nctId":2150,"briefTitle":2151,"status":376,"phases":2152,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2155,"conditions":2156,"interventions":2158},"NCT00705510","Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction",[92],"2010-10","2008-05",70,[2157],"Meibomian Gland Dysfunction",[2137],{"trials":2160,"activeCount":100},[],{"intervention":2162,"totalTrials":139,"cells":2163},"celecoxib",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2183},{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":100},[],{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[2174],{"nctId":2175,"briefTitle":2176,"status":376,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":1636,"enrollment":1637,"conditions":2179,"interventions":2182},"NCT00520338","Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial",[92],"2009-12",[21,2180,2181],"Thyroidectomy","Cyclooxygenase 2 Inhibitors",[2162],{"trials":2184,"activeCount":100},[],{"intervention":2186,"totalTrials":139,"cells":2187},"tozinameran",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2211},{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[2198],{"nctId":2199,"briefTitle":2200,"status":376,"phases":2201,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":2205,"conditions":2206,"interventions":2210},"NCT05406908","Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases",[92],"2023-03-20","2023-05-01","2022-06-15",109,[2207,2208,2209],"Bullous Dermatoses","Psoriasis","COVID-19 Vaccines",[2186],{"trials":2212,"activeCount":100},[],{"intervention":1363,"totalTrials":139,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2229},{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[],{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":100},[],{"trials":2224,"activeCount":100},[2225],{"nctId":1353,"briefTitle":1354,"status":110,"phases":2226,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":1359,"conditions":2227,"interventions":2228},[92],[1361],[1044,1363],{"trials":2230,"activeCount":100},[],{"intervention":2232,"totalTrials":139,"cells":2233},"tacrolimus ointment",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2242,"NA":2253},{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"trials":2241,"activeCount":100},[],{"trials":2243,"activeCount":100},[2244],{"nctId":2245,"briefTitle":2246,"status":110,"phases":2247,"primaryCompletion":1188,"completion":871,"start":2248,"enrollment":434,"conditions":2249,"interventions":2251},"NCT01333410","Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo",[92],"2009-06",[2250],"Vitiligo",[2232,2252],"Mometasone furoate",{"trials":2254,"activeCount":100},[],{"intervention":2252,"totalTrials":139,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2265,"NA":2271},{"trials":2258,"activeCount":100},[],{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[2267],{"nctId":2245,"briefTitle":2246,"status":110,"phases":2268,"primaryCompletion":1188,"completion":871,"start":2248,"enrollment":434,"conditions":2269,"interventions":2270},[92],[2250],[2232,2252],{"trials":2272,"activeCount":100},[],{"intervention":2274,"totalTrials":139,"cells":2275},"Nailprotex",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2297},{"trials":2277,"activeCount":100},[],{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[2286],{"nctId":2287,"briefTitle":2288,"status":376,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":2291,"enrollment":2292,"conditions":2293,"interventions":2296},"NCT02464826","A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment",[92],"2016-06","2015-07",19,[2294,2295],"Onychomycosis","Chronic Paronychia",[2274],{"trials":2298,"activeCount":100},[],{"intervention":2300,"totalTrials":139,"cells":2301},"Low-dose intravenous cyclophosphamide",{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2323},{"trials":2303,"activeCount":100},[],{"trials":2305,"activeCount":100},[],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[2312],{"nctId":2313,"briefTitle":2314,"status":365,"phases":2315,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":380,"conditions":2318,"interventions":2321},"NCT01861561","Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children",[92],"2019-05","2013-05",[2319,2320],"Renal Insufficiency","Infection",[2300,2322],"High-dose intravenous cyclophosphamide",{"trials":2324,"activeCount":100},[],{"intervention":2322,"totalTrials":139,"cells":2326},{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2341},{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":100},[],{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[2337],{"nctId":2313,"briefTitle":2314,"status":365,"phases":2338,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":380,"conditions":2339,"interventions":2340},[92],[2319,2320],[2300,2322],{"trials":2342,"activeCount":100},[],{"intervention":2344,"totalTrials":139,"cells":2345},"Ketamine Hydrochloride",{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2354,"NA":2367},{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[2356],{"nctId":2357,"briefTitle":2358,"status":376,"phases":2359,"primaryCompletion":2360,"completion":2361,"start":2362,"enrollment":600,"conditions":2363,"interventions":2365},"NCT05026203","Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression",[92],"2022-07-31","2023-11-30","2021-09-01",[2364],"Depression",[2344,2366],"Midazolam",{"trials":2368,"activeCount":100},[],{"intervention":2366,"totalTrials":139,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2385},{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[2381],{"nctId":2357,"briefTitle":2358,"status":376,"phases":2382,"primaryCompletion":2360,"completion":2361,"start":2362,"enrollment":600,"conditions":2383,"interventions":2384},[92],[2364],[2344,2366],{"trials":2386,"activeCount":100},[],{"intervention":2388,"totalTrials":139,"cells":2389},"Metformin",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2407},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[2400],{"nctId":2401,"briefTitle":2402,"status":110,"phases":2403,"primaryCompletion":1950,"completion":1950,"start":367,"enrollment":787,"conditions":2404,"interventions":2406},"NCT01342744","Metformin in Postmenopausal Women With Metabolic Syndrome",[92],[2405],"Metabolic Syndrome",[2388],{"trials":2408,"activeCount":100},[],{"intervention":2410,"totalTrials":139,"cells":2411},"HAVRIX",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2433},{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[],{"trials":2419,"activeCount":100},[],{"trials":2421,"activeCount":100},[2422],{"nctId":2423,"briefTitle":2424,"status":110,"phases":2425,"primaryCompletion":2426,"completion":2427,"start":2428,"enrollment":575,"conditions":2429,"interventions":2432},"NCT06277882","Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis",[92],"2025-03-01","2025-05-31","2024-02-29",[450,2430,2431],"Hep A","Vaccination",[2410],{"trials":2434,"activeCount":100},[],{"intervention":2436,"totalTrials":139,"cells":2437},"Artesunate",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2458},{"trials":2439,"activeCount":100},[],{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[2448],{"nctId":2449,"briefTitle":2450,"status":110,"phases":2451,"primaryCompletion":1909,"completion":1909,"start":2452,"enrollment":2453,"conditions":2454,"interventions":2456},"NCT01662700","Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand",[92],"2012-10",120,[2455],"Acute Uncomplicated Malaria With P.Vivax Infection",[2436,2457],"Chloroquine",{"trials":2459,"activeCount":100},[],{"intervention":2457,"totalTrials":139,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2466,"PHASE3":2468,"PHASE4":2470,"NA":2476},{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[2472],{"nctId":2449,"briefTitle":2450,"status":110,"phases":2473,"primaryCompletion":1909,"completion":1909,"start":2452,"enrollment":2453,"conditions":2474,"interventions":2475},[92],[2455],[2436,2457],{"trials":2477,"activeCount":100},[],{"intervention":2479,"totalTrials":139,"cells":2480},"Isobaric marcaine",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2487,"PHASE4":2489,"NA":2505},{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":100},[],{"trials":2488,"activeCount":100},[],{"trials":2490,"activeCount":100},[2491],{"nctId":2492,"briefTitle":2493,"status":376,"phases":2494,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":2498,"conditions":2499,"interventions":2503},"NCT02737813","Cardiac Output Changes During Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Cesarean Section",[92],"2016-11-11","2016-11-15","2016-03-29",168,[2500,2501,2502],"Cardiac Output","Hypotension","Anesthesia, Spinal",[2479,2504],"Hyperbaric marcaine",{"trials":2506,"activeCount":100},[],{"intervention":2504,"totalTrials":139,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2517,"NA":2523},{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[2519],{"nctId":2492,"briefTitle":2493,"status":376,"phases":2520,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":2498,"conditions":2521,"interventions":2522},[92],[2500,2501,2502],[2479,2504],{"trials":2524,"activeCount":100},[],{"intervention":2526,"totalTrials":139,"cells":2527},"Oral",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2534,"PHASE4":2536,"NA":2546},{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[],{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":100},[2538],{"nctId":2539,"briefTitle":2540,"status":376,"phases":2541,"primaryCompletion":2542,"completion":2204,"start":1499,"enrollment":787,"conditions":2543,"interventions":2545},"NCT03220074","Linezolid for Treatment of Nontuberculous Mycobacterial Diseases",[92],"2021-06-15",[2544],"Non-tuberculous Mycobacterial Infections",[2526],{"trials":2547,"activeCount":100},[],{"intervention":2549,"totalTrials":139,"cells":2550},"nalbuphine",{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2555,"PHASE3":2557,"PHASE4":2559,"NA":2570},{"trials":2552,"activeCount":100},[],{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[2561],{"nctId":2562,"briefTitle":2563,"status":376,"phases":2564,"primaryCompletion":2565,"completion":1028,"start":2566,"enrollment":234,"conditions":2567,"interventions":2569},"NCT00707824","Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus",[92],"2005-12","2000-06",[2568],"Cesarean Section",[2549,2549],{"trials":2571,"activeCount":100},[],{"intervention":2573,"totalTrials":139,"cells":2574},"Calcium carbonate",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2583,"NA":2599},{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[2585],{"nctId":2586,"briefTitle":2587,"status":376,"phases":2588,"primaryCompletion":2589,"completion":2361,"start":2590,"enrollment":2591,"conditions":2592,"interventions":2597},"NCT05313477","The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF",[92],"2023-08-31","2022-05-01",64,[2593,2594,2595,2596],"Parathyroid Hormone","Tenofovir Disoproxil Fumarate","Chronic Hepatitis B Virus","Vitamin D",[2598,2573],"Ergocalciferol",{"trials":2600,"activeCount":100},[],{"intervention":2602,"totalTrials":139,"cells":2603},"Subtenon 20-mg triamcinolone",{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2622},{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[],{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[2614],{"nctId":2615,"briefTitle":2616,"status":110,"phases":2617,"primaryCompletion":2291,"completion":2291,"start":1008,"enrollment":507,"conditions":2618,"interventions":2621},"NCT01801774","Efficacy Comparison Study of Steroids to Control Post-operative Inflammation",[92],[2619,2620],"Inflammation","Intraocular Pressure",[2602],{"trials":2623,"activeCount":100},[],{"intervention":1337,"totalTrials":139,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2640},{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[2636],{"nctId":1330,"briefTitle":1331,"status":110,"phases":2637,"primaryCompletion":1187,"completion":1333,"start":1334,"enrollment":162,"conditions":2638,"interventions":2639},[92],[1001],[1305,1337],{"trials":2641,"activeCount":100},[],{"intervention":2643,"totalTrials":139,"cells":2644},"Pregabalin",{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2651,"PHASE4":2653,"NA":2665},{"trials":2646,"activeCount":100},[],{"trials":2648,"activeCount":100},[],{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[2655],{"nctId":2656,"briefTitle":2657,"status":376,"phases":2658,"primaryCompletion":2659,"completion":2660,"start":2661,"enrollment":2662,"conditions":2663,"interventions":2664},"NCT02285010","Effect of Pregabalin on Post Operative Pain in Abdominal Hysterectomy Under Spinal Anesthesia With Intrathecal Morphine",[92],"2016-01","2016-08","2014-11",125,[2112],[2643],{"trials":2666,"activeCount":100},[],{"intervention":2668,"totalTrials":139,"cells":2669},"high dose dexmedethomidine",{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2678,"NA":2690},{"trials":2671,"activeCount":100},[],{"trials":2673,"activeCount":100},[],{"trials":2675,"activeCount":100},[],{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[2680],{"nctId":2681,"briefTitle":2682,"status":110,"phases":2683,"primaryCompletion":2684,"completion":2685,"start":1318,"enrollment":1296,"conditions":2686,"interventions":2688},"NCT03132259","Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach",[92],"2017-05","2018-06",[2687],"Pituitary Tumor",[2668,2689],"low dose dexmedethomidine",{"trials":2691,"activeCount":100},[],{"intervention":2689,"totalTrials":139,"cells":2693},{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2700,"PHASE4":2702,"NA":2708},{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[],{"trials":2701,"activeCount":100},[],{"trials":2703,"activeCount":100},[2704],{"nctId":2681,"briefTitle":2682,"status":110,"phases":2705,"primaryCompletion":2684,"completion":2685,"start":1318,"enrollment":1296,"conditions":2706,"interventions":2707},[92],[2687],[2668,2689],{"trials":2709,"activeCount":100},[],{"intervention":2711,"totalTrials":139,"cells":2712},"Bupivacaine plus lidocaine",{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2721,"NA":2734},{"trials":2714,"activeCount":100},[],{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[2723],{"nctId":2724,"briefTitle":2725,"status":110,"phases":2726,"primaryCompletion":368,"completion":2727,"start":2728,"enrollment":2729,"conditions":2730,"interventions":2732},"NCT00993746","2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula",[92],"2011-09","2009-10",90,[2731],"Infraclavicular Brachial Plexus Block",[2711,2733],"Bupivacaine 30 ml",{"trials":2735,"activeCount":100},[],{"intervention":2733,"totalTrials":139,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2752},{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[],{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[2748],{"nctId":2724,"briefTitle":2725,"status":110,"phases":2749,"primaryCompletion":368,"completion":2727,"start":2728,"enrollment":2729,"conditions":2750,"interventions":2751},[92],[2731],[2711,2733],{"trials":2753,"activeCount":100},[],{"intervention":2755,"totalTrials":139,"cells":2756},"Whitfield solution",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2779},{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[2767],{"nctId":2768,"briefTitle":2769,"status":376,"phases":2770,"primaryCompletion":2771,"completion":2771,"start":2772,"enrollment":2773,"conditions":2774,"interventions":2776},"NCT05901961","Effectiveness and Safety of Whitfield's Solution, Zinc Oxide Nanoparticles Solution or Combination for the Treatment of Fungal Feet Infection",[92],"2023-09-09","2023-06-02",84,[2775],"Fungal Foot Infection",[2755,2777,2778],"Zinc oxide nanoparticles solution","Combined Whitfield and Zinc oxide nanoparticles solution",{"trials":2780,"activeCount":100},[],{"intervention":2777,"totalTrials":139,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2789,"PHASE4":2791,"NA":2797},{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[2793],{"nctId":2768,"briefTitle":2769,"status":376,"phases":2794,"primaryCompletion":2771,"completion":2771,"start":2772,"enrollment":2773,"conditions":2795,"interventions":2796},[92],[2775],[2755,2777,2778],{"trials":2798,"activeCount":100},[],{"intervention":2778,"totalTrials":139,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2815},{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[2811],{"nctId":2768,"briefTitle":2769,"status":376,"phases":2812,"primaryCompletion":2771,"completion":2771,"start":2772,"enrollment":2773,"conditions":2813,"interventions":2814},[92],[2775],[2755,2777,2778],{"trials":2816,"activeCount":100},[],{"intervention":2818,"totalTrials":139,"cells":2819},"Tigecycline",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2826,"PHASE4":2828,"NA":2838},{"trials":2821,"activeCount":100},[],{"trials":2823,"activeCount":100},[],{"trials":2825,"activeCount":100},[],{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[2830],{"nctId":2831,"briefTitle":2832,"status":110,"phases":2833,"primaryCompletion":872,"completion":2834,"start":2040,"enrollment":434,"conditions":2835,"interventions":2837},"NCT01342731","Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii",[92],"2012-12",[2836],"Antibiotic Resistant Infection",[2818],{"trials":2839,"activeCount":100},[],{"intervention":2841,"totalTrials":139,"cells":2842},"L-ornithine-L-aspartate and lactulose",{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2849,"PHASE4":2851,"NA":2863},{"trials":2844,"activeCount":100},[],{"trials":2846,"activeCount":100},[],{"trials":2848,"activeCount":100},[],{"trials":2850,"activeCount":100},[],{"trials":2852,"activeCount":100},[2853],{"nctId":2854,"briefTitle":2855,"status":376,"phases":2856,"primaryCompletion":2857,"completion":2858,"start":1471,"enrollment":2859,"conditions":2860,"interventions":2862},"NCT00740142","Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy",[92],"2010-08","2011-10",35,[2861],"Hepatic Encephalopathy",[2841],{"trials":2864,"activeCount":100},[],{"intervention":2866,"totalTrials":139,"cells":2867},"Liquid powder",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2876,"NA":2888},{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[2878],{"nctId":2879,"briefTitle":2880,"status":376,"phases":2881,"primaryCompletion":2882,"completion":2882,"start":2883,"enrollment":787,"conditions":2884,"interventions":2886},"NCT04325490","Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream",[92],"2020-09-30","2019-10-01",[2885],"Intertrigo",[2866,2887],"Hydrocortisone cream 1%",{"trials":2889,"activeCount":100},[],{"intervention":2887,"totalTrials":139,"cells":2891},{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2898,"PHASE4":2900,"NA":2906},{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[],{"trials":2897,"activeCount":100},[],{"trials":2899,"activeCount":100},[],{"trials":2901,"activeCount":100},[2902],{"nctId":2879,"briefTitle":2880,"status":376,"phases":2903,"primaryCompletion":2882,"completion":2882,"start":2883,"enrollment":787,"conditions":2904,"interventions":2905},[92],[2885],[2866,2887],{"trials":2907,"activeCount":100},[],{"intervention":2909,"totalTrials":139,"cells":2910},"Atropine 0.6 mg",{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2919,"NA":2932},{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[2921],{"nctId":2922,"briefTitle":2923,"status":376,"phases":2924,"primaryCompletion":2925,"completion":2925,"start":1950,"enrollment":787,"conditions":2926,"interventions":2930},"NCT02186132","0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant",[92],"2013-02",[2927,2928,2929],"Bradycardia","Neostigmine Adverse Reaction","Adverse Reaction to Belladonna or Atropine",[2909,2931],"Atropine 1.2 mg",{"trials":2933,"activeCount":100},[],{"intervention":2931,"totalTrials":139,"cells":2935},{"EARLY_PHASE1":2936,"PHASE1":2938,"PHASE2":2940,"PHASE3":2942,"PHASE4":2944,"NA":2950},{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[2946],{"nctId":2922,"briefTitle":2923,"status":376,"phases":2947,"primaryCompletion":2925,"completion":2925,"start":1950,"enrollment":787,"conditions":2948,"interventions":2949},[92],[2927,2928,2929],[2909,2931],{"trials":2951,"activeCount":100},[],{"intervention":2953,"totalTrials":139,"cells":2954},"2% povidone-iodine",{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2961,"PHASE4":2963,"NA":2974},{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[],{"trials":2960,"activeCount":100},[],{"trials":2962,"activeCount":100},[],{"trials":2964,"activeCount":100},[2965],{"nctId":2966,"briefTitle":2967,"status":376,"phases":2968,"primaryCompletion":2178,"completion":2178,"start":2969,"enrollment":2970,"conditions":2971,"interventions":2973},"NCT01179412","Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine",[92],"2004-07",172,[2972],"Viral Conjunctivitis",[2953,2953],{"trials":2975,"activeCount":100},[],{"intervention":2977,"totalTrials":139,"cells":2978},"1.5 mg estradiol and 2.5 mg nomegestrol acetate",{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":2985,"PHASE4":2987,"NA":2999},{"trials":2980,"activeCount":100},[],{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[2989],{"nctId":2990,"briefTitle":2991,"status":365,"phases":2992,"primaryCompletion":2993,"completion":2994,"start":1282,"enrollment":1359,"conditions":2995,"interventions":2997},"NCT03531437","Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT",[92],"2018-01","2018-04-18",[1298,2996],"Hypercoagulability",[2977,2998],"15 µg ethinylestradiol and 60 µg gestodene",{"trials":3000,"activeCount":100},[],{"intervention":2998,"totalTrials":139,"cells":3002},{"EARLY_PHASE1":3003,"PHASE1":3005,"PHASE2":3007,"PHASE3":3009,"PHASE4":3011,"NA":3017},{"trials":3004,"activeCount":100},[],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"trials":3010,"activeCount":100},[],{"trials":3012,"activeCount":100},[3013],{"nctId":2990,"briefTitle":2991,"status":365,"phases":3014,"primaryCompletion":2993,"completion":2994,"start":1282,"enrollment":1359,"conditions":3015,"interventions":3016},[92],[1298,2996],[2977,2998],{"trials":3018,"activeCount":100},[],{"intervention":3020,"totalTrials":139,"cells":3021},"Switching to Tenofovir Alafenamide",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3040},{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[],{"trials":3027,"activeCount":100},[],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[3032],{"nctId":3033,"briefTitle":3034,"status":110,"phases":3035,"primaryCompletion":2360,"completion":2360,"start":3036,"enrollment":1637,"conditions":3037,"interventions":3039},"NCT04391608","TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment",[92],"2019-11-09",[2319,3038],"Tenofovir",[3020],{"trials":3041,"activeCount":100},[],{"intervention":3043,"totalTrials":139,"cells":3044},"Amoxicillin",{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3063},{"trials":3046,"activeCount":100},[],{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[3055],{"nctId":3056,"briefTitle":3057,"status":365,"phases":3058,"primaryCompletion":1975,"completion":1975,"start":3059,"enrollment":828,"conditions":3060,"interventions":3062},"NCT02131818","Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term",[92],"2014-05",[3061],"Perineal Wound Infection",[3043],{"trials":3064,"activeCount":100},[],{"intervention":3066,"totalTrials":139,"cells":3067},"amphotericin B in 30% DMSO",{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3074,"PHASE4":3076,"NA":3090},{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":100},[3078],{"nctId":3079,"briefTitle":3080,"status":376,"phases":3081,"primaryCompletion":3082,"completion":3083,"start":3084,"enrollment":2292,"conditions":3085,"interventions":3088},"NCT03814343","Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis",[92],"2020-11-15","2020-11-30","2019-01-15",[3086,2294,3087],"Fungal Infection","Fungus, Nail",[3066,3089],"30% DMSO",{"trials":3091,"activeCount":100},[],{"intervention":3089,"totalTrials":139,"cells":3093},{"EARLY_PHASE1":3094,"PHASE1":3096,"PHASE2":3098,"PHASE3":3100,"PHASE4":3102,"NA":3108},{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[3104],{"nctId":3079,"briefTitle":3080,"status":376,"phases":3105,"primaryCompletion":3082,"completion":3083,"start":3084,"enrollment":2292,"conditions":3106,"interventions":3107},[92],[3086,2294,3087],[3066,3089],{"trials":3109,"activeCount":100},[],{"intervention":1083,"totalTrials":139,"cells":3111},{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3118,"PHASE4":3120,"NA":3126},{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[3122],{"nctId":1073,"briefTitle":1074,"status":376,"phases":3123,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":3124,"interventions":3125},[92],[1081],[1083,1048],{"trials":3127,"activeCount":100},[],{"intervention":3129,"totalTrials":139,"cells":3130},"30 mcg ethinylestradiol\u002F2 mg chlormadinone acetate",{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3137,"PHASE4":3139,"NA":3150},{"trials":3132,"activeCount":100},[],{"trials":3134,"activeCount":100},[],{"trials":3136,"activeCount":100},[],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[3141],{"nctId":3142,"briefTitle":3143,"status":110,"phases":3144,"primaryCompletion":2659,"completion":3145,"start":872,"enrollment":162,"conditions":3146,"interventions":3148},"NCT01608698","Comparison of Body Weight Change During Contraception With Belara and Yasmin",[92],"2016-02",[3147],"Body Weight Changes",[3129,3149],"30 mcg ethinylestradiol\u002F3 mg drospirenone",{"trials":3151,"activeCount":100},[],{"intervention":3149,"totalTrials":139,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3162,"NA":3168},{"trials":3155,"activeCount":100},[],{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[3164],{"nctId":3142,"briefTitle":3143,"status":110,"phases":3165,"primaryCompletion":2659,"completion":3145,"start":872,"enrollment":162,"conditions":3166,"interventions":3167},[92],[3147],[3129,3149],{"trials":3169,"activeCount":100},[],{"intervention":3171,"totalTrials":139,"cells":3172},"Ayurved Siriraj Prasaplai with or without mefenamic acid",{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3179,"PHASE4":3181,"NA":3192},{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":100},[],{"trials":3180,"activeCount":100},[],{"trials":3182,"activeCount":100},[3183],{"nctId":3184,"briefTitle":3185,"status":376,"phases":3186,"primaryCompletion":3187,"completion":1333,"start":3188,"enrollment":787,"conditions":3189,"interventions":3191},"NCT01598012","The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea",[92],"2013-07","2011-12",[3190],"Primary Dysmenorrhea",[3171],{"trials":3193,"activeCount":100},[],{"intervention":3195,"totalTrials":139,"cells":3196},"Risedronate",{"EARLY_PHASE1":3197,"PHASE1":3199,"PHASE2":3201,"PHASE3":3203,"PHASE4":3205,"NA":3215},{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[3207],{"nctId":3208,"briefTitle":3209,"status":110,"phases":3210,"primaryCompletion":3211,"completion":3211,"start":1188,"enrollment":425,"conditions":3212,"interventions":3214},"NCT02148848","Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty",[92],"2017-10",[3213,370],"Osteoporotic Fractures",[3195],{"trials":3216,"activeCount":100},[],{"intervention":3218,"totalTrials":139,"cells":3219},"Neomycin",{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3224,"PHASE3":3226,"PHASE4":3228,"NA":3238},{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"trials":3229,"activeCount":100},[3230],{"nctId":3231,"briefTitle":3232,"status":110,"phases":3233,"primaryCompletion":445,"completion":3234,"start":1358,"enrollment":1134,"conditions":3235,"interventions":3237},"NCT05593601","Decolonization of Carbapenem-resistant Enterobacterales (CRE) in Patients With Faecal Carriage of CRE With Neomycin",[92],"2024-03-31",[3236],"Colonization, Asymptomatic",[3218],{"trials":3239,"activeCount":100},[],{"intervention":3241,"totalTrials":139,"cells":3242},"Ascorbic acid",{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3247,"PHASE3":3249,"PHASE4":3251,"NA":3262},{"trials":3244,"activeCount":100},[],{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[],{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":100},[3253],{"nctId":3254,"briefTitle":3255,"status":110,"phases":3256,"primaryCompletion":3257,"completion":277,"start":279,"enrollment":1285,"conditions":3258,"interventions":3260},"NCT06384833","Combination of Vitamin C and N-Acetylcysteine to Improve Functional Outcome After Rotator Cuff Repair",[92],"2025-09-01",[3259],"Rotator Cuff Tears",[3241,3261],"N-acetyl cysteine",{"trials":3263,"activeCount":100},[],{"intervention":3261,"totalTrials":139,"cells":3265},{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3280},{"trials":3267,"activeCount":100},[],{"trials":3269,"activeCount":100},[],{"trials":3271,"activeCount":100},[],{"trials":3273,"activeCount":100},[],{"trials":3275,"activeCount":100},[3276],{"nctId":3254,"briefTitle":3255,"status":110,"phases":3277,"primaryCompletion":3257,"completion":277,"start":279,"enrollment":1285,"conditions":3278,"interventions":3279},[92],[3259],[3241,3261],{"trials":3281,"activeCount":100},[],{"intervention":3283,"totalTrials":139,"cells":3284},"trivalent inactivated influenza",{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3291,"PHASE4":3293,"NA":3304},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[],{"trials":3292,"activeCount":100},[],{"trials":3294,"activeCount":100},[3295],{"nctId":3296,"briefTitle":3297,"status":376,"phases":3298,"primaryCompletion":3299,"completion":3299,"start":1284,"enrollment":3300,"conditions":3301,"interventions":3303},"NCT02101749","Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.",[92],"2014-03",221,[3302],"Influenza, Human",[3283],{"trials":3305,"activeCount":100},[],{"intervention":3307,"totalTrials":139,"cells":3308},"Egg-derived standard dose trivalent influenza vaccine",{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3315,"PHASE4":3317,"NA":3330},{"trials":3310,"activeCount":100},[],{"trials":3312,"activeCount":100},[],{"trials":3314,"activeCount":100},[],{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[3319],{"nctId":3320,"briefTitle":3321,"status":110,"phases":3322,"primaryCompletion":1839,"completion":1122,"start":3323,"enrollment":3324,"conditions":3325,"interventions":3329},"NCT05070494","Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients",[92],"2021-03-01",175,[3326,3327,3328],"ESRD","Influenza Vaccine","Seroprotection",[3307],{"trials":3331,"activeCount":100},[],{"intervention":3333,"totalTrials":139,"cells":3334},"Low-dose colchicine",{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3356},{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[3345],{"nctId":3346,"briefTitle":3347,"status":110,"phases":3348,"primaryCompletion":1254,"completion":3349,"start":3350,"enrollment":2773,"conditions":3351,"interventions":3355},"NCT05168137","Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy",[92],"2022-12-31","2020-02-01",[3352,3353,3354],"HIV Infections","Inflammatory Markers","Colchicine Adverse Reaction",[3333],{"trials":3357,"activeCount":100},[],{"intervention":3359,"totalTrials":139,"cells":3360},"0.05%cyclosporin eye drop",{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3365,"PHASE3":3367,"PHASE4":3369,"NA":3381},{"trials":3362,"activeCount":100},[],{"trials":3364,"activeCount":100},[],{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[3371],{"nctId":3372,"briefTitle":3373,"status":376,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":3377,"conditions":3378,"interventions":3380},"NCT01488396","Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye",[92],"2009-07","2007-02",31,[3379],"Stevens-Johnson Syndrome",[3359],{"trials":3382,"activeCount":100},[],{"intervention":3384,"totalTrials":139,"cells":3385},"Generic alendronate",{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3392,"PHASE4":3394,"NA":3404},{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[3396],{"nctId":3397,"briefTitle":3398,"status":376,"phases":3399,"primaryCompletion":3400,"completion":3400,"start":1797,"enrollment":507,"conditions":3401,"interventions":3403},"NCT02371252","Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment",[92],"2016-12",[3402],"Osteoporosis",[3384],{"trials":3405,"activeCount":100},[],{"intervention":3407,"totalTrials":139,"cells":3408},"Ivermectin Pill",{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3413,"PHASE3":3415,"PHASE4":3417,"NA":3431},{"trials":3410,"activeCount":100},[],{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[3419],{"nctId":3420,"briefTitle":3421,"status":110,"phases":3422,"primaryCompletion":3423,"completion":3424,"start":3425,"enrollment":1637,"conditions":3426,"interventions":3429},"NCT04435587","Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection",[92],"2021-06","2021-11","2020-07-13",[3427,3428],"Asymptomatic Infections","SARS-CoV2 Infection",[3407,3430],"Combined ART\u002Fhydroxychloroquine",{"trials":3432,"activeCount":100},[],{"intervention":3430,"totalTrials":139,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3441,"PHASE4":3443,"NA":3449},{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[3445],{"nctId":3420,"briefTitle":3421,"status":110,"phases":3446,"primaryCompletion":3423,"completion":3424,"start":3425,"enrollment":1637,"conditions":3447,"interventions":3448},[92],[3427,3428],[3407,3430],{"trials":3450,"activeCount":100},[],{"intervention":3452,"totalTrials":139,"cells":3453},"etoricoxib",{"EARLY_PHASE1":3454,"PHASE1":3456,"PHASE2":3458,"PHASE3":3460,"PHASE4":3462,"NA":3475},{"trials":3455,"activeCount":100},[],{"trials":3457,"activeCount":100},[],{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[3464],{"nctId":3465,"briefTitle":3466,"status":376,"phases":3467,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":3470,"conditions":3471,"interventions":3472},"NCT00440739","Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)",[92],"2007-12","2005-09",128,[24],[3452,3473,3474],"flavoxate","etoricoxib, flavoxate",{"trials":3476,"activeCount":100},[],{"intervention":3473,"totalTrials":139,"cells":3478},{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3493},{"trials":3480,"activeCount":100},[],{"trials":3482,"activeCount":100},[],{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[3489],{"nctId":3465,"briefTitle":3466,"status":376,"phases":3490,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":3470,"conditions":3491,"interventions":3492},[92],[24],[3452,3473,3474],{"trials":3494,"activeCount":100},[],{"intervention":3474,"totalTrials":139,"cells":3496},{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3501,"PHASE3":3503,"PHASE4":3505,"NA":3511},{"trials":3498,"activeCount":100},[],{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[3507],{"nctId":3465,"briefTitle":3466,"status":376,"phases":3508,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":3470,"conditions":3509,"interventions":3510},[92],[24],[3452,3473,3474],{"trials":3512,"activeCount":100},[],{"intervention":3514,"totalTrials":139,"cells":3515},"Spinal morphine 0.05 mg",{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3520,"PHASE3":3522,"PHASE4":3524,"NA":3535},{"trials":3517,"activeCount":100},[],{"trials":3519,"activeCount":100},[],{"trials":3521,"activeCount":100},[],{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[3526],{"nctId":3527,"briefTitle":3528,"status":110,"phases":3529,"primaryCompletion":3188,"completion":3188,"start":1178,"enrollment":3530,"conditions":3531,"interventions":3533},"NCT01079754","0.05 Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy",[92],72,[24,3532],"Vaginal Hysterectomy",[3514,3534],"Spinal morphine 0.1 mg",{"trials":3536,"activeCount":100},[],{"intervention":3534,"totalTrials":139,"cells":3538},{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3547,"NA":3553},{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[3549],{"nctId":3527,"briefTitle":3528,"status":110,"phases":3550,"primaryCompletion":3188,"completion":3188,"start":1178,"enrollment":3530,"conditions":3551,"interventions":3552},[92],[24,3532],[3514,3534],{"trials":3554,"activeCount":100},[],{"intervention":3556,"totalTrials":139,"cells":3557},"Spinal morphine",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3575},{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[3568],{"nctId":3569,"briefTitle":3570,"status":110,"phases":3571,"primaryCompletion":3400,"completion":3400,"start":3572,"enrollment":787,"conditions":3573,"interventions":3574},"NCT01979354","0.15 mg Spinal Morphine vs. no Treatment for Morphine Requirement After VATs.",[92],"2014-02",[21],[3556],{"trials":3576,"activeCount":100},[],{"intervention":3578,"totalTrials":139,"cells":3579},"Bupivacaine, morphine",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3598},{"trials":3581,"activeCount":100},[],{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[3590],{"nctId":3591,"briefTitle":3592,"status":110,"phases":3593,"primaryCompletion":3594,"completion":3594,"start":368,"enrollment":1637,"conditions":3595,"interventions":3597},"NCT01219088","Intrathecal Morphine,Femoral Nerve Block,Periarticular Bupivacaine Infiltration for Pain After Intramedullary Hip Screw",[92],"2012-09",[3596],"Femoral Neck Fractures",[3578],{"trials":3599,"activeCount":100},[],{"intervention":3601,"totalTrials":139,"cells":3602},"Levobupivacaine",{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3609,"PHASE4":3611,"NA":3620},{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[],{"trials":3612,"activeCount":100},[3613],{"nctId":3614,"briefTitle":3615,"status":376,"phases":3616,"primaryCompletion":2660,"completion":2660,"start":1317,"enrollment":3470,"conditions":3617,"interventions":3619},"NCT02558569","The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block",[92],[3618],"Brain Tumor",[3601],{"trials":3621,"activeCount":100},[],{"intervention":3623,"totalTrials":139,"cells":3624},"Zoely",{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3633,"NA":3645},{"trials":3626,"activeCount":100},[],{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[3635],{"nctId":3636,"briefTitle":3637,"status":376,"phases":3638,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":9,"conditions":3641,"interventions":3643},"NCT03077555","Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception",[92],"2018-02-28","2017-01-21",[3642],"Ovulation Inhibition",[3623,3644],"Meliane ED",{"trials":3646,"activeCount":100},[],{"intervention":3644,"totalTrials":139,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3663},{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[3659],{"nctId":3636,"briefTitle":3637,"status":376,"phases":3660,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":9,"conditions":3661,"interventions":3662},[92],[3642],[3623,3644],{"trials":3664,"activeCount":100},[],{"intervention":3666,"totalTrials":139,"cells":3667},"1 mg morphine soak in epidural oxidized cellulose",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3686},{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"trials":3673,"activeCount":100},[],{"trials":3675,"activeCount":100},[],{"trials":3677,"activeCount":100},[3678],{"nctId":3679,"briefTitle":3680,"status":376,"phases":3681,"primaryCompletion":871,"completion":3682,"start":1009,"enrollment":2292,"conditions":3683,"interventions":3684},"NCT02067338","Epidural Low Dose Morphine in Postoperative Pain After Posterior Lumbar Spinal Surgery",[92],"2014-01",[407],[3666,3685],"normal saline",{"trials":3687,"activeCount":100},[],{"intervention":877,"totalTrials":139,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3704},{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[3700],{"nctId":868,"briefTitle":869,"status":376,"phases":3701,"primaryCompletion":871,"completion":871,"start":872,"enrollment":694,"conditions":3702,"interventions":3703},[92],[874],[876,877],{"trials":3705,"activeCount":100},[],{"intervention":3707,"totalTrials":139,"cells":3708},"Ferli-6®",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3717,"NA":3729},{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[3719],{"nctId":3720,"briefTitle":3721,"status":376,"phases":3722,"primaryCompletion":1178,"completion":3723,"start":1471,"enrollment":1637,"conditions":3724,"interventions":3727},"NCT00746551","Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment",[92],"2010-04",[3725,3726],"Anemia","Pregnancy Complications",[3707,3728],"Venofer®",{"trials":3730,"activeCount":100},[],{"intervention":3728,"totalTrials":139,"cells":3732},{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3747},{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[3743],{"nctId":3720,"briefTitle":3721,"status":376,"phases":3744,"primaryCompletion":1178,"completion":3723,"start":1471,"enrollment":1637,"conditions":3745,"interventions":3746},[92],[3725,3726],[3707,3728],{"trials":3748,"activeCount":100},[],{"intervention":3750,"totalTrials":139,"cells":3751},"etomidate",{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3771},{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[3762],{"nctId":3763,"briefTitle":3764,"status":376,"phases":3765,"primaryCompletion":871,"completion":871,"start":3188,"enrollment":1018,"conditions":3766,"interventions":3769},"NCT01495949","The Cortisol Levels During Cardiac Surgery. The Comparison Between Etomidate and Thiopentone",[92],[3767,3768],"Coronary Artery Disease","Valvular Heart Disease",[3750,3770],"thiopentone",{"trials":3772,"activeCount":100},[],{"intervention":3770,"totalTrials":139,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3789},{"trials":3776,"activeCount":100},[],{"trials":3778,"activeCount":100},[],{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[3785],{"nctId":3763,"briefTitle":3764,"status":376,"phases":3786,"primaryCompletion":871,"completion":871,"start":3188,"enrollment":1018,"conditions":3787,"interventions":3788},[92],[3767,3768],[3750,3770],{"trials":3790,"activeCount":100},[],{"intervention":3792,"totalTrials":139,"cells":3793},"Amorolfine",{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3800,"PHASE4":3802,"NA":3813},{"trials":3795,"activeCount":100},[],{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[3804],{"nctId":3805,"briefTitle":3806,"status":376,"phases":3807,"primaryCompletion":3808,"completion":3809,"start":2660,"enrollment":1134,"conditions":3810,"interventions":3812},"NCT02812043","Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis",[92],"2019-06","2019-12",[3811],"Non-dermatophyte Onychomycosis",[3792],{"trials":3814,"activeCount":100},[],{"intervention":1220,"totalTrials":139,"cells":3816},{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3831},{"trials":3818,"activeCount":100},[],{"trials":3820,"activeCount":100},[],{"trials":3822,"activeCount":100},[],{"trials":3824,"activeCount":100},[],{"trials":3826,"activeCount":100},[3827],{"nctId":1212,"briefTitle":1213,"status":376,"phases":3828,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":787,"conditions":3829,"interventions":3830},[92],[1218],[1220,1221],{"trials":3832,"activeCount":100},[],{"intervention":3834,"totalTrials":139,"cells":3835},"Double dose of PPI",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3842,"PHASE4":3844,"NA":3858},{"trials":3837,"activeCount":100},[],{"trials":3839,"activeCount":100},[],{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":100},[3846],{"nctId":3847,"briefTitle":3848,"status":376,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":2317,"enrollment":1090,"conditions":3852,"interventions":3856},"NCT01888237","High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication",[92],"2014-08","2014-09",[3853,3854,3855],"Dyspepsia","Helicobacter-associated Gastritis","Stomach Disorders",[3834,3857],"sequence of drug use",{"trials":3859,"activeCount":100},[],{"intervention":3857,"totalTrials":139,"cells":3861},{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3868,"PHASE4":3870,"NA":3876},{"trials":3863,"activeCount":100},[],{"trials":3865,"activeCount":100},[],{"trials":3867,"activeCount":100},[],{"trials":3869,"activeCount":100},[],{"trials":3871,"activeCount":100},[3872],{"nctId":3847,"briefTitle":3848,"status":376,"phases":3873,"primaryCompletion":3850,"completion":3851,"start":2317,"enrollment":1090,"conditions":3874,"interventions":3875},[92],[3853,3854,3855],[3834,3857],{"trials":3877,"activeCount":100},[],{"intervention":3879,"totalTrials":409,"cells":3880},"Ivermectin",{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3906,"PHASE4":3918,"NA":3920},{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[3887,3897],{"nctId":3888,"briefTitle":3889,"status":110,"phases":3890,"primaryCompletion":3891,"completion":3891,"start":3892,"enrollment":3893,"conditions":3894,"interventions":3896},"NCT05155527","Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients",[90],"2022-06","2022-02-10",200,[3895],"COVID-19",[3879],{"nctId":3898,"briefTitle":3899,"status":376,"phases":3900,"primaryCompletion":3901,"completion":3901,"start":3902,"enrollment":600,"conditions":3903,"interventions":3905},"NCT03432442","Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients",[90],"2020-09-22","2018-09-04",[3904],"Dengue Hemorrhagic Fever",[3879],{"trials":3907,"activeCount":100},[3908],{"nctId":3909,"briefTitle":3910,"status":376,"phases":3911,"primaryCompletion":3723,"completion":3723,"start":3912,"enrollment":2729,"conditions":3913,"interventions":3915},"NCT00765024","Ivermectin Versus Albendazole for Chronic Strongyloidiasis",[91],"2008-07",[3914],"Chronic Strongyloidiasis",[3879,3916,3917],"ivermectin","Albendazole",{"trials":3919,"activeCount":100},[],{"trials":3921,"activeCount":100},[],{"intervention":3923,"totalTrials":96,"cells":3924},"GPO Tri Fluvac vaccine",{"EARLY_PHASE1":3925,"PHASE1":3927,"PHASE2":3929,"PHASE3":3931,"PHASE4":3953,"NA":3955},{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[3933,3944],{"nctId":3934,"briefTitle":3935,"status":376,"phases":3936,"primaryCompletion":3937,"completion":3938,"start":3939,"enrollment":3940,"conditions":3941,"interventions":3942},"NCT03390166","Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults",[90,91],"2018-03-31","2019-02-12","2017-07-24",945,[720],[3923,3943],"Licensed influenza vaccine",{"nctId":3945,"briefTitle":3946,"status":110,"phases":3947,"primaryCompletion":3948,"completion":445,"start":3949,"enrollment":3950,"conditions":3951,"interventions":3952},"NCT04548518","Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly",[91],"2023-06-30","2020-08-03",816,[720],[3923,3943],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"intervention":3943,"totalTrials":96,"cells":3958},{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3963,"PHASE3":3965,"PHASE4":3975,"NA":3977},{"trials":3960,"activeCount":100},[],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[3967,3971],{"nctId":3934,"briefTitle":3935,"status":376,"phases":3968,"primaryCompletion":3937,"completion":3938,"start":3939,"enrollment":3940,"conditions":3969,"interventions":3970},[90,91],[720],[3923,3943],{"nctId":3945,"briefTitle":3946,"status":110,"phases":3972,"primaryCompletion":3948,"completion":445,"start":3949,"enrollment":3950,"conditions":3973,"interventions":3974},[91],[720],[3923,3943],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[],{"intervention":3980,"totalTrials":96,"cells":3981},"Lactated Ringer's solution",{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3995,"PHASE3":3997,"PHASE4":4008,"NA":4010},{"trials":3983,"activeCount":100},[],{"trials":3985,"activeCount":100},[3986],{"nctId":3987,"briefTitle":3988,"status":110,"phases":3989,"primaryCompletion":3990,"completion":1283,"start":1728,"enrollment":2729,"conditions":3991,"interventions":3992},"NCT01250886","Acid-base Balance in Patients Undergoing Colonoscopy",[89],"2015-10",[2086,2087],[3980,3993,3994],"Normal saline solution","Acetate Ringer's solution",{"trials":3996,"activeCount":100},[],{"trials":3998,"activeCount":100},[3999],{"nctId":4000,"briefTitle":4001,"status":376,"phases":4002,"primaryCompletion":4003,"completion":4003,"start":3850,"enrollment":4004,"conditions":4005,"interventions":4007},"NCT02821546","Aggressive Fluid Hydration for the Prevention of Post-ERCP Pancreatitis",[91],"2017-02",286,[4006],"Pancreatitis",[3980],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[],{"intervention":4013,"totalTrials":96,"cells":4014},"Simvastatin",{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4040,"NA":4042},{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[4023,4031],{"nctId":4024,"briefTitle":4025,"status":376,"phases":4026,"primaryCompletion":3145,"completion":1282,"start":905,"enrollment":4027,"conditions":4028,"interventions":4029},"NCT01266434","The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma",[91],44,[31],[4013,4030],"B1-6-12",{"nctId":4032,"briefTitle":4033,"status":376,"phases":4034,"primaryCompletion":1422,"completion":4035,"start":1472,"enrollment":4036,"conditions":4037,"interventions":4038},"NCT00792337","The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma",[91],"2009-09",53,[31],[4039,4030],"simvastatin",{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"intervention":4030,"totalTrials":96,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4048,"PHASE2":4050,"PHASE3":4052,"PHASE4":4062,"NA":4064},{"trials":4047,"activeCount":100},[],{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[4054,4058],{"nctId":4024,"briefTitle":4025,"status":376,"phases":4055,"primaryCompletion":3145,"completion":1282,"start":905,"enrollment":4027,"conditions":4056,"interventions":4057},[91],[31],[4013,4030],{"nctId":4032,"briefTitle":4033,"status":376,"phases":4059,"primaryCompletion":1422,"completion":4035,"start":1472,"enrollment":4036,"conditions":4060,"interventions":4061},[91],[31],[4039,4030],{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"intervention":4067,"totalTrials":139,"cells":4068},"Omeprazole",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4075,"PHASE4":4088,"NA":4090},{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[4077],{"nctId":4078,"briefTitle":4079,"status":376,"phases":4080,"primaryCompletion":4081,"completion":4082,"start":4083,"enrollment":787,"conditions":4084,"interventions":4086},"NCT03205228","Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors",[91],"2018-06-26","2018-07-28","2017-07-07",[4085],"Globus",[4067,4087],"Flupentixol +Melitracen",{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"intervention":4087,"totalTrials":139,"cells":4093},{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4098,"PHASE3":4100,"PHASE4":4106,"NA":4108},{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[4102],{"nctId":4078,"briefTitle":4079,"status":376,"phases":4103,"primaryCompletion":4081,"completion":4082,"start":4083,"enrollment":787,"conditions":4104,"interventions":4105},[91],[4085],[4067,4087],{"trials":4107,"activeCount":100},[],{"trials":4109,"activeCount":100},[],{"intervention":4111,"totalTrials":139,"cells":4112},"2% chlorhexidine wipe",{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4117,"PHASE3":4119,"PHASE4":4130,"NA":4132},{"trials":4114,"activeCount":100},[],{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[4121],{"nctId":4122,"briefTitle":4123,"status":376,"phases":4124,"primaryCompletion":4125,"completion":1795,"start":871,"enrollment":4126,"conditions":4127,"interventions":4128},"NCT01989416","Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients",[91],"2015-01",481,[2836],[4111,4129],"Soap",{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"intervention":4129,"totalTrials":139,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4148,"NA":4150},{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[4144],{"nctId":4122,"briefTitle":4123,"status":376,"phases":4145,"primaryCompletion":4125,"completion":1795,"start":871,"enrollment":4126,"conditions":4146,"interventions":4147},[91],[2836],[4111,4129],{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"intervention":4153,"totalTrials":139,"cells":4154},"0.5% timolol maleate eye drop",{"EARLY_PHASE1":4155,"PHASE1":4157,"PHASE2":4159,"PHASE3":4161,"PHASE4":4171,"NA":4173},{"trials":4156,"activeCount":100},[],{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[4163],{"nctId":4164,"briefTitle":4165,"status":376,"phases":4166,"primaryCompletion":4167,"completion":4167,"start":3594,"enrollment":447,"conditions":4168,"interventions":4170},"NCT01685398","Topical Timolol for Superficial Infantile Hemangioma",[91],"2023-03",[4169],"Hemangioma",[4153,1071],{"trials":4172,"activeCount":100},[],{"trials":4174,"activeCount":100},[],{"intervention":4176,"totalTrials":139,"cells":4177},"Dexamethasone, desmopressin",{"EARLY_PHASE1":4178,"PHASE1":4180,"PHASE2":4182,"PHASE3":4184,"PHASE4":4195,"NA":4197},{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[4186],{"nctId":4187,"briefTitle":4188,"status":365,"phases":4189,"primaryCompletion":4190,"completion":4190,"start":4191,"enrollment":2591,"conditions":4192,"interventions":4194},"NCT00592566","Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis",[90,91],"2006-10","2003-07",[4193],"Leptospirosis",[4176],{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[],{"intervention":4200,"totalTrials":139,"cells":4201},"imipramine",{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4208,"PHASE4":4218,"NA":4220},{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[],{"trials":4209,"activeCount":100},[4210],{"nctId":4211,"briefTitle":4212,"status":376,"phases":4213,"primaryCompletion":4214,"completion":4214,"start":2834,"enrollment":8,"conditions":4215,"interventions":4217},"NCT01753128","Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity\u002F Functional Heartburn",[91],"2013-09",[4216],"Gastroesophageal Reflux Disease",[4200],{"trials":4219,"activeCount":100},[],{"trials":4221,"activeCount":100},[],{"intervention":4223,"totalTrials":139,"cells":4224},"Curcuma domestica extracts",{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4229,"PHASE3":4231,"PHASE4":4242,"NA":4244},{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[],{"trials":4230,"activeCount":100},[],{"trials":4232,"activeCount":100},[4233],{"nctId":4234,"briefTitle":4235,"status":376,"phases":4236,"primaryCompletion":2452,"completion":2452,"start":1472,"enrollment":4237,"conditions":4238,"interventions":4240},"NCT00792818","The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen in Knee Osteoarthritis",[91],367,[4239],"Osteoarthritis",[4223,4241],"Ibuprofen",{"trials":4243,"activeCount":100},[],{"trials":4245,"activeCount":100},[],{"intervention":4241,"totalTrials":139,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4252,"PHASE3":4254,"PHASE4":4260,"NA":4262},{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":100},[],{"trials":4255,"activeCount":100},[4256],{"nctId":4234,"briefTitle":4235,"status":376,"phases":4257,"primaryCompletion":2452,"completion":2452,"start":1472,"enrollment":4237,"conditions":4258,"interventions":4259},[91],[4239],[4223,4241],{"trials":4261,"activeCount":100},[],{"trials":4263,"activeCount":100},[],{"intervention":4265,"totalTrials":139,"cells":4266},"Urea cream",{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4273,"PHASE4":4286,"NA":4288},{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[],{"trials":4274,"activeCount":100},[4275],{"nctId":4276,"briefTitle":4277,"status":110,"phases":4278,"primaryCompletion":4279,"completion":4280,"start":4281,"enrollment":4282,"conditions":4283,"interventions":4285},"NCT05348278","Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome",[90,91],"2023-05","2023-08","2021-12-20",214,[4284],"Hand-Foot Syndrome",[4265],{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"intervention":4291,"totalTrials":139,"cells":4292},"Lidocaine",{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4297,"PHASE3":4299,"PHASE4":4312,"NA":4314},{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[4301],{"nctId":4302,"briefTitle":4303,"status":376,"phases":4304,"primaryCompletion":4305,"completion":4306,"start":4307,"enrollment":4308,"conditions":4309,"interventions":4311},"NCT02217267","Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain",[91],"2017-12-29","2018-02","2014-08-01",29,[4310],"Peripheral Neuropathy",[4291],{"trials":4313,"activeCount":100},[],{"trials":4315,"activeCount":100},[],{"intervention":4317,"totalTrials":139,"cells":4318},"curcumin",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4325,"PHASE4":4335,"NA":4337},{"trials":4320,"activeCount":100},[],{"trials":4322,"activeCount":100},[],{"trials":4324,"activeCount":100},[],{"trials":4326,"activeCount":100},[4327],{"nctId":4328,"briefTitle":4329,"status":376,"phases":4330,"completion":3468,"start":4331,"enrollment":2155,"conditions":4332,"interventions":4334},"NCT00528151","A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)",[91],"2005-05",[4333],"Optic Atrophy, Hereditary, Leber",[4317],{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[],{"intervention":4340,"totalTrials":139,"cells":4341},"sorafenib",{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4348,"PHASE4":4358,"NA":4360},{"trials":4343,"activeCount":100},[],{"trials":4345,"activeCount":100},[],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[4350],{"nctId":4351,"briefTitle":4352,"status":376,"phases":4353,"primaryCompletion":1422,"completion":1178,"start":4354,"enrollment":762,"conditions":4355,"interventions":4357},"NCT00478114","Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)",[91],"2007-05",[4356],"Renal Cell Carcinoma",[4340],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[],{"intervention":4363,"totalTrials":139,"cells":4364},"Inhaled colistin",{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4369,"PHASE3":4371,"PHASE4":4383,"NA":4385},{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[],{"trials":4372,"activeCount":100},[4373],{"nctId":4374,"briefTitle":4375,"status":110,"phases":4376,"primaryCompletion":2684,"completion":4377,"start":4378,"enrollment":4379,"conditions":4380,"interventions":4382},"NCT02619786","Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin",[91],"2017-12","2015-12",62,[4381],"Bronchitis",[4363],{"trials":4384,"activeCount":100},[],{"trials":4386,"activeCount":100},[],{"intervention":4388,"totalTrials":139,"cells":4389},"simvastatin, placebo",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4404,"NA":4406},{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[4398],{"nctId":4399,"briefTitle":4400,"status":376,"phases":4401,"primaryCompletion":3850,"completion":3850,"start":4214,"enrollment":600,"conditions":4402,"interventions":4403},"NCT01944176","The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients",[91],[577],[4388],{"trials":4405,"activeCount":100},[],{"trials":4407,"activeCount":100},[],{"intervention":1003,"totalTrials":139,"cells":4409},{"EARLY_PHASE1":4410,"PHASE1":4412,"PHASE2":4414,"PHASE3":4416,"PHASE4":4422,"NA":4424},{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[4418],{"nctId":996,"briefTitle":997,"status":110,"phases":4419,"primaryCompletion":871,"completion":871,"start":906,"enrollment":999,"conditions":4420,"interventions":4421},[91],[1001],[985,1003],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[],{"intervention":4427,"totalTrials":139,"cells":4428},"Vitamin D3",{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4435,"PHASE4":4444,"NA":4446},{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[4437],{"nctId":4438,"briefTitle":4439,"status":110,"phases":4440,"primaryCompletion":3400,"completion":3400,"start":3990,"enrollment":787,"conditions":4441,"interventions":4443},"NCT02594579","Effect of Vitamin D3 Supplementation on Muscle Mass in ICU Patient",[91],[4442,427,28],"Vitamin D Deficiency",[4427],{"trials":4445,"activeCount":100},[],{"trials":4447,"activeCount":100},[],{"intervention":4449,"totalTrials":139,"cells":4450},"Cream from Zingiber cassumunar Roxb. extract",{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4455,"PHASE3":4457,"PHASE4":4465,"NA":4467},{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":100},[],{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[4459],{"nctId":4460,"briefTitle":4461,"status":110,"phases":4462,"primaryCompletion":871,"completion":871,"start":2834,"enrollment":162,"conditions":4463,"interventions":4464},"NCT01794260","Efficacy and Safety of Topical Essential Oil Extracted From Zingiber Cassumunar Rokb in Osteoarthritis",[90,91],[4239],[4449],{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[],{"intervention":4470,"totalTrials":139,"cells":4471},"nebulized colistin",{"EARLY_PHASE1":4472,"PHASE1":4474,"PHASE2":4476,"PHASE3":4478,"PHASE4":4489,"NA":4491},{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[4480],{"nctId":4481,"briefTitle":4482,"status":110,"phases":4483,"primaryCompletion":1178,"start":4484,"enrollment":507,"conditions":4485,"interventions":4487},"NCT00920270","Nebulized Colistin for Hospital-Acquired Pneumonia",[91],"2006-06",[4486],"Pneumonia",[4470,4488],"antibiotics",{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[],{"intervention":4488,"totalTrials":139,"cells":4494},{"EARLY_PHASE1":4495,"PHASE1":4497,"PHASE2":4499,"PHASE3":4501,"PHASE4":4507,"NA":4509},{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[4503],{"nctId":4481,"briefTitle":4482,"status":110,"phases":4504,"primaryCompletion":1178,"start":4484,"enrollment":507,"conditions":4505,"interventions":4506},[91],[4486],[4470,4488],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"intervention":4512,"totalTrials":139,"cells":4513},"cimicifuga racemosa",{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4520,"PHASE4":4529,"NA":4531},{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":100},[],{"trials":4519,"activeCount":100},[],{"trials":4521,"activeCount":100},[4522],{"nctId":4523,"briefTitle":4524,"status":110,"phases":4525,"primaryCompletion":2452,"completion":2452,"start":3188,"enrollment":999,"conditions":4526,"interventions":4528},"NCT01487694","Black Cohosh Extract for the Management of Moderate to Severe Menopausal Symptoms in Thai Women",[91],[4527],"Hot Flashes",[4512],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"intervention":4534,"totalTrials":139,"cells":4535},"2 days Ivermectin",{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4542,"PHASE4":4553,"NA":4555},{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[4544],{"nctId":4545,"briefTitle":4546,"status":110,"phases":4547,"primaryCompletion":3145,"completion":1282,"start":3572,"enrollment":4548,"conditions":4549,"interventions":4551},"NCT02045069","Efficacy and Safety of Ivermectin Against Dengue Infection",[90,91],360,[4550],"Dengue Fever",[4534,4552],"3 days Ivermectin",{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"intervention":4552,"totalTrials":139,"cells":4558},{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4565,"PHASE4":4571,"NA":4573},{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[4567],{"nctId":4545,"briefTitle":4546,"status":110,"phases":4568,"primaryCompletion":3145,"completion":1282,"start":3572,"enrollment":4548,"conditions":4569,"interventions":4570},[90,91],[4550],[4534,4552],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[],{"intervention":4576,"totalTrials":139,"cells":4577},"Everolimus + low dose cyclosporin A + prednisolone",{"EARLY_PHASE1":4578,"PHASE1":4580,"PHASE2":4582,"PHASE3":4584,"PHASE4":4597,"NA":4599},{"trials":4579,"activeCount":100},[],{"trials":4581,"activeCount":100},[],{"trials":4583,"activeCount":100},[],{"trials":4585,"activeCount":100},[4586],{"nctId":4587,"briefTitle":4588,"status":110,"phases":4589,"primaryCompletion":4590,"completion":4590,"start":906,"enrollment":447,"conditions":4591,"interventions":4595},"NCT02314312","Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors",[91],"2015-06",[4592,4593,4594],"Transplantation of Kidney","Expanded Criteria Donor","ECD",[4576,4596],"Standard immunosupressive regimen",{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"intervention":4596,"totalTrials":139,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4607,"PHASE3":4609,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[],{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[4611],{"nctId":4587,"briefTitle":4588,"status":110,"phases":4612,"primaryCompletion":4590,"completion":4590,"start":906,"enrollment":447,"conditions":4613,"interventions":4614},[91],[4592,4593,4594],[4576,4596],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"intervention":4620,"totalTrials":139,"cells":4621},"Thiamine Mononitrate",{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4626,"PHASE3":4628,"PHASE4":4640,"NA":4642},{"trials":4623,"activeCount":100},[],{"trials":4625,"activeCount":100},[],{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[4630],{"nctId":4631,"briefTitle":4632,"status":110,"phases":4633,"primaryCompletion":4634,"completion":4635,"start":4636,"enrollment":1134,"conditions":4637,"interventions":4639},"NCT03989700","Effect of Thiamin Supplementation on Thiamin Status in Children With Heart Disease Receiving Diuretic Drugs",[91],"2020-06-30","2020-07-31","2019-07-01",[4638],"Heart Diseases",[4620],{"trials":4641,"activeCount":100},[],{"trials":4643,"activeCount":100},[],{"intervention":4645,"totalTrials":139,"cells":4646},"0.75% capsaicin nanoparticle cream",{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4651,"PHASE3":4653,"PHASE4":4663,"NA":4665},{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[4655],{"nctId":4656,"briefTitle":4657,"status":110,"phases":4658,"primaryCompletion":4659,"completion":871,"start":4035,"enrollment":1134,"conditions":4660,"interventions":4662},"NCT01125215","Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy",[90,91],"2013-10",[4661],"Painful Diabetic Neuropathy",[4645],{"trials":4664,"activeCount":100},[],{"trials":4666,"activeCount":100},[],{"intervention":1013,"totalTrials":139,"cells":4668},{"EARLY_PHASE1":4669,"PHASE1":4671,"PHASE2":4673,"PHASE3":4675,"PHASE4":4681,"NA":4683},{"trials":4670,"activeCount":100},[],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[4677],{"nctId":1005,"briefTitle":1006,"status":110,"phases":4678,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":953,"conditions":4679,"interventions":4680},[91],[1001],[985,1013],{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"intervention":1022,"totalTrials":139,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4693,"PHASE4":4699,"NA":4701},{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[],{"trials":4694,"activeCount":100},[4695],{"nctId":1015,"briefTitle":1016,"status":110,"phases":4696,"primaryCompletion":1008,"completion":1008,"start":1010,"enrollment":1018,"conditions":4697,"interventions":4698},[91],[1001],[1021,1022],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"intervention":4704,"totalTrials":139,"cells":4705},"Hyaluronic Acid",{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4712,"PHASE4":4725,"NA":4727},{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"trials":4713,"activeCount":100},[4714],{"nctId":4715,"briefTitle":4716,"status":110,"phases":4717,"primaryCompletion":4718,"completion":4719,"start":4720,"enrollment":2453,"conditions":4721,"interventions":4723},"NCT03131882","Efficacy of Ultrasound Guided Hyaluronic Injection in Treatment of Trigger Finger",[90,91],"2017-06-30","2017-09-30","2016-10-01",[4722],"Trigger Digit",[4704,4724],"Triamcinolone Acetonide",{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"intervention":4724,"totalTrials":139,"cells":4730},{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4735,"PHASE3":4737,"PHASE4":4743,"NA":4745},{"trials":4732,"activeCount":100},[],{"trials":4734,"activeCount":100},[],{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[4739],{"nctId":4715,"briefTitle":4716,"status":110,"phases":4740,"primaryCompletion":4718,"completion":4719,"start":4720,"enrollment":2453,"conditions":4741,"interventions":4742},[90,91],[4722],[4704,4724],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"intervention":4748,"totalTrials":139,"cells":4749},"Andrographis Paniculata",{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4769,"NA":4771},{"trials":4751,"activeCount":100},[],{"trials":4753,"activeCount":100},[],{"trials":4755,"activeCount":100},[],{"trials":4757,"activeCount":100},[4758],{"nctId":4759,"briefTitle":4760,"status":110,"phases":4761,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":4764,"conditions":4765,"interventions":4767},"NCT05019326","Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19",[91],"2022-05-30","2021-08-30",3060,[4766],"Covid19",[4748,4768],"Boesenbergia",{"trials":4770,"activeCount":100},[],{"trials":4772,"activeCount":100},[],{"intervention":4768,"totalTrials":139,"cells":4774},{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4779,"PHASE3":4781,"PHASE4":4787,"NA":4789},{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[],{"trials":4780,"activeCount":100},[],{"trials":4782,"activeCount":100},[4783],{"nctId":4759,"briefTitle":4760,"status":110,"phases":4784,"primaryCompletion":4762,"completion":4762,"start":4763,"enrollment":4764,"conditions":4785,"interventions":4786},[91],[4766],[4748,4768],{"trials":4788,"activeCount":100},[],{"trials":4790,"activeCount":100},[],{"intervention":3917,"totalTrials":139,"cells":4792},{"EARLY_PHASE1":4793,"PHASE1":4795,"PHASE2":4797,"PHASE3":4799,"PHASE4":4805,"NA":4807},{"trials":4794,"activeCount":100},[],{"trials":4796,"activeCount":100},[],{"trials":4798,"activeCount":100},[],{"trials":4800,"activeCount":100},[4801],{"nctId":3909,"briefTitle":3910,"status":376,"phases":4802,"primaryCompletion":3723,"completion":3723,"start":3912,"enrollment":2729,"conditions":4803,"interventions":4804},[91],[3914],[3879,3916,3917],{"trials":4806,"activeCount":100},[],{"trials":4808,"activeCount":100},[],{"intervention":4810,"totalTrials":139,"cells":4811},"Peripheral blood mononuclear cell",{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4830,"NA":4832},{"trials":4813,"activeCount":100},[],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[4820],{"nctId":4821,"briefTitle":4822,"status":376,"phases":4823,"primaryCompletion":4377,"completion":4377,"start":1187,"enrollment":29,"conditions":4824,"interventions":4829},"NCT01833585","Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells",[91],[4825,4826,4827,4828],"Critical Limb Ischemia","Atherosclerosis","Ischemic Ulcer","Gangrene",[4810],{"trials":4831,"activeCount":100},[],{"trials":4833,"activeCount":100},[],{"intervention":4835,"totalTrials":139,"cells":4836},"Commercial Hepatitis B vaccine",{"EARLY_PHASE1":4837,"PHASE1":4839,"PHASE2":4841,"PHASE3":4843,"PHASE4":4855,"NA":4857},{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[],{"trials":4844,"activeCount":100},[4845],{"nctId":4846,"briefTitle":4847,"status":110,"phases":4848,"primaryCompletion":3639,"completion":4849,"start":4850,"enrollment":4851,"conditions":4852,"interventions":4854},"NCT03405597","HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg",[91],"2018-06-30","2017-03-30",97,[4853],"Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine",[4835],{"trials":4856,"activeCount":100},[],{"trials":4858,"activeCount":100},[],{"intervention":4860,"totalTrials":139,"cells":4861},"10% Argireline",{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4868,"PHASE4":4878,"NA":4880},{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[4870],{"nctId":4871,"briefTitle":4872,"status":376,"phases":4873,"primaryCompletion":4035,"completion":4035,"start":4874,"enrollment":2155,"conditions":4875,"interventions":4877},"NCT01381484","Argireline in Treatment of Periorbital Wrinkles",[91],"2009-03",[4876],"Wrinkles",[4860],{"trials":4879,"activeCount":100},[],{"trials":4881,"activeCount":100},[],{"intervention":478,"totalTrials":139,"cells":4883},{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4890,"PHASE4":4896,"NA":4898},{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":100},[],{"trials":4891,"activeCount":100},[4892],{"nctId":468,"briefTitle":469,"status":110,"phases":4893,"primaryCompletion":471,"completion":472,"start":473,"enrollment":474,"conditions":4894,"interventions":4895},[91],[476],[478,479,457],{"trials":4897,"activeCount":100},[],{"trials":4899,"activeCount":100},[],{"intervention":479,"totalTrials":139,"cells":4901},{"EARLY_PHASE1":4902,"PHASE1":4904,"PHASE2":4906,"PHASE3":4908,"PHASE4":4914,"NA":4916},{"trials":4903,"activeCount":100},[],{"trials":4905,"activeCount":100},[],{"trials":4907,"activeCount":100},[],{"trials":4909,"activeCount":100},[4910],{"nctId":468,"briefTitle":469,"status":110,"phases":4911,"primaryCompletion":471,"completion":472,"start":473,"enrollment":474,"conditions":4912,"interventions":4913},[91],[476],[478,479,457],{"trials":4915,"activeCount":100},[],{"trials":4917,"activeCount":100},[],{"intervention":4919,"totalTrials":139,"cells":4920},"Mitomicin C",{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4927,"PHASE4":4940,"NA":4942},{"trials":4922,"activeCount":100},[],{"trials":4924,"activeCount":100},[],{"trials":4926,"activeCount":100},[],{"trials":4928,"activeCount":100},[4929],{"nctId":4930,"briefTitle":4931,"status":376,"phases":4932,"primaryCompletion":4933,"completion":4933,"start":1662,"enrollment":4934,"conditions":4935,"interventions":4938},"NCT02106793","Mitomicin C for Prevention Postoperative Endoscopic Sinus Surgery Synechia and QOL in Chronic Rhinosinusitis",[91],"2017-12-01",224,[4936,4937],"Chronic Rhinosinusitis","Postoperative Nasal Synerchia",[4919,4939],"Identical placebo solution",{"trials":4941,"activeCount":100},[],{"trials":4943,"activeCount":100},[],{"intervention":4939,"totalTrials":139,"cells":4945},{"EARLY_PHASE1":4946,"PHASE1":4948,"PHASE2":4950,"PHASE3":4952,"PHASE4":4958,"NA":4960},{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[],{"trials":4953,"activeCount":100},[4954],{"nctId":4930,"briefTitle":4931,"status":376,"phases":4955,"primaryCompletion":4933,"completion":4933,"start":1662,"enrollment":4934,"conditions":4956,"interventions":4957},[91],[4936,4937],[4919,4939],{"trials":4959,"activeCount":100},[],{"trials":4961,"activeCount":100},[],{"intervention":4963,"totalTrials":139,"cells":4964},"Magnesium group",{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4971,"PHASE4":4983,"NA":4985},{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[4973],{"nctId":4974,"briefTitle":4975,"status":376,"phases":4976,"primaryCompletion":4977,"completion":4978,"start":1295,"enrollment":1637,"conditions":4979,"interventions":4981},"NCT03558516","Magnesium and Intraoperative Blood Loss in Meningioma Surgery",[91],"2020-02-03","2020-02-18",[4980],"Meningioma",[4963,4982],"Normal saline group",{"trials":4984,"activeCount":100},[],{"trials":4986,"activeCount":100},[],{"intervention":4982,"totalTrials":139,"cells":4988},{"EARLY_PHASE1":4989,"PHASE1":4991,"PHASE2":4993,"PHASE3":4995,"PHASE4":5001,"NA":5003},{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[4997],{"nctId":4974,"briefTitle":4975,"status":376,"phases":4998,"primaryCompletion":4977,"completion":4978,"start":1295,"enrollment":1637,"conditions":4999,"interventions":5000},[91],[4980],[4963,4982],{"trials":5002,"activeCount":100},[],{"trials":5004,"activeCount":100},[],{"intervention":5006,"totalTrials":139,"cells":5007},"Intranasal Drug",{"EARLY_PHASE1":5008,"PHASE1":5010,"PHASE2":5012,"PHASE3":5014,"PHASE4":5028,"NA":5030},{"trials":5009,"activeCount":100},[],{"trials":5011,"activeCount":100},[],{"trials":5013,"activeCount":100},[],{"trials":5015,"activeCount":100},[5016],{"nctId":5017,"briefTitle":5018,"status":376,"phases":5019,"primaryCompletion":5020,"completion":5021,"start":5022,"enrollment":5023,"conditions":5024,"interventions":5027},"NCT05299086","As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis",[91],"2025-03-30","2025-04-30","2022-04-04",68,[5025,5026],"Perennial Allergic Rhinitis","Child, Only",[5006],{"trials":5029,"activeCount":100},[],{"trials":5031,"activeCount":100},[],{"intervention":5033,"totalTrials":139,"cells":5034},"Intra-articular Hyaluronic Acid and Ketorolac",{"EARLY_PHASE1":5035,"PHASE1":5037,"PHASE2":5039,"PHASE3":5041,"PHASE4":5054,"NA":5056},{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[],{"trials":5042,"activeCount":100},[5043],{"nctId":5044,"briefTitle":5045,"status":376,"phases":5046,"primaryCompletion":5047,"completion":5047,"start":5048,"enrollment":5049,"conditions":5050,"interventions":5052},"NCT07183436","Intra-articular Corticosteroids Are Widely Used for Adhesive Capsulitis, But Alternatives Are Required for Patients With Contraindications. Hyaluronic Acid (HA) and Ketorolac Have Shown Individual Benefits. However, Evidence on Their Combination Remains Limited.",[91],"2025-07-01","2023-11-01",56,[5051],"Adhesive Capsulitis of the Shoulder",[5033,5053],"Intra-articular Ketorolac",{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":100},[],{"intervention":5053,"totalTrials":139,"cells":5059},{"EARLY_PHASE1":5060,"PHASE1":5062,"PHASE2":5064,"PHASE3":5066,"PHASE4":5072,"NA":5074},{"trials":5061,"activeCount":100},[],{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[],{"trials":5067,"activeCount":100},[5068],{"nctId":5044,"briefTitle":5045,"status":376,"phases":5069,"primaryCompletion":5047,"completion":5047,"start":5048,"enrollment":5049,"conditions":5070,"interventions":5071},[91],[5051],[5033,5053],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"intervention":5077,"totalTrials":139,"cells":5078},"Budesonide",{"EARLY_PHASE1":5079,"PHASE1":5081,"PHASE2":5083,"PHASE3":5085,"PHASE4":5096,"NA":5098},{"trials":5080,"activeCount":100},[],{"trials":5082,"activeCount":100},[],{"trials":5084,"activeCount":100},[],{"trials":5086,"activeCount":100},[5087],{"nctId":5088,"briefTitle":5089,"status":376,"phases":5090,"primaryCompletion":5091,"completion":2178,"start":5092,"enrollment":1565,"conditions":5093,"interventions":5095},"NCT00826163","Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],"2009-11","2009-01",[5094],"Chronic Obstructive Pulmonary Disease",[5077],{"trials":5097,"activeCount":100},[],{"trials":5099,"activeCount":100},[],{"intervention":5101,"totalTrials":139,"cells":5102},"JEVAC",{"EARLY_PHASE1":5103,"PHASE1":5105,"PHASE2":5107,"PHASE3":5109,"PHASE4":5119,"NA":5121},{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[5111],{"nctId":5112,"briefTitle":5113,"status":376,"phases":5114,"primaryCompletion":2452,"completion":2834,"start":5115,"enrollment":908,"conditions":5116,"interventions":5118},"NCT01408537","Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children",[91],"2010-05",[5117],"Encephalitis, Japanese B",[5101],{"trials":5120,"activeCount":100},[],{"trials":5122,"activeCount":100},[],{"intervention":5124,"totalTrials":139,"cells":5125},"Sereflo",{"EARLY_PHASE1":5126,"PHASE1":5128,"PHASE2":5130,"PHASE3":5132,"PHASE4":5143,"NA":5145},{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[],{"trials":5133,"activeCount":100},[5134],{"nctId":5135,"briefTitle":5136,"status":376,"phases":5137,"primaryCompletion":1187,"completion":3187,"start":5138,"enrollment":5139,"conditions":5140,"interventions":5141},"NCT01274325","Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma",[91],"2011-02",51,[31],[5124,5142],"Seretide",{"trials":5144,"activeCount":100},[],{"trials":5146,"activeCount":100},[],{"intervention":5142,"totalTrials":139,"cells":5148},{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5155,"PHASE4":5161,"NA":5163},{"trials":5150,"activeCount":100},[],{"trials":5152,"activeCount":100},[],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[5157],{"nctId":5135,"briefTitle":5136,"status":376,"phases":5158,"primaryCompletion":1187,"completion":3187,"start":5138,"enrollment":5139,"conditions":5159,"interventions":5160},[91],[31],[5124,5142],{"trials":5162,"activeCount":100},[],{"trials":5164,"activeCount":100},[],{"intervention":5166,"totalTrials":139,"cells":5167},"Medroxyprogesterone acetate",{"EARLY_PHASE1":5168,"PHASE1":5170,"PHASE2":5172,"PHASE3":5174,"PHASE4":5185,"NA":5187},{"trials":5169,"activeCount":100},[],{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[5176],{"nctId":5177,"briefTitle":5178,"status":110,"phases":5179,"primaryCompletion":1589,"completion":5180,"start":1333,"enrollment":301,"conditions":5181,"interventions":5183},"NCT02103764","Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB",[91],"2018-12",[5182],"Dysfunctional Uterine Bleeding",[5184,5166],"Desogestrel",{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[],{"intervention":5190,"totalTrials":139,"cells":5191},"Derris scandens Benth extracts",{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5198,"PHASE4":5209,"NA":5211},{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[],{"trials":5199,"activeCount":100},[5200],{"nctId":5201,"briefTitle":5202,"status":376,"phases":5203,"primaryCompletion":4874,"completion":4874,"start":5204,"enrollment":2453,"conditions":5205,"interventions":5207},"NCT00503828","Derris Scandens Benth Extract VS Naproxen in Knee OA",[91],"2007-07",[5206],"Knee Osteoarthritis",[5190,5208],"naproxen",{"trials":5210,"activeCount":100},[],{"trials":5212,"activeCount":100},[],{"intervention":5208,"totalTrials":139,"cells":5214},{"EARLY_PHASE1":5215,"PHASE1":5217,"PHASE2":5219,"PHASE3":5221,"PHASE4":5227,"NA":5229},{"trials":5216,"activeCount":100},[],{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"trials":5222,"activeCount":100},[5223],{"nctId":5201,"briefTitle":5202,"status":376,"phases":5224,"primaryCompletion":4874,"completion":4874,"start":5204,"enrollment":2453,"conditions":5225,"interventions":5226},[91],[5206],[5190,5208],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[],{"intervention":5232,"totalTrials":139,"cells":5233},"100% Autologous platelet rich plasma",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5253,"NA":5255},{"trials":5235,"activeCount":100},[],{"trials":5237,"activeCount":100},[],{"trials":5239,"activeCount":100},[],{"trials":5241,"activeCount":100},[5242],{"nctId":5243,"briefTitle":5244,"status":376,"phases":5245,"primaryCompletion":5246,"completion":5247,"start":5248,"enrollment":1319,"conditions":5249,"interventions":5251},"NCT04683796","Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease",[91],"2023-02-28","2023-03-30","2021-02-01",[5250],"Dry Eye Disease",[5232,5252],"100% Autologous serum",{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"intervention":5252,"totalTrials":139,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5271,"NA":5273},{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[5267],{"nctId":5243,"briefTitle":5244,"status":376,"phases":5268,"primaryCompletion":5246,"completion":5247,"start":5248,"enrollment":1319,"conditions":5269,"interventions":5270},[91],[5250],[5232,5252],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"intervention":5276,"totalTrials":139,"cells":5277},"Nail gel",{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5284,"PHASE4":5293,"NA":5295},{"trials":5279,"activeCount":100},[],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[5286],{"nctId":5287,"briefTitle":5288,"status":110,"phases":5289,"primaryCompletion":1282,"completion":2290,"start":1317,"enrollment":1565,"conditions":5290,"interventions":5292},"NCT02582762","Pilot Study of Efficacy of Nail Gel in Finger Nail Surface Abnormality",[91],[5291],"Nail Abnormalities",[5276],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"intervention":5298,"totalTrials":139,"cells":5299},"Supplemental 3LPM oxygen via canula",{"EARLY_PHASE1":5300,"PHASE1":5302,"PHASE2":5304,"PHASE3":5306,"PHASE4":5317,"NA":5319},{"trials":5301,"activeCount":100},[],{"trials":5303,"activeCount":100},[],{"trials":5305,"activeCount":100},[],{"trials":5307,"activeCount":100},[5308],{"nctId":5309,"briefTitle":5310,"status":376,"phases":5311,"primaryCompletion":5312,"completion":5312,"start":1950,"enrollment":5313,"conditions":5314,"interventions":5316},"NCT01530971","Effect of Maternal and Neonatal Oxygenation",[91],"2013-03",325,[5315],"Peer Review, Research",[5298],{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[],{"intervention":5322,"totalTrials":96,"cells":5323},"Avian Flu Vaccine",{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5335,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[5328],{"nctId":5329,"briefTitle":5330,"status":376,"phases":5331,"primaryCompletion":1009,"start":1008,"conditions":5332,"interventions":5334},"NCT01656356","Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A\u002F17\u002FTurkey\u002FTurkey\u002F05\u002F133 (H5N2) in Healthy Thai Volunteers",[89],[5333],"Preventive Avian Flu",[5322],{"trials":5336,"activeCount":100},[5337],{"nctId":5338,"briefTitle":5339,"status":376,"phases":5340,"primaryCompletion":2317,"completion":1188,"start":5341,"enrollment":5342,"conditions":5343,"interventions":5345},"NCT01841918","Safety and Immunogenicity of Live Attenuated Influenza H5N2",[90],"2013-01",150,[5344],"Influenza Due to Influenza A Virus Subtype H5N2",[5322],{"trials":5347,"activeCount":100},[],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"intervention":5353,"totalTrials":96,"cells":5354},"normal saline solution",{"EARLY_PHASE1":5355,"PHASE1":5357,"PHASE2":5363,"PHASE3":5381,"PHASE4":5383,"NA":5385},{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[5359],{"nctId":3987,"briefTitle":3988,"status":110,"phases":5360,"primaryCompletion":3990,"completion":1283,"start":1728,"enrollment":2729,"conditions":5361,"interventions":5362},[89],[2086,2087],[3980,3993,3994],{"trials":5364,"activeCount":100},[5365],{"nctId":5366,"briefTitle":5367,"status":110,"phases":5368,"primaryCompletion":5369,"completion":5370,"start":5371,"enrollment":301,"conditions":5372,"interventions":5379},"NCT05818826","Early Versus Conventional Cessation of Hydrocortisone in Septic Shock",[90],"2025-04","2025-05","2023-07-05",[15,5373,5374,5375,5376,5377,5378],"Adverse Event","Hydrocortisone","Hyperglycemia","Hypernatremia","Muscle Weakness","Superimposed Infection",[5353,5380],"Hydrocortisone and normal saline solution",{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[],{"trials":5386,"activeCount":100},[],{"intervention":5388,"totalTrials":139,"cells":5389},"Sevoflurane",{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5406,"PHASE4":5408,"NA":5410},{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[],{"trials":5395,"activeCount":100},[5396],{"nctId":5397,"briefTitle":5398,"status":376,"phases":5399,"primaryCompletion":5400,"completion":5400,"start":5401,"enrollment":787,"conditions":5402,"interventions":5404},"NCT02559297","Effects of Sevoflurane and Desflurane on Treg",[90],"2017-06-03","2015-08-10",[5403],"Transplant; Failure, Kidney",[5388,5405],"Desflurane",{"trials":5407,"activeCount":100},[],{"trials":5409,"activeCount":100},[],{"trials":5411,"activeCount":100},[],{"intervention":5405,"totalTrials":139,"cells":5413},{"EARLY_PHASE1":5414,"PHASE1":5416,"PHASE2":5418,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5415,"activeCount":100},[],{"trials":5417,"activeCount":100},[],{"trials":5419,"activeCount":100},[5420],{"nctId":5397,"briefTitle":5398,"status":376,"phases":5421,"primaryCompletion":5400,"completion":5400,"start":5401,"enrollment":787,"conditions":5422,"interventions":5423},[90],[5403],[5388,5405],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[],{"intervention":5431,"totalTrials":139,"cells":5432},"Milrinone",{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5437,"PHASE3":5448,"PHASE4":5450,"NA":5452},{"trials":5434,"activeCount":100},[],{"trials":5436,"activeCount":100},[],{"trials":5438,"activeCount":100},[5439],{"nctId":5440,"briefTitle":5441,"status":110,"phases":5442,"primaryCompletion":5443,"completion":5444,"start":5445,"enrollment":2591,"conditions":5446,"interventions":5447},"NCT05122884","Milrinone Versus Placebo in Patients With Septic Shock",[90],"2024-12","2025-06","2021-12-01",[15,2500],[5431],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"trials":5453,"activeCount":100},[],{"intervention":5455,"totalTrials":139,"cells":5456},"conventional liberal fluid regimen",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5471,"PHASE4":5473,"NA":5475},{"trials":5458,"activeCount":100},[],{"trials":5460,"activeCount":100},[],{"trials":5462,"activeCount":100},[5463],{"nctId":5464,"briefTitle":5465,"status":110,"phases":5466,"primaryCompletion":1188,"completion":4214,"start":2858,"enrollment":787,"conditions":5467,"interventions":5469},"NCT01350076","Liberal Versus Goal-directed Intraoperative Fluid Therapy in Pediatric Patients",[90],[5468],"Adverse Anesthesia Outcome",[5455,5470],"restricted fluid regimen",{"trials":5472,"activeCount":100},[],{"trials":5474,"activeCount":100},[],{"trials":5476,"activeCount":100},[],{"intervention":5470,"totalTrials":139,"cells":5478},{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5489,"PHASE4":5491,"NA":5493},{"trials":5480,"activeCount":100},[],{"trials":5482,"activeCount":100},[],{"trials":5484,"activeCount":100},[5485],{"nctId":5464,"briefTitle":5465,"status":110,"phases":5486,"primaryCompletion":1188,"completion":4214,"start":2858,"enrollment":787,"conditions":5487,"interventions":5488},[90],[5468],[5455,5470],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[],{"intervention":5496,"totalTrials":139,"cells":5497},"Full dose of Ad26.COV2. 5x10^10vp",{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5502,"PHASE3":5514,"PHASE4":5516,"NA":5518},{"trials":5499,"activeCount":100},[],{"trials":5501,"activeCount":100},[],{"trials":5503,"activeCount":100},[5504],{"nctId":5505,"briefTitle":5506,"status":110,"phases":5507,"primaryCompletion":5508,"completion":5443,"start":4281,"enrollment":5509,"conditions":5510,"interventions":5512},"NCT05109559","Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine",[89,90],"2023-12",690,[5511],"SARS-CoV-2 Infection",[5496,5513,5496],"Half dose of Ad26.COV2. 2.5x10^10vp",{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[],{"trials":5519,"activeCount":100},[],{"intervention":5513,"totalTrials":139,"cells":5521},{"EARLY_PHASE1":5522,"PHASE1":5524,"PHASE2":5526,"PHASE3":5532,"PHASE4":5534,"NA":5536},{"trials":5523,"activeCount":100},[],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[5528],{"nctId":5505,"briefTitle":5506,"status":110,"phases":5529,"primaryCompletion":5508,"completion":5443,"start":4281,"enrollment":5509,"conditions":5530,"interventions":5531},[89,90],[5511],[5496,5513,5496],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[],{"intervention":5539,"totalTrials":139,"cells":5540},"NDV-HXP-S vaccine",{"EARLY_PHASE1":5541,"PHASE1":5543,"PHASE2":5545,"PHASE3":5561,"PHASE4":5563,"NA":5565},{"trials":5542,"activeCount":100},[],{"trials":5544,"activeCount":100},[],{"trials":5546,"activeCount":100},[5547],{"nctId":5548,"briefTitle":5549,"status":376,"phases":5550,"primaryCompletion":5551,"completion":5551,"start":5552,"enrollment":5553,"conditions":5554,"interventions":5559},"NCT04764422","Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand",[89,90],"2022-09-12","2021-03-20",455,[5555,5556,5557,5558],"Covid-19","SARS Pneumonia","Pneumonia, Viral","Covid-19 Vaccine",[5560,5539],"Normal Saline",{"trials":5562,"activeCount":100},[],{"trials":5564,"activeCount":100},[],{"trials":5566,"activeCount":100},[],{"intervention":5568,"totalTrials":139,"cells":5569},"Sorafenib and Gemcitabine",{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5574,"PHASE3":5585,"PHASE4":5587,"NA":5589},{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[],{"trials":5575,"activeCount":100},[5576],{"nctId":5577,"briefTitle":5578,"status":376,"phases":5579,"primaryCompletion":907,"completion":5580,"start":1729,"enrollment":5581,"conditions":5582,"interventions":5584},"NCT00703365","Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)",[90],"2011-08",45,[5583],"Carcinoma, Hepatocellular",[5568],{"trials":5586,"activeCount":100},[],{"trials":5588,"activeCount":100},[],{"trials":5590,"activeCount":100},[],{"intervention":5592,"totalTrials":139,"cells":5593},"Terlipressin",{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5598,"PHASE3":5610,"PHASE4":5612,"NA":5614},{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":100},[],{"trials":5599,"activeCount":100},[5600],{"nctId":5601,"briefTitle":5602,"status":110,"phases":5603,"primaryCompletion":5604,"completion":716,"start":5605,"enrollment":953,"conditions":5606,"interventions":5609},"NCT04339868","Terlipressin for Refractory Septic Shock",[90],"2025-03-31","2020-04-03",[15,5607,5608],"Refractory Shock","Norepinephrine Adverse Reaction",[5592],{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"intervention":5617,"totalTrials":139,"cells":5618},"chemotherapy followed by Zevalin",{"EARLY_PHASE1":5619,"PHASE1":5621,"PHASE2":5623,"PHASE3":5633,"PHASE4":5635,"NA":5637},{"trials":5620,"activeCount":100},[],{"trials":5622,"activeCount":100},[],{"trials":5624,"activeCount":100},[5625],{"nctId":5626,"briefTitle":5627,"status":376,"phases":5628,"primaryCompletion":2727,"completion":1008,"start":5629,"enrollment":762,"conditions":5630,"interventions":5632},"NCT00440583","The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP",[90],"2006-09",[5631],"Diffuse Large B-cell Lymphoma",[5617],{"trials":5634,"activeCount":100},[],{"trials":5636,"activeCount":100},[],{"trials":5638,"activeCount":100},[],{"intervention":5640,"totalTrials":139,"cells":5641},"Epinephrine or normal saline",{"EARLY_PHASE1":5642,"PHASE1":5644,"PHASE2":5646,"PHASE3":5660,"PHASE4":5662,"NA":5664},{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[5648],{"nctId":5649,"briefTitle":5650,"status":376,"phases":5651,"primaryCompletion":5652,"completion":5653,"start":5654,"enrollment":5655,"conditions":5656,"interventions":5659},"NCT03963115","Can Epinephrine Coated Syringe for Subcutaneous Immunotherapy (SCIT) Reduce Large Local Reaction?",[89,90],"2019-08-25","2019-09-01","2018-10-24",17,[5657,5658],"Injection Reactions Site","Systemic Reactions",[5640],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[],{"trials":5665,"activeCount":100},[],{"intervention":1324,"totalTrials":139,"cells":5667},{"EARLY_PHASE1":5668,"PHASE1":5670,"PHASE2":5672,"PHASE3":5678,"PHASE4":5680,"NA":5682},{"trials":5669,"activeCount":100},[],{"trials":5671,"activeCount":100},[],{"trials":5673,"activeCount":100},[5674],{"nctId":1314,"briefTitle":1315,"status":110,"phases":5675,"primaryCompletion":1317,"completion":1318,"start":1237,"enrollment":1319,"conditions":5676,"interventions":5677},[90],[1321,1322],[1324,1305],{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[],{"trials":5683,"activeCount":100},[],{"intervention":5380,"totalTrials":139,"cells":5685},{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5696,"PHASE4":5698,"NA":5700},{"trials":5687,"activeCount":100},[],{"trials":5689,"activeCount":100},[],{"trials":5691,"activeCount":100},[5692],{"nctId":5366,"briefTitle":5367,"status":110,"phases":5693,"primaryCompletion":5369,"completion":5370,"start":5371,"enrollment":301,"conditions":5694,"interventions":5695},[90],[15,5373,5374,5375,5376,5377,5378],[5353,5380],{"trials":5697,"activeCount":100},[],{"trials":5699,"activeCount":100},[],{"trials":5701,"activeCount":100},[],{"intervention":5703,"totalTrials":139,"cells":5704},"an inactivated influenza vaccine",{"EARLY_PHASE1":5705,"PHASE1":5707,"PHASE2":5709,"PHASE3":5720,"PHASE4":5722,"NA":5724},{"trials":5706,"activeCount":100},[],{"trials":5708,"activeCount":100},[],{"trials":5710,"activeCount":100},[5711],{"nctId":5712,"briefTitle":5713,"status":376,"phases":5714,"primaryCompletion":5715,"completion":5716,"start":1975,"enrollment":5717,"conditions":5718,"interventions":5719},"NCT02894840","Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults",[89,90],"2016-07","2016-11",340,[720],[5703],{"trials":5721,"activeCount":100},[],{"trials":5723,"activeCount":100},[],{"trials":5725,"activeCount":100},[],{"intervention":5727,"totalTrials":139,"cells":5728},"Palbociclib",{"EARLY_PHASE1":5729,"PHASE1":5731,"PHASE2":5733,"PHASE3":5746,"PHASE4":5748,"NA":5750},{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[5735],{"nctId":5736,"briefTitle":5737,"status":110,"phases":5738,"primaryCompletion":5739,"completion":2081,"start":5740,"enrollment":668,"conditions":5741,"interventions":5744},"NCT03024489","Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma",[89,90],"2024-03-11","2017-07-19",[5742,5743],"Head and Neck Cancer","Locally Advanced",[5727,5727,5727,5727,5745],"Cetuximab",{"trials":5747,"activeCount":100},[],{"trials":5749,"activeCount":100},[],{"trials":5751,"activeCount":100},[],{"intervention":5745,"totalTrials":139,"cells":5753},{"EARLY_PHASE1":5754,"PHASE1":5756,"PHASE2":5758,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5755,"activeCount":100},[],{"trials":5757,"activeCount":100},[],{"trials":5759,"activeCount":100},[5760],{"nctId":5736,"briefTitle":5737,"status":110,"phases":5761,"primaryCompletion":5739,"completion":2081,"start":5740,"enrollment":668,"conditions":5762,"interventions":5763},[89,90],[5742,5743],[5727,5727,5727,5727,5745],{"trials":5765,"activeCount":100},[],{"trials":5767,"activeCount":100},[],{"trials":5769,"activeCount":100},[],{"intervention":5771,"totalTrials":139,"cells":5772},"mirtazapine",{"EARLY_PHASE1":5773,"PHASE1":5775,"PHASE2":5777,"PHASE3":5786,"PHASE4":5788,"NA":5790},{"trials":5774,"activeCount":100},[],{"trials":5776,"activeCount":100},[],{"trials":5778,"activeCount":100},[5779],{"nctId":5780,"briefTitle":5781,"status":376,"phases":5782,"primaryCompletion":2858,"completion":3188,"start":1472,"enrollment":1637,"conditions":5783,"interventions":5785},"NCT00919295","Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome",[90],[5784],"Fibromyalgia Syndrome",[5771],{"trials":5787,"activeCount":100},[],{"trials":5789,"activeCount":100},[],{"trials":5791,"activeCount":100},[],{"intervention":5793,"totalTrials":139,"cells":5794},"Ipomea pes-caprae ointment",{"EARLY_PHASE1":5795,"PHASE1":5797,"PHASE2":5799,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5796,"activeCount":100},[],{"trials":5798,"activeCount":100},[],{"trials":5800,"activeCount":100},[5801],{"nctId":5802,"briefTitle":5803,"status":376,"phases":5804,"primaryCompletion":5805,"completion":5805,"start":3375,"enrollment":999,"conditions":5806,"interventions":5809},"NCT00944203","Efficacy of Ipomea Pes-caprae Ointment as an add-on Therapy in Patient With Jellyfish Dermatitis",[90],"2017-03",[5807,5808],"Jellyfish Dermatitis","Jellyfish Venoms",[5793],{"trials":5811,"activeCount":100},[],{"trials":5813,"activeCount":100},[],{"trials":5815,"activeCount":100},[],{"intervention":5817,"totalTrials":139,"cells":5818},"Rosiglitazone",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5835,"PHASE4":5837,"NA":5839},{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[],{"trials":5824,"activeCount":100},[5825],{"nctId":5826,"briefTitle":5827,"status":376,"phases":5828,"primaryCompletion":5829,"completion":5830,"start":5831,"enrollment":507,"conditions":5832,"interventions":5834},"NCT00149383","Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria",[89,90],"2005-11","2006-01","2004-12",[5833],"Falciparum Malaria",[5817],{"trials":5836,"activeCount":100},[],{"trials":5838,"activeCount":100},[],{"trials":5840,"activeCount":100},[],{"intervention":5842,"totalTrials":139,"cells":5843},"Rabies vaccine",{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5848,"PHASE3":5859,"PHASE4":5861,"NA":5863},{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[5850],{"nctId":5851,"briefTitle":5852,"status":376,"phases":5853,"primaryCompletion":5854,"completion":3469,"start":5855,"enrollment":3893,"conditions":5856,"interventions":5858},"NCT00703521","Rabies Immunization Concomitant With JEV in Children",[90],"2002-10","2002-08",[5857],"Rabies",[5842],{"trials":5860,"activeCount":100},[],{"trials":5862,"activeCount":100},[],{"trials":5864,"activeCount":100},[],{"intervention":5866,"totalTrials":139,"cells":5867},"Bortezomib",{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5885,"PHASE4":5887,"NA":5889},{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[5874],{"nctId":5875,"briefTitle":5876,"status":110,"phases":5877,"primaryCompletion":5878,"completion":5879,"start":5880,"enrollment":828,"conditions":5881,"interventions":5883},"NCT03103555","Treatment of Adult-Onset Immunodeficiency With Bortezomib",[90],"2018-11-01","2019-11-01","2017-02-27",[5882],"Adult-onset Immunodeficiency",[5866,5884],"Cyclophosphamide",{"trials":5886,"activeCount":100},[],{"trials":5888,"activeCount":100},[],{"trials":5890,"activeCount":100},[],{"intervention":5884,"totalTrials":139,"cells":5892},{"EARLY_PHASE1":5893,"PHASE1":5895,"PHASE2":5897,"PHASE3":5903,"PHASE4":5905,"NA":5907},{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[],{"trials":5898,"activeCount":100},[5899],{"nctId":5875,"briefTitle":5876,"status":110,"phases":5900,"primaryCompletion":5878,"completion":5879,"start":5880,"enrollment":828,"conditions":5901,"interventions":5902},[90],[5882],[5866,5884],{"trials":5904,"activeCount":100},[],{"trials":5906,"activeCount":100},[],{"trials":5908,"activeCount":100},[],{"intervention":5910,"totalTrials":139,"cells":5911},"Ginger",{"EARLY_PHASE1":5912,"PHASE1":5914,"PHASE2":5916,"PHASE3":5925,"PHASE4":5927,"NA":5929},{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[5918],{"nctId":5919,"briefTitle":5920,"status":376,"phases":5921,"primaryCompletion":3145,"completion":3145,"start":1662,"enrollment":2041,"conditions":5922,"interventions":5924},"NCT02390648","Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting",[90],[5923],"Chemotherapy-induced Nausea and Vomiting",[5910],{"trials":5926,"activeCount":100},[],{"trials":5928,"activeCount":100},[],{"trials":5930,"activeCount":100},[],{"intervention":5932,"totalTrials":139,"cells":5933},"Vaccine A\u002F17\u002FCA\u002F2009\u002F38",{"EARLY_PHASE1":5934,"PHASE1":5936,"PHASE2":5938,"PHASE3":5948,"PHASE4":5950,"NA":5952},{"trials":5935,"activeCount":100},[],{"trials":5937,"activeCount":100},[],{"trials":5939,"activeCount":100},[5940],{"nctId":5941,"briefTitle":5942,"status":376,"phases":5943,"completion":906,"start":4035,"enrollment":5944,"conditions":5945,"interventions":5947},"NCT01666262","Phase I\u002FII Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A\u002F17\u002FCA\u002F2009\u002F38 (H1N1) in Healthy Thais",[89,90],363,[5946],"Healthy",[5932],{"trials":5949,"activeCount":100},[],{"trials":5951,"activeCount":100},[],{"trials":5953,"activeCount":100},[],{"intervention":5955,"totalTrials":139,"cells":5956},"Camella sinensis gel",{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5961,"PHASE3":5970,"PHASE4":5972,"NA":5974},{"trials":5958,"activeCount":100},[],{"trials":5960,"activeCount":100},[],{"trials":5962,"activeCount":100},[5963],{"nctId":5964,"briefTitle":5965,"status":110,"phases":5966,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":447,"conditions":5967,"interventions":5969},"NCT00918060","Clinical Effects of Locally-delivered Gel Containing Camella Sinensis Extracts as an Adjunct in Peridontitis Treatment",[90],[5968],"Periodontitis",[5955],{"trials":5971,"activeCount":100},[],{"trials":5973,"activeCount":100},[],{"trials":5975,"activeCount":100},[],{"intervention":5977,"totalTrials":139,"cells":5978},"MetFORMIN 500 Mg Oral",{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5980,"activeCount":100},[],{"trials":5982,"activeCount":100},[],{"trials":5984,"activeCount":100},[5985],{"nctId":5986,"briefTitle":5987,"status":110,"phases":5988,"primaryCompletion":3349,"completion":112,"start":5989,"enrollment":1637,"conditions":5990,"interventions":5992},"NCT05215990","Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis",[89,90],"2022-01-15",[5991],"Tuberculosis, Pulmonary",[5977],{"trials":5994,"activeCount":100},[],{"trials":5996,"activeCount":100},[],{"trials":5998,"activeCount":100},[],{"intervention":6000,"totalTrials":139,"cells":6001},"Vitamin C 500 MG Oral",{"EARLY_PHASE1":6002,"PHASE1":6004,"PHASE2":6006,"PHASE3":6018,"PHASE4":6020,"NA":6022},{"trials":6003,"activeCount":100},[],{"trials":6005,"activeCount":100},[],{"trials":6007,"activeCount":100},[6008],{"nctId":6009,"briefTitle":6010,"status":110,"phases":6011,"primaryCompletion":6012,"completion":6013,"start":6014,"enrollment":434,"conditions":6015,"interventions":6017},"NCT03269799","Vitamin C as an Adjunct in Periodontal Treatment in Type 2 Diabetes Mellitus Patients",[90],"2018-02-19","2018-08-19","2017-08-30",[6016,5968],"Diabetes Mellitus Type 2 With Hyperglycemia",[6000],{"trials":6019,"activeCount":100},[],{"trials":6021,"activeCount":100},[],{"trials":6023,"activeCount":100},[],{"intervention":6025,"totalTrials":139,"cells":6026},"depot medroxyprogesterone acetate",{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6040,"PHASE4":6042,"NA":6044},{"trials":6028,"activeCount":100},[],{"trials":6030,"activeCount":100},[],{"trials":6032,"activeCount":100},[6033],{"nctId":6034,"briefTitle":6035,"status":376,"phases":6036,"primaryCompletion":5312,"completion":5312,"start":1950,"enrollment":787,"conditions":6037,"interventions":6039},"NCT01791413","Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas",[89,90],[6038],"Endometriosis",[6025],{"trials":6041,"activeCount":100},[],{"trials":6043,"activeCount":100},[],{"trials":6045,"activeCount":100},[],{"intervention":1244,"totalTrials":139,"cells":6047},{"EARLY_PHASE1":6048,"PHASE1":6050,"PHASE2":6052,"PHASE3":6058,"PHASE4":6060,"NA":6062},{"trials":6049,"activeCount":100},[],{"trials":6051,"activeCount":100},[],{"trials":6053,"activeCount":100},[6054],{"nctId":1234,"briefTitle":1235,"status":376,"phases":6055,"primaryCompletion":1237,"completion":871,"start":1238,"enrollment":1239,"conditions":6056,"interventions":6057},[89,90],[1241,1242],[1225,1244],{"trials":6059,"activeCount":100},[],{"trials":6061,"activeCount":100},[],{"trials":6063,"activeCount":100},[],{"intervention":6065,"totalTrials":139,"cells":6066},"OrniFlu® inactivated vaccine",{"EARLY_PHASE1":6067,"PHASE1":6069,"PHASE2":6071,"PHASE3":6081,"PHASE4":6083,"NA":6085},{"trials":6068,"activeCount":100},[],{"trials":6070,"activeCount":100},[],{"trials":6072,"activeCount":100},[6073],{"nctId":6074,"briefTitle":6075,"status":376,"phases":6076,"primaryCompletion":3851,"completion":3851,"start":6077,"enrollment":1134,"conditions":6078,"interventions":6080},"NCT02229357","Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine",[90],"2014-06",[6079],"Avian Influenza",[6065],{"trials":6082,"activeCount":100},[],{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[],{"intervention":6088,"totalTrials":139,"cells":6089},"Camellia sinensis mouthwash",{"EARLY_PHASE1":6090,"PHASE1":6092,"PHASE2":6094,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6091,"activeCount":100},[],{"trials":6093,"activeCount":100},[],{"trials":6095,"activeCount":100},[6096],{"nctId":6097,"briefTitle":6098,"status":376,"phases":6099,"primaryCompletion":4035,"completion":2178,"start":6100,"enrollment":1134,"conditions":6101,"interventions":6104},"NCT00932347","Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor",[90],"2008-01",[6102,6103],"Gingivitis","Halitosis",[6088],{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[],{"trials":6110,"activeCount":100},[],{"intervention":6112,"totalTrials":139,"cells":6113},"7 days course of antibiotic treatment",{"EARLY_PHASE1":6114,"PHASE1":6116,"PHASE2":6118,"PHASE3":6130,"PHASE4":6132,"NA":6134},{"trials":6115,"activeCount":100},[],{"trials":6117,"activeCount":100},[],{"trials":6119,"activeCount":100},[6120],{"nctId":6121,"briefTitle":6122,"status":376,"phases":6123,"primaryCompletion":2659,"completion":3145,"start":6124,"enrollment":1565,"conditions":6125,"interventions":6128},"NCT02575495","A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation",[90],"2015-02",[6126,6127,3427],"Kidney Transplantation","Bacteriuria",[6112,6129],"14 days course of antibiotic treatment",{"trials":6131,"activeCount":100},[],{"trials":6133,"activeCount":100},[],{"trials":6135,"activeCount":100},[],{"intervention":6129,"totalTrials":139,"cells":6137},{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6142,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[],{"trials":6143,"activeCount":100},[6144],{"nctId":6121,"briefTitle":6122,"status":376,"phases":6145,"primaryCompletion":2659,"completion":3145,"start":6124,"enrollment":1565,"conditions":6146,"interventions":6147},[90],[6126,6127,3427],[6112,6129],{"trials":6149,"activeCount":100},[],{"trials":6151,"activeCount":100},[],{"trials":6153,"activeCount":100},[],{"intervention":6155,"totalTrials":139,"cells":6156},"0.6 mg 1:1000 epinephrine",{"EARLY_PHASE1":6157,"PHASE1":6159,"PHASE2":6161,"PHASE3":6171,"PHASE4":6173,"NA":6175},{"trials":6158,"activeCount":100},[],{"trials":6160,"activeCount":100},[],{"trials":6162,"activeCount":100},[6163],{"nctId":6164,"briefTitle":6165,"status":110,"phases":6166,"primaryCompletion":6167,"completion":6167,"start":6168,"enrollment":115,"conditions":6169,"interventions":6170},"NCT03549221","Efficacy of Adrenaline in Periarticular Analgesic Injection on Postoperative Pain Control After Total Knee Arthroplasty",[90],"2018-10-31","2018-01-26",[21],[6155],{"trials":6172,"activeCount":100},[],{"trials":6174,"activeCount":100},[],{"trials":6176,"activeCount":100},[],{"intervention":6178,"totalTrials":139,"cells":6179},"Alemtuzumab",{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6184,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6181,"activeCount":100},[],{"trials":6183,"activeCount":100},[],{"trials":6185,"activeCount":100},[6186],{"nctId":6187,"briefTitle":6188,"status":365,"phases":6189,"completion":1422,"start":5629,"enrollment":350,"conditions":6190,"interventions":6192},"NCT00441025","The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL",[90],[6191],"Peripheral T-Cell Lymphoma",[6178],{"trials":6194,"activeCount":100},[],{"trials":6196,"activeCount":100},[],{"trials":6198,"activeCount":100},[],{"intervention":6200,"totalTrials":139,"cells":6201},"AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose",{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6222,"PHASE4":6224,"NA":6226},{"trials":6203,"activeCount":100},[],{"trials":6205,"activeCount":100},[],{"trials":6207,"activeCount":100},[6208],{"nctId":6209,"briefTitle":6210,"status":376,"phases":6211,"primaryCompletion":6212,"completion":6212,"start":6213,"enrollment":6214,"conditions":6215,"interventions":6218},"NCT05049226","Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine",[90],"2022-02-22","2021-09-24",1250,[6216,6217],"COVID-19 Infection","COVID-19 VACCINE",[6200,6219,6220,6221],"Pfizer\u002FBioNTech BNT162b2 vaccine (PF) full dose","AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose","Pfizer\u002FBioNTech BNT162b2 vaccine (PF) half dose",{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[],{"trials":6227,"activeCount":100},[],{"intervention":6219,"totalTrials":139,"cells":6229},{"EARLY_PHASE1":6230,"PHASE1":6232,"PHASE2":6234,"PHASE3":6240,"PHASE4":6242,"NA":6244},{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[],{"trials":6235,"activeCount":100},[6236],{"nctId":6209,"briefTitle":6210,"status":376,"phases":6237,"primaryCompletion":6212,"completion":6212,"start":6213,"enrollment":6214,"conditions":6238,"interventions":6239},[90],[6216,6217],[6200,6219,6220,6221],{"trials":6241,"activeCount":100},[],{"trials":6243,"activeCount":100},[],{"trials":6245,"activeCount":100},[],{"intervention":6220,"totalTrials":139,"cells":6247},{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6252,"PHASE3":6258,"PHASE4":6260,"NA":6262},{"trials":6249,"activeCount":100},[],{"trials":6251,"activeCount":100},[],{"trials":6253,"activeCount":100},[6254],{"nctId":6209,"briefTitle":6210,"status":376,"phases":6255,"primaryCompletion":6212,"completion":6212,"start":6213,"enrollment":6214,"conditions":6256,"interventions":6257},[90],[6216,6217],[6200,6219,6220,6221],{"trials":6259,"activeCount":100},[],{"trials":6261,"activeCount":100},[],{"trials":6263,"activeCount":100},[],{"intervention":6221,"totalTrials":139,"cells":6265},{"EARLY_PHASE1":6266,"PHASE1":6268,"PHASE2":6270,"PHASE3":6276,"PHASE4":6278,"NA":6280},{"trials":6267,"activeCount":100},[],{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[6272],{"nctId":6209,"briefTitle":6210,"status":376,"phases":6273,"primaryCompletion":6212,"completion":6212,"start":6213,"enrollment":6214,"conditions":6274,"interventions":6275},[90],[6216,6217],[6200,6219,6220,6221],{"trials":6277,"activeCount":100},[],{"trials":6279,"activeCount":100},[],{"trials":6281,"activeCount":100},[],{"intervention":3994,"totalTrials":139,"cells":6283},{"EARLY_PHASE1":6284,"PHASE1":6286,"PHASE2":6292,"PHASE3":6294,"PHASE4":6296,"NA":6298},{"trials":6285,"activeCount":100},[],{"trials":6287,"activeCount":100},[6288],{"nctId":3987,"briefTitle":3988,"status":110,"phases":6289,"primaryCompletion":3990,"completion":1283,"start":1728,"enrollment":2729,"conditions":6290,"interventions":6291},[89],[2086,2087],[3980,3993,3994],{"trials":6293,"activeCount":100},[],{"trials":6295,"activeCount":100},[],{"trials":6297,"activeCount":100},[],{"trials":6299,"activeCount":100},[],{"intervention":6301,"totalTrials":139,"cells":6302},"Efavirenz",{"EARLY_PHASE1":6303,"PHASE1":6305,"PHASE2":6316,"PHASE3":6318,"PHASE4":6320,"NA":6322},{"trials":6304,"activeCount":100},[],{"trials":6306,"activeCount":100},[6307],{"nctId":6308,"briefTitle":6309,"status":110,"phases":6310,"primaryCompletion":1797,"start":1187,"enrollment":6311,"conditions":6312,"interventions":6315},"NCT02421289","Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients",[89],190,[6313,6301,6314],"Cytochrome P-450 CYP2B6","HIV",[6301,6301],{"trials":6317,"activeCount":100},[],{"trials":6319,"activeCount":100},[],{"trials":6321,"activeCount":100},[],{"trials":6323,"activeCount":100},[],{"intervention":6325,"totalTrials":139,"cells":6326},"oseltamivir",{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6342,"PHASE3":6344,"PHASE4":6346,"NA":6348},{"trials":6328,"activeCount":100},[],{"trials":6330,"activeCount":100},[6331],{"nctId":6332,"briefTitle":6333,"status":376,"phases":6334,"primaryCompletion":6335,"completion":6335,"start":6336,"enrollment":6337,"conditions":6338,"interventions":6340},"NCT00439530","Pharmacologic Study of Oseltamivir in Healthy Volunteers",[89],"2007-04","2006-11",21,[6339],"Avian Influenza A Virus",[6325,6341],"probenecid",{"trials":6343,"activeCount":100},[],{"trials":6345,"activeCount":100},[],{"trials":6347,"activeCount":100},[],{"trials":6349,"activeCount":100},[],{"intervention":6341,"totalTrials":139,"cells":6351},{"EARLY_PHASE1":6352,"PHASE1":6354,"PHASE2":6360,"PHASE3":6362,"PHASE4":6364,"NA":6366},{"trials":6353,"activeCount":100},[],{"trials":6355,"activeCount":100},[6356],{"nctId":6332,"briefTitle":6333,"status":376,"phases":6357,"primaryCompletion":6335,"completion":6335,"start":6336,"enrollment":6337,"conditions":6358,"interventions":6359},[89],[6339],[6325,6341],{"trials":6361,"activeCount":100},[],{"trials":6363,"activeCount":100},[],{"trials":6365,"activeCount":100},[],{"trials":6367,"activeCount":100},[],{"intervention":6369,"totalTrials":139,"cells":6370},"Tdap vaccine",{"EARLY_PHASE1":6371,"PHASE1":6383,"PHASE2":6385,"PHASE3":6387,"PHASE4":6389,"NA":6391},{"trials":6372,"activeCount":100},[6373],{"nctId":6374,"briefTitle":6375,"status":376,"phases":6376,"primaryCompletion":6377,"completion":6377,"start":6378,"enrollment":6379,"conditions":6380,"interventions":6382},"NCT03498300","Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women",[88],"2019-04-13","2018-05-09",129,[326,6381],"Pregnancy Related",[6369],{"trials":6384,"activeCount":100},[],{"trials":6386,"activeCount":100},[],{"trials":6388,"activeCount":100},[],{"trials":6390,"activeCount":100},[],{"trials":6392,"activeCount":100},[],{"intervention":1071,"totalTrials":29,"cells":6394},{"EARLY_PHASE1":6395,"PHASE1":6397,"PHASE2":6399,"PHASE3":6405,"PHASE4":6411,"NA":6425},{"trials":6396,"activeCount":100},[],{"trials":6398,"activeCount":100},[],{"trials":6400,"activeCount":100},[6401],{"nctId":5548,"briefTitle":5549,"status":376,"phases":6402,"primaryCompletion":5551,"completion":5551,"start":5552,"enrollment":5553,"conditions":6403,"interventions":6404},[89,90],[5555,5556,5557,5558],[5560,5539],{"trials":6406,"activeCount":100},[6407],{"nctId":4164,"briefTitle":4165,"status":376,"phases":6408,"primaryCompletion":4167,"completion":4167,"start":3594,"enrollment":447,"conditions":6409,"interventions":6410},[91],[4169],[4153,1071],{"trials":6412,"activeCount":100},[6413,6417,6421],{"nctId":1061,"briefTitle":1062,"status":376,"phases":6414,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":11,"conditions":6415,"interventions":6416},[92],[1067,1068,1069],[1048,1071],{"nctId":1085,"briefTitle":1086,"status":376,"phases":6418,"primaryCompletion":1088,"completion":1039,"start":1089,"enrollment":1090,"conditions":6419,"interventions":6420},[92],[1092,26],[1048,1071],{"nctId":3679,"briefTitle":3680,"status":376,"phases":6422,"primaryCompletion":871,"completion":3682,"start":1009,"enrollment":2292,"conditions":6423,"interventions":6424},[92],[407],[3666,3685],{"trials":6426,"activeCount":100},[6427,6437,6445],{"nctId":6428,"briefTitle":6429,"status":110,"phases":6430,"primaryCompletion":6431,"completion":3211,"start":2661,"enrollment":6432,"conditions":6433,"interventions":6435},"NCT02520804","Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function",[93],"2017-06",107,[602,6434],"Shock",[6436,3685],"sterofundin",{"nctId":6438,"briefTitle":6439,"status":376,"phases":6440,"primaryCompletion":2728,"completion":5115,"start":2110,"enrollment":1134,"conditions":6441,"interventions":6443},"NCT00890942","Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal Morphine Induced Pruritus After Cesarean Section",[93],[6442],"Morphine Adverse Reaction",[6444,3685],"naloxone",{"nctId":6446,"briefTitle":6447,"status":110,"phases":6448,"primaryCompletion":6449,"completion":6450,"start":6451,"enrollment":575,"conditions":6452,"interventions":6454},"NCT03955705","Analgesic Effectiveness of Nefopam in Patients Undergoing Anterior Cervical Spine Surgery",[93],"2021-04-30","2021-05-31","2019-05-15",[6453],"Cervical Spine Degeneration",[6455,1071],"Nefopam 20 mg\u002Fml",{"intervention":407,"totalTrials":828,"cells":6457},{"EARLY_PHASE1":6458,"PHASE1":6460,"PHASE2":6462,"PHASE3":6464,"PHASE4":6466,"NA":6486},{"trials":6459,"activeCount":100},[],{"trials":6461,"activeCount":100},[],{"trials":6463,"activeCount":100},[],{"trials":6465,"activeCount":100},[],{"trials":6467,"activeCount":100},[6468,6476,6480],{"nctId":6469,"briefTitle":6470,"status":376,"phases":6471,"primaryCompletion":2659,"completion":2659,"start":3572,"enrollment":6472,"conditions":6473,"interventions":6475},"NCT01917448","Low-dose Spinal Morphine for Post-Thoracotomy Pain After Video-Assisted Thoracoscopic Surgery",[92],36,[6474],"Video-assisted Thoracoscopic Surgery",[407],{"nctId":363,"briefTitle":364,"status":365,"phases":6477,"primaryCompletion":367,"completion":367,"start":368,"enrollment":19,"conditions":6478,"interventions":6479},[92],[370],[372,66],{"nctId":6481,"briefTitle":6482,"status":110,"phases":6483,"primaryCompletion":2834,"completion":2834,"start":1178,"enrollment":3530,"conditions":6484,"interventions":6485},"NCT01080911","0.05 mg Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy",[92],[24],[407,407],{"trials":6487,"activeCount":100},[6488,6492],{"nctId":397,"briefTitle":398,"status":376,"phases":6489,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":6490,"interventions":6491},[93],[405],[407,66],{"nctId":6493,"briefTitle":6494,"status":376,"phases":6495,"primaryCompletion":2660,"completion":6496,"start":4590,"enrollment":1637,"conditions":6497,"interventions":6501},"NCT02458742","Spinal Morphine Provides an Effective Pain Control in Patients Undergoing Transurethral Resection of Prostate Gland",[93],"2016-09",[6498,6499,6500],"Spinal Anesthesia","Transurethral Resection of Prostate","Analgesia",[407],{"intervention":6503,"totalTrials":409,"cells":6504},"Dexmedetomidine",{"EARLY_PHASE1":6505,"PHASE1":6507,"PHASE2":6509,"PHASE3":6511,"PHASE4":6513,"NA":6515},{"trials":6506,"activeCount":100},[],{"trials":6508,"activeCount":100},[],{"trials":6510,"activeCount":100},[],{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"trials":6516,"activeCount":100},[6517,6524,6536],{"nctId":6518,"briefTitle":6519,"status":110,"phases":6520,"primaryCompletion":1685,"completion":1685,"start":1318,"enrollment":162,"conditions":6521,"interventions":6523},"NCT02819089","Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant",[93],[6522],"Cervical Spondylosis",[6503],{"nctId":6525,"briefTitle":6526,"status":110,"phases":6527,"primaryCompletion":6528,"completion":827,"start":6529,"enrollment":6530,"conditions":6531,"interventions":6533},"NCT03120442","Postoperative Delirium After Total Knee Arthroplasty Under Regional Anesthesia",[93],"2022-05","2017-06-14",600,[6532],"Postoperative Delirium",[6534,6503,6535],"Propofol","Fentanyl",{"nctId":6537,"briefTitle":6538,"status":376,"phases":6539,"primaryCompletion":3572,"completion":3572,"start":2834,"enrollment":787,"conditions":6540,"interventions":6542},"NCT02083055","Anesthetic Advantages of Dexmedetomidine for Hypotensive Anesthesia",[93],[6541,2501],"Anesthesia",[6503,6543],"Nitroglycerin",{"intervention":6535,"totalTrials":409,"cells":6545},{"EARLY_PHASE1":6546,"PHASE1":6548,"PHASE2":6550,"PHASE3":6552,"PHASE4":6554,"NA":6564},{"trials":6547,"activeCount":100},[],{"trials":6549,"activeCount":100},[],{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[],{"trials":6555,"activeCount":100},[6556],{"nctId":6557,"briefTitle":6558,"status":376,"phases":6559,"primaryCompletion":6560,"completion":6560,"start":1753,"enrollment":1296,"conditions":6561,"interventions":6562},"NCT02733705","Intravenous Propofol and Fentanyl vs Propofol for Sedation in TRUS Biopsy",[92],"2018-05-31",[24],[6535,6563],"propofol",{"trials":6565,"activeCount":100},[6566,6570],{"nctId":6525,"briefTitle":6526,"status":110,"phases":6567,"primaryCompletion":6528,"completion":827,"start":6529,"enrollment":6530,"conditions":6568,"interventions":6569},[93],[6532],[6534,6503,6535],{"nctId":6571,"briefTitle":6572,"status":376,"phases":6573,"primaryCompletion":3145,"completion":3145,"start":3059,"enrollment":2041,"conditions":6574,"interventions":6576},"NCT02174913","Awakening in Spine Surgery: A Comparison Between Clinical Signs and Bispectral Index",[93],[6575],"Spine Diseases",[6577,6535,6578],"Target controlled infusion of propofol","Atracurium",{"intervention":6580,"totalTrials":96,"cells":6581},"Misoprostol",{"EARLY_PHASE1":6582,"PHASE1":6584,"PHASE2":6586,"PHASE3":6588,"PHASE4":6590,"NA":6601},{"trials":6583,"activeCount":100},[],{"trials":6585,"activeCount":100},[],{"trials":6587,"activeCount":100},[],{"trials":6589,"activeCount":100},[],{"trials":6591,"activeCount":100},[6592],{"nctId":6593,"briefTitle":6594,"status":376,"phases":6595,"primaryCompletion":2178,"completion":1178,"start":2110,"enrollment":2591,"conditions":6596,"interventions":6599},"NCT00886860","The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol",[92],[6597,6598],"Cervical Ripening","Labor Induction",[6600,6600],"misoprostol",{"trials":6602,"activeCount":100},[6603],{"nctId":6604,"briefTitle":6605,"status":110,"phases":6606,"primaryCompletion":1188,"completion":1188,"start":1237,"enrollment":529,"conditions":6607,"interventions":6609},"NCT01762319","Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol",[93],[6608],"Abnormal Uterine Bleeding Unrelated to Menstrual Cycle",[6580,6610],"Vitamin B6",{"intervention":6612,"totalTrials":96,"cells":6613},"magnesium sulphate",{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6620,"PHASE4":6622,"NA":6632},{"trials":6615,"activeCount":100},[],{"trials":6617,"activeCount":100},[],{"trials":6619,"activeCount":100},[],{"trials":6621,"activeCount":100},[],{"trials":6623,"activeCount":100},[6624],{"nctId":6625,"briefTitle":6626,"status":365,"phases":6627,"primaryCompletion":2834,"completion":2834,"start":5138,"enrollment":11,"conditions":6628,"interventions":6631},"NCT01261702","Magnesium Infusion for Pain Relief After Thoracotomy. A Randomized Controlled Trial.",[92],[6629,6630,24],"Magnesium Sulphate","Post Pulmonary Resection",[6612],{"trials":6633,"activeCount":100},[6634],{"nctId":6635,"briefTitle":6636,"status":110,"phases":6637,"primaryCompletion":4377,"completion":2993,"start":907,"enrollment":3470,"conditions":6638,"interventions":6640},"NCT01049464","Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient",[93],[6639],"Atrial Fibrillation",[6641],"Magnesium sulphate",{"intervention":6534,"totalTrials":96,"cells":6643},{"EARLY_PHASE1":6644,"PHASE1":6646,"PHASE2":6648,"PHASE3":6650,"PHASE4":6652,"NA":6658},{"trials":6645,"activeCount":100},[],{"trials":6647,"activeCount":100},[],{"trials":6649,"activeCount":100},[],{"trials":6651,"activeCount":100},[],{"trials":6653,"activeCount":100},[6654],{"nctId":6557,"briefTitle":6558,"status":376,"phases":6655,"primaryCompletion":6560,"completion":6560,"start":1753,"enrollment":1296,"conditions":6656,"interventions":6657},[92],[24],[6535,6563],{"trials":6659,"activeCount":100},[6660],{"nctId":6525,"briefTitle":6526,"status":110,"phases":6661,"primaryCompletion":6528,"completion":827,"start":6529,"enrollment":6530,"conditions":6662,"interventions":6663},[93],[6532],[6534,6503,6535],{"intervention":6665,"totalTrials":96,"cells":6666},"Pertagen",{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6671,"PHASE3":6673,"PHASE4":6675,"NA":6677},{"trials":6668,"activeCount":100},[],{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[],{"trials":6674,"activeCount":100},[],{"trials":6676,"activeCount":100},[],{"trials":6678,"activeCount":100},[6679,6690],{"nctId":6680,"briefTitle":6681,"status":376,"phases":6682,"primaryCompletion":6683,"completion":6684,"start":4081,"enrollment":6685,"conditions":6686,"interventions":6687},"NCT04102137","3-year Follow-up After a Single Dose Acellular Pertussis Vaccination",[],"2018-07-31","2018-08-27",181,[326],[6665,6688,6689],"Boostagen","Adacel",{"nctId":6691,"briefTitle":6692,"status":376,"phases":6693,"primaryCompletion":6694,"completion":6695,"start":6696,"enrollment":6697,"conditions":6698,"interventions":6699},"NCT04113655","2-year Follow-up After a Single Dose Acellular Pertussis Vaccination",[],"2017-07-04","2017-07-31","2017-06-20",180,[326],[6665,6688,6689],{"intervention":6688,"totalTrials":96,"cells":6701},{"EARLY_PHASE1":6702,"PHASE1":6704,"PHASE2":6706,"PHASE3":6708,"PHASE4":6710,"NA":6712},{"trials":6703,"activeCount":100},[],{"trials":6705,"activeCount":100},[],{"trials":6707,"activeCount":100},[],{"trials":6709,"activeCount":100},[],{"trials":6711,"activeCount":100},[],{"trials":6713,"activeCount":100},[6714,6718],{"nctId":6680,"briefTitle":6681,"status":376,"phases":6715,"primaryCompletion":6683,"completion":6684,"start":4081,"enrollment":6685,"conditions":6716,"interventions":6717},[],[326],[6665,6688,6689],{"nctId":6691,"briefTitle":6692,"status":376,"phases":6719,"primaryCompletion":6694,"completion":6695,"start":6696,"enrollment":6697,"conditions":6720,"interventions":6721},[],[326],[6665,6688,6689],{"intervention":6689,"totalTrials":96,"cells":6723},{"EARLY_PHASE1":6724,"PHASE1":6726,"PHASE2":6728,"PHASE3":6730,"PHASE4":6732,"NA":6734},{"trials":6725,"activeCount":100},[],{"trials":6727,"activeCount":100},[],{"trials":6729,"activeCount":100},[],{"trials":6731,"activeCount":100},[],{"trials":6733,"activeCount":100},[],{"trials":6735,"activeCount":100},[6736,6740],{"nctId":6680,"briefTitle":6681,"status":376,"phases":6737,"primaryCompletion":6683,"completion":6684,"start":4081,"enrollment":6685,"conditions":6738,"interventions":6739},[],[326],[6665,6688,6689],{"nctId":6691,"briefTitle":6692,"status":376,"phases":6741,"primaryCompletion":6694,"completion":6695,"start":6696,"enrollment":6697,"conditions":6742,"interventions":6743},[],[326],[6665,6688,6689],{"intervention":2598,"totalTrials":96,"cells":6745},{"EARLY_PHASE1":6746,"PHASE1":6748,"PHASE2":6750,"PHASE3":6752,"PHASE4":6754,"NA":6760},{"trials":6747,"activeCount":100},[],{"trials":6749,"activeCount":100},[],{"trials":6751,"activeCount":100},[],{"trials":6753,"activeCount":100},[],{"trials":6755,"activeCount":100},[6756],{"nctId":2586,"briefTitle":2587,"status":376,"phases":6757,"primaryCompletion":2589,"completion":2361,"start":2590,"enrollment":2591,"conditions":6758,"interventions":6759},[92],[2593,2594,2595,2596],[2598,2573],{"trials":6761,"activeCount":100},[6762],{"nctId":6763,"briefTitle":6764,"status":110,"phases":6765,"primaryCompletion":6766,"completion":6766,"start":6767,"enrollment":6472,"conditions":6768,"interventions":6770},"NCT04829487","The Role of Vitamin D Supplementation on Pain in Women With Primary Dysmenorrhea and Hypovitaminosis D",[93],"2023-04-30","2021-05-01",[6769],"Hypovitaminosis D",[2598],{"intervention":6772,"totalTrials":96,"cells":6773},"Intrathecal morphine",{"EARLY_PHASE1":6774,"PHASE1":6776,"PHASE2":6778,"PHASE3":6780,"PHASE4":6782,"NA":6784},{"trials":6775,"activeCount":100},[],{"trials":6777,"activeCount":100},[],{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[],{"trials":6783,"activeCount":100},[],{"trials":6785,"activeCount":100},[6786,6799],{"nctId":6787,"briefTitle":6788,"status":376,"phases":6789,"primaryCompletion":6790,"completion":6791,"start":6792,"enrollment":2729,"conditions":6793,"interventions":6796},"NCT03199170","Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section",[93],"2019-01-01","2019-08-01","2017-09-01",[6794,6498,6795,6500],"Caesarean Section","Quadratus Lumborum Block",[6772,6797,6798],"Bilateral Quadratus Lumborum Block","Intrathecal morphine with bilateral Quadratus Lumborum Block",{"nctId":6800,"briefTitle":6801,"status":110,"phases":6802,"primaryCompletion":6803,"completion":6803,"start":6804,"enrollment":6805,"conditions":6806,"interventions":6810},"NCT04104204","The Efficacy of Pain Control After Total Hip Replacement Between Ultrasound Guided Supra-inguinal Fascia Iliaca Block and Intrathecal Morphine",[93],"2021-12","2019-12-03",98,[6807,6808,6809,21],"Total Hip Replacement","Ultrasound Guided Supra-inguinal Fascia Iliaca Block","Intrathecal Morphine",[6772,6811],"Ultrasound guided supra-inguinal fascia iliaca block",{"intervention":6813,"totalTrials":96,"cells":6814},"Rilpivirine",{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6821,"PHASE4":6829,"NA":6831},{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[],{"trials":6820,"activeCount":100},[],{"trials":6822,"activeCount":100},[6823],{"nctId":6824,"briefTitle":6825,"status":110,"phases":6826,"primaryCompletion":6431,"completion":4377,"start":2291,"enrollment":162,"conditions":6827,"interventions":6828},"NCT03033368","Rilpivirine in Virologically Suppressed Adolescents",[90,91],[6314],[6813],{"trials":6830,"activeCount":100},[],{"trials":6832,"activeCount":100},[6833],{"nctId":6834,"briefTitle":6835,"status":376,"phases":6836,"primaryCompletion":6837,"completion":6837,"start":6838,"enrollment":6839,"conditions":6840,"interventions":6842},"NCT03664440","Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients",[93],"2017-10-31","2016-12-01",106,[6841],"Efficacy of Rilpivirine-based Regimens as Switch Therapy",[6843,6813],"Nevirapine",{"intervention":6455,"totalTrials":96,"cells":6845},{"EARLY_PHASE1":6846,"PHASE1":6848,"PHASE2":6850,"PHASE3":6852,"PHASE4":6854,"NA":6866},{"trials":6847,"activeCount":100},[],{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[],{"trials":6853,"activeCount":100},[],{"trials":6855,"activeCount":100},[6856],{"nctId":6857,"briefTitle":6858,"status":376,"phases":6859,"primaryCompletion":6860,"completion":6861,"start":6862,"enrollment":3530,"conditions":6863,"interventions":6864},"NCT04241640","Nefopam for Post Video-Assisted Thoracoscopic Lobectomy",[92],"2022-08-01","2023-03-01","2020-09-01",[26],[6865],"Nefopam 20 MG\u002FML",{"trials":6867,"activeCount":100},[6868],{"nctId":6446,"briefTitle":6447,"status":110,"phases":6869,"primaryCompletion":6449,"completion":6450,"start":6451,"enrollment":575,"conditions":6870,"interventions":6871},[93],[6453],[6455,1071],{"intervention":5184,"totalTrials":96,"cells":6873},{"EARLY_PHASE1":6874,"PHASE1":6876,"PHASE2":6878,"PHASE3":6880,"PHASE4":6886,"NA":6888},{"trials":6875,"activeCount":100},[],{"trials":6877,"activeCount":100},[],{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[6882],{"nctId":5177,"briefTitle":5178,"status":110,"phases":6883,"primaryCompletion":1589,"completion":5180,"start":1333,"enrollment":301,"conditions":6884,"interventions":6885},[91],[5182],[5184,5166],{"trials":6887,"activeCount":100},[],{"trials":6889,"activeCount":100},[6890],{"nctId":6891,"briefTitle":6892,"status":376,"phases":6893,"primaryCompletion":6894,"completion":6894,"start":906,"enrollment":787,"conditions":6895,"interventions":6896},"NCT01559480","Postoperative Desogestrel for Endometriosis Related Pain",[93],"2014-10",[6038],[5184],{"intervention":6898,"totalTrials":139,"cells":6899},"Ringer acetate",{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6906,"PHASE4":6908,"NA":6910},{"trials":6901,"activeCount":100},[],{"trials":6903,"activeCount":100},[],{"trials":6905,"activeCount":100},[],{"trials":6907,"activeCount":100},[],{"trials":6909,"activeCount":100},[],{"trials":6911,"activeCount":100},[6912],{"nctId":6913,"briefTitle":6914,"status":110,"phases":6915,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":5023,"conditions":6919,"interventions":6921},"NCT05061836","Effect of Using Dextrose-containing Intraoperative Fluid in Children",[93],"2022-09","2022-12","2021-10",[6920],"Pediatric Surgery",[6898,6922,6923,6924],"1.25%Dextrose equivalence","2.5%Dextrose equivalence","Dextrose 5",{"intervention":6922,"totalTrials":139,"cells":6926},{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6931,"PHASE3":6933,"PHASE4":6935,"NA":6937},{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[],{"trials":6932,"activeCount":100},[],{"trials":6934,"activeCount":100},[],{"trials":6936,"activeCount":100},[],{"trials":6938,"activeCount":100},[6939],{"nctId":6913,"briefTitle":6914,"status":110,"phases":6940,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":5023,"conditions":6941,"interventions":6942},[93],[6920],[6898,6922,6923,6924],{"intervention":6923,"totalTrials":139,"cells":6944},{"EARLY_PHASE1":6945,"PHASE1":6947,"PHASE2":6949,"PHASE3":6951,"PHASE4":6953,"NA":6955},{"trials":6946,"activeCount":100},[],{"trials":6948,"activeCount":100},[],{"trials":6950,"activeCount":100},[],{"trials":6952,"activeCount":100},[],{"trials":6954,"activeCount":100},[],{"trials":6956,"activeCount":100},[6957],{"nctId":6913,"briefTitle":6914,"status":110,"phases":6958,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":5023,"conditions":6959,"interventions":6960},[93],[6920],[6898,6922,6923,6924],{"intervention":6924,"totalTrials":139,"cells":6962},{"EARLY_PHASE1":6963,"PHASE1":6965,"PHASE2":6967,"PHASE3":6969,"PHASE4":6971,"NA":6973},{"trials":6964,"activeCount":100},[],{"trials":6966,"activeCount":100},[],{"trials":6968,"activeCount":100},[],{"trials":6970,"activeCount":100},[],{"trials":6972,"activeCount":100},[],{"trials":6974,"activeCount":100},[6975],{"nctId":6913,"briefTitle":6914,"status":110,"phases":6976,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":5023,"conditions":6977,"interventions":6978},[93],[6920],[6898,6922,6923,6924],{"intervention":6980,"totalTrials":139,"cells":6981},"Nicardipine",{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6986,"PHASE3":6988,"PHASE4":6990,"NA":6992},{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[],{"trials":6987,"activeCount":100},[],{"trials":6989,"activeCount":100},[],{"trials":6991,"activeCount":100},[],{"trials":6993,"activeCount":100},[6994],{"nctId":6995,"briefTitle":6996,"status":110,"phases":6997,"primaryCompletion":5508,"completion":6998,"start":6999,"enrollment":6311,"conditions":7000,"interventions":7002},"NCT05920538","Effects of Subcutaneously Infiltrated Nicardipine on the Success Rate of Radial Artety Cannulation",[93],"2024-01","2023-03-13",[7001],"Radial Artery Cannulation",[6980],{"intervention":7004,"totalTrials":139,"cells":7005},"Equine Rabies Immunoglobulin",{"EARLY_PHASE1":7006,"PHASE1":7008,"PHASE2":7010,"PHASE3":7012,"PHASE4":7014,"NA":7016},{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[],{"trials":7011,"activeCount":100},[],{"trials":7013,"activeCount":100},[],{"trials":7015,"activeCount":100},[],{"trials":7017,"activeCount":100},[7018],{"nctId":7019,"briefTitle":7020,"status":376,"phases":7021,"primaryCompletion":7022,"completion":5716,"start":1662,"enrollment":1134,"conditions":7023,"interventions":7024},"NCT03093545","Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients",[93],"2016-10",[5857],[7004,7025],"Purified chick-embryo cell rabies vaccine",{"intervention":7025,"totalTrials":139,"cells":7027},{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7032,"PHASE3":7034,"PHASE4":7036,"NA":7038},{"trials":7029,"activeCount":100},[],{"trials":7031,"activeCount":100},[],{"trials":7033,"activeCount":100},[],{"trials":7035,"activeCount":100},[],{"trials":7037,"activeCount":100},[],{"trials":7039,"activeCount":100},[7040],{"nctId":7019,"briefTitle":7020,"status":376,"phases":7041,"primaryCompletion":7022,"completion":5716,"start":1662,"enrollment":1134,"conditions":7042,"interventions":7043},[93],[5857],[7004,7025],{"intervention":6610,"totalTrials":139,"cells":7045},{"EARLY_PHASE1":7046,"PHASE1":7048,"PHASE2":7050,"PHASE3":7052,"PHASE4":7054,"NA":7056},{"trials":7047,"activeCount":100},[],{"trials":7049,"activeCount":100},[],{"trials":7051,"activeCount":100},[],{"trials":7053,"activeCount":100},[],{"trials":7055,"activeCount":100},[],{"trials":7057,"activeCount":100},[7058],{"nctId":6604,"briefTitle":6605,"status":110,"phases":7059,"primaryCompletion":1188,"completion":1188,"start":1237,"enrollment":529,"conditions":7060,"interventions":7061},[93],[6608],[6580,6610],{"intervention":7063,"totalTrials":139,"cells":7064},"Ondansetron",{"EARLY_PHASE1":7065,"PHASE1":7067,"PHASE2":7069,"PHASE3":7071,"PHASE4":7073,"NA":7075},{"trials":7066,"activeCount":100},[],{"trials":7068,"activeCount":100},[],{"trials":7070,"activeCount":100},[],{"trials":7072,"activeCount":100},[],{"trials":7074,"activeCount":100},[],{"trials":7076,"activeCount":100},[7077],{"nctId":7078,"briefTitle":7079,"status":376,"phases":7080,"primaryCompletion":1662,"completion":1662,"start":378,"enrollment":2498,"conditions":7081,"interventions":7083},"NCT02194192","Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section",[93],[7082],"Anesthesia; Adverse Effect, Spinal and Epidural",[7063,7084],"Ephedrine",{"intervention":7084,"totalTrials":139,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7093,"PHASE4":7095,"NA":7097},{"trials":7088,"activeCount":100},[],{"trials":7090,"activeCount":100},[],{"trials":7092,"activeCount":100},[],{"trials":7094,"activeCount":100},[],{"trials":7096,"activeCount":100},[],{"trials":7098,"activeCount":100},[7099],{"nctId":7078,"briefTitle":7079,"status":376,"phases":7100,"primaryCompletion":1662,"completion":1662,"start":378,"enrollment":2498,"conditions":7101,"interventions":7102},[93],[7082],[7063,7084],{"intervention":7104,"totalTrials":139,"cells":7105},"Lactated Ringer",{"EARLY_PHASE1":7106,"PHASE1":7108,"PHASE2":7110,"PHASE3":7112,"PHASE4":7114,"NA":7116},{"trials":7107,"activeCount":100},[],{"trials":7109,"activeCount":100},[],{"trials":7111,"activeCount":100},[],{"trials":7113,"activeCount":100},[],{"trials":7115,"activeCount":100},[],{"trials":7117,"activeCount":100},[7118],{"nctId":7119,"briefTitle":7120,"status":376,"phases":7121,"primaryCompletion":7122,"completion":7122,"start":7123,"enrollment":3893,"conditions":7124,"interventions":7126},"NCT04051580","Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia",[93],"2020-12-31","2019-08-05",[7125],"Myocardial Injury",[7104],{"intervention":7128,"totalTrials":139,"cells":7129},"SNP: CYP3A5 gene polymorphisms",{"EARLY_PHASE1":7130,"PHASE1":7132,"PHASE2":7134,"PHASE3":7136,"PHASE4":7138,"NA":7140},{"trials":7131,"activeCount":100},[],{"trials":7133,"activeCount":100},[],{"trials":7135,"activeCount":100},[],{"trials":7137,"activeCount":100},[],{"trials":7139,"activeCount":100},[],{"trials":7141,"activeCount":100},[7142],{"nctId":7143,"briefTitle":7144,"status":110,"phases":7145,"primaryCompletion":1317,"completion":3990,"start":378,"enrollment":7146,"conditions":7147,"interventions":7149},"NCT02377791","Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Concentrations and Outcomes in Thai Transplant Recipients",[],170,[7148],"Kidney Transplant",[7128],{"intervention":7151,"totalTrials":139,"cells":7152},"Dexmedetomidine plus propofol",{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7163},{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":100},[],{"trials":7158,"activeCount":100},[],{"trials":7160,"activeCount":100},[],{"trials":7162,"activeCount":100},[],{"trials":7164,"activeCount":100},[7165],{"nctId":7166,"briefTitle":7167,"status":110,"phases":7168,"primaryCompletion":7169,"completion":7170,"start":7171,"enrollment":529,"conditions":7172,"interventions":7175},"NCT04051099","Bilateral Superficial Cervical Plexus Block in Thyroid\u002FParathyroid Surgery",[93],"2021-09-30","2021-12-15","2018-03-01",[7173,7174],"Benign Tumor of Thyroid","Hyperparathyroidism",[7151],{"intervention":7177,"totalTrials":139,"cells":7178},"Isotonic crystalloid solution resuscitation",{"EARLY_PHASE1":7179,"PHASE1":7181,"PHASE2":7183,"PHASE3":7185,"PHASE4":7187,"NA":7189},{"trials":7180,"activeCount":100},[],{"trials":7182,"activeCount":100},[],{"trials":7184,"activeCount":100},[],{"trials":7186,"activeCount":100},[],{"trials":7188,"activeCount":100},[],{"trials":7190,"activeCount":100},[7191],{"nctId":7192,"briefTitle":7193,"status":110,"phases":7194,"primaryCompletion":1590,"completion":7195,"start":3851,"enrollment":7196,"conditions":7197,"interventions":7199},"NCT02782819","A Comparison of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation",[93],"2018-11",320,[7198],"Hypotension and Shock",[7177,7200],"Colloid solution resuscitation",{"intervention":7200,"totalTrials":139,"cells":7202},{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7209,"PHASE4":7211,"NA":7213},{"trials":7204,"activeCount":100},[],{"trials":7206,"activeCount":100},[],{"trials":7208,"activeCount":100},[],{"trials":7210,"activeCount":100},[],{"trials":7212,"activeCount":100},[],{"trials":7214,"activeCount":100},[7215],{"nctId":7192,"briefTitle":7193,"status":110,"phases":7216,"primaryCompletion":1590,"completion":7195,"start":3851,"enrollment":7196,"conditions":7217,"interventions":7218},[93],[7198],[7177,7200],{"intervention":7220,"totalTrials":139,"cells":7221},"bupivacaine 100 mg",{"EARLY_PHASE1":7222,"PHASE1":7224,"PHASE2":7226,"PHASE3":7228,"PHASE4":7230,"NA":7232},{"trials":7223,"activeCount":100},[],{"trials":7225,"activeCount":100},[],{"trials":7227,"activeCount":100},[],{"trials":7229,"activeCount":100},[],{"trials":7231,"activeCount":100},[],{"trials":7233,"activeCount":100},[7234],{"nctId":7235,"briefTitle":7236,"status":376,"phases":7237,"primaryCompletion":7238,"completion":7238,"start":7239,"enrollment":1134,"conditions":7240,"interventions":7242},"NCT03249662","Efficacy of Pain Control in Different Bupivacaine Dose in Periarticular Injection in Bilateral Total Knee Arthroplasty",[93],"2020-09-14","2017-09-27",[7241],"Bilateral Total Knee Arthroplasty",[7220],{"intervention":7244,"totalTrials":139,"cells":7245},"Diclofenac Potassium",{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7250,"PHASE3":7252,"PHASE4":7254,"NA":7256},{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":100},[],{"trials":7251,"activeCount":100},[],{"trials":7253,"activeCount":100},[],{"trials":7255,"activeCount":100},[],{"trials":7257,"activeCount":100},[7258],{"nctId":7259,"briefTitle":7260,"status":110,"phases":7261,"primaryCompletion":1188,"completion":1188,"start":1237,"enrollment":2729,"conditions":7262,"interventions":7263},"NCT01762306","Efficacy of Diclofenac on Pain During Endometrial Sampling",[93],[6608],[7244,7264],"Folic Acid",{"intervention":7264,"totalTrials":139,"cells":7266},{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7273,"PHASE4":7275,"NA":7277},{"trials":7268,"activeCount":100},[],{"trials":7270,"activeCount":100},[],{"trials":7272,"activeCount":100},[],{"trials":7274,"activeCount":100},[],{"trials":7276,"activeCount":100},[],{"trials":7278,"activeCount":100},[7279],{"nctId":7259,"briefTitle":7260,"status":110,"phases":7280,"primaryCompletion":1188,"completion":1188,"start":1237,"enrollment":2729,"conditions":7281,"interventions":7282},[93],[6608],[7244,7264],{"intervention":7284,"totalTrials":139,"cells":7285},"dexamethasone",{"EARLY_PHASE1":7286,"PHASE1":7288,"PHASE2":7290,"PHASE3":7292,"PHASE4":7294,"NA":7296},{"trials":7287,"activeCount":100},[],{"trials":7289,"activeCount":100},[],{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"trials":7295,"activeCount":100},[],{"trials":7297,"activeCount":100},[7298],{"nctId":7299,"briefTitle":7300,"status":110,"phases":7301,"primaryCompletion":3723,"completion":367,"start":2110,"enrollment":2453,"conditions":7302,"interventions":7305},"NCT00892996","Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section",[93],[7303,7304],"Pregnancy","PONV",[7284,7306],"dexamethasone 5 mg",{"intervention":7306,"totalTrials":139,"cells":7308},{"EARLY_PHASE1":7309,"PHASE1":7311,"PHASE2":7313,"PHASE3":7315,"PHASE4":7317,"NA":7319},{"trials":7310,"activeCount":100},[],{"trials":7312,"activeCount":100},[],{"trials":7314,"activeCount":100},[],{"trials":7316,"activeCount":100},[],{"trials":7318,"activeCount":100},[],{"trials":7320,"activeCount":100},[7321],{"nctId":7299,"briefTitle":7300,"status":110,"phases":7322,"primaryCompletion":3723,"completion":367,"start":2110,"enrollment":2453,"conditions":7323,"interventions":7324},[93],[7303,7304],[7284,7306],{"intervention":7326,"totalTrials":139,"cells":7327},"DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later",{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7332,"PHASE3":7334,"PHASE4":7336,"NA":7338},{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[],{"trials":7335,"activeCount":100},[],{"trials":7337,"activeCount":100},[],{"trials":7339,"activeCount":100},[7340],{"nctId":7341,"briefTitle":7342,"status":110,"phases":7343,"primaryCompletion":7344,"completion":7344,"start":7022,"enrollment":1134,"conditions":7345,"interventions":7347},"NCT03104829","DSME or DSME + MI in T1DM on Glycemic Control",[93],"2018-10",[7346],"Diabetes Mellitus",[7326],{"intervention":7349,"totalTrials":139,"cells":7350},"No PB-MNC therapy",{"EARLY_PHASE1":7351,"PHASE1":7353,"PHASE2":7355,"PHASE3":7357,"PHASE4":7359,"NA":7361},{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":100},[],{"trials":7356,"activeCount":100},[],{"trials":7358,"activeCount":100},[],{"trials":7360,"activeCount":100},[],{"trials":7362,"activeCount":100},[7363],{"nctId":7364,"briefTitle":7365,"status":110,"phases":7366,"primaryCompletion":445,"completion":445,"start":7367,"enrollment":787,"conditions":7368,"interventions":7372},"NCT03683628","Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC",[93],"2018-10-01",[7369,7370,7371],"Intermittent Claudication","PAD","Atherosclerotic Ischemic Disease",[7349],{"intervention":7374,"totalTrials":139,"cells":7375},"prolong-release methylphenidate",{"EARLY_PHASE1":7376,"PHASE1":7378,"PHASE2":7380,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7377,"activeCount":100},[],{"trials":7379,"activeCount":100},[],{"trials":7381,"activeCount":100},[],{"trials":7383,"activeCount":100},[],{"trials":7385,"activeCount":100},[],{"trials":7387,"activeCount":100},[7388],{"nctId":7389,"briefTitle":7390,"status":110,"phases":7391,"primaryCompletion":7392,"completion":7392,"start":7393,"enrollment":694,"conditions":7394,"interventions":7396},"NCT05410626","The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original",[93],"2022-08-31","2022-06-01",[7395],"Adhd",[7374],{"intervention":7398,"totalTrials":139,"cells":7399},"azithromycin",{"EARLY_PHASE1":7400,"PHASE1":7402,"PHASE2":7404,"PHASE3":7406,"PHASE4":7408,"NA":7410},{"trials":7401,"activeCount":100},[],{"trials":7403,"activeCount":100},[],{"trials":7405,"activeCount":100},[],{"trials":7407,"activeCount":100},[],{"trials":7409,"activeCount":100},[],{"trials":7411,"activeCount":100},[7412],{"nctId":7413,"briefTitle":7414,"status":376,"phases":7415,"primaryCompletion":4378,"completion":4378,"start":1422,"enrollment":787,"conditions":7416,"interventions":7418},"NCT00944515","Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children",[93],[7417],"Sinusitis",[7398],{"intervention":7420,"totalTrials":139,"cells":7421},"erythropoietin",{"EARLY_PHASE1":7422,"PHASE1":7424,"PHASE2":7426,"PHASE3":7428,"PHASE4":7430,"NA":7432},{"trials":7423,"activeCount":100},[],{"trials":7425,"activeCount":100},[],{"trials":7427,"activeCount":100},[],{"trials":7429,"activeCount":100},[],{"trials":7431,"activeCount":100},[],{"trials":7433,"activeCount":100},[7434],{"nctId":7435,"briefTitle":7436,"status":376,"phases":7437,"primaryCompletion":1238,"completion":368,"start":5091,"enrollment":908,"conditions":7438,"interventions":7440},"NCT01049711","Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients",[],[7439],"Chronic Renal Failure",[7420],{"intervention":6797,"totalTrials":139,"cells":7442},{"EARLY_PHASE1":7443,"PHASE1":7445,"PHASE2":7447,"PHASE3":7449,"PHASE4":7451,"NA":7453},{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[],{"trials":7450,"activeCount":100},[],{"trials":7452,"activeCount":100},[],{"trials":7454,"activeCount":100},[7455],{"nctId":6787,"briefTitle":6788,"status":376,"phases":7456,"primaryCompletion":6790,"completion":6791,"start":6792,"enrollment":2729,"conditions":7457,"interventions":7458},[93],[6794,6498,6795,6500],[6772,6797,6798],{"intervention":6798,"totalTrials":139,"cells":7460},{"EARLY_PHASE1":7461,"PHASE1":7463,"PHASE2":7465,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7462,"activeCount":100},[],{"trials":7464,"activeCount":100},[],{"trials":7466,"activeCount":100},[],{"trials":7468,"activeCount":100},[],{"trials":7470,"activeCount":100},[],{"trials":7472,"activeCount":100},[7473],{"nctId":6787,"briefTitle":6788,"status":376,"phases":7474,"primaryCompletion":6790,"completion":6791,"start":6792,"enrollment":2729,"conditions":7475,"interventions":7476},[93],[6794,6498,6795,6500],[6772,6797,6798],{"intervention":6577,"totalTrials":139,"cells":7478},{"EARLY_PHASE1":7479,"PHASE1":7481,"PHASE2":7483,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7480,"activeCount":100},[],{"trials":7482,"activeCount":100},[],{"trials":7484,"activeCount":100},[],{"trials":7486,"activeCount":100},[],{"trials":7488,"activeCount":100},[],{"trials":7490,"activeCount":100},[7491],{"nctId":6571,"briefTitle":6572,"status":376,"phases":7492,"primaryCompletion":3145,"completion":3145,"start":3059,"enrollment":2041,"conditions":7493,"interventions":7494},[93],[6575],[6577,6535,6578],{"intervention":6578,"totalTrials":139,"cells":7496},{"EARLY_PHASE1":7497,"PHASE1":7499,"PHASE2":7501,"PHASE3":7503,"PHASE4":7505,"NA":7507},{"trials":7498,"activeCount":100},[],{"trials":7500,"activeCount":100},[],{"trials":7502,"activeCount":100},[],{"trials":7504,"activeCount":100},[],{"trials":7506,"activeCount":100},[],{"trials":7508,"activeCount":100},[7509],{"nctId":6571,"briefTitle":6572,"status":376,"phases":7510,"primaryCompletion":3145,"completion":3145,"start":3059,"enrollment":2041,"conditions":7511,"interventions":7512},[93],[6575],[6577,6535,6578],{"intervention":7514,"totalTrials":139,"cells":7515},"paracervical block with 1%lidocaine",{"EARLY_PHASE1":7516,"PHASE1":7518,"PHASE2":7520,"PHASE3":7522,"PHASE4":7524,"NA":7526},{"trials":7517,"activeCount":100},[],{"trials":7519,"activeCount":100},[],{"trials":7521,"activeCount":100},[],{"trials":7523,"activeCount":100},[],{"trials":7525,"activeCount":100},[],{"trials":7527,"activeCount":100},[7528],{"nctId":7529,"briefTitle":7530,"status":376,"phases":7531,"primaryCompletion":3299,"completion":3850,"start":4214,"enrollment":2453,"conditions":7532,"interventions":7535},"NCT01908738","Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy",[93],[7533,7534],"Endometrial Biopsy","Abnormal Uterine Bleeding",[7514,7536],"10%lidocaine spray",{"intervention":7536,"totalTrials":139,"cells":7538},{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7543,"PHASE3":7545,"PHASE4":7547,"NA":7549},{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":100},[],{"trials":7546,"activeCount":100},[],{"trials":7548,"activeCount":100},[],{"trials":7550,"activeCount":100},[7551],{"nctId":7529,"briefTitle":7530,"status":376,"phases":7552,"primaryCompletion":3299,"completion":3850,"start":4214,"enrollment":2453,"conditions":7553,"interventions":7554},[93],[7533,7534],[7514,7536],{"intervention":7556,"totalTrials":139,"cells":7557},"Current practice",{"EARLY_PHASE1":7558,"PHASE1":7560,"PHASE2":7562,"PHASE3":7564,"PHASE4":7566,"NA":7568},{"trials":7559,"activeCount":100},[],{"trials":7561,"activeCount":100},[],{"trials":7563,"activeCount":100},[],{"trials":7565,"activeCount":100},[],{"trials":7567,"activeCount":100},[],{"trials":7569,"activeCount":100},[7570],{"nctId":7571,"briefTitle":7572,"status":365,"phases":7573,"primaryCompletion":7574,"completion":7574,"start":7575,"enrollment":4308,"conditions":7576,"interventions":7578},"NCT04111406","Comparison of the Incidence of Inadequate Epidural Analgesia Between Protocol Based and Current Practice",[93],"2021-10-28","2019-01-09",[7577,21],"Epidural Analgesia",[7556,7579],"Protocol based",{"intervention":7579,"totalTrials":139,"cells":7581},{"EARLY_PHASE1":7582,"PHASE1":7584,"PHASE2":7586,"PHASE3":7588,"PHASE4":7590,"NA":7592},{"trials":7583,"activeCount":100},[],{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"trials":7591,"activeCount":100},[],{"trials":7593,"activeCount":100},[7594],{"nctId":7571,"briefTitle":7572,"status":365,"phases":7595,"primaryCompletion":7574,"completion":7574,"start":7575,"enrollment":4308,"conditions":7596,"interventions":7597},[93],[7577,21],[7556,7579],{"intervention":7599,"totalTrials":139,"cells":7600},"Biological\u002FVaccine: Pertagen",{"EARLY_PHASE1":7601,"PHASE1":7603,"PHASE2":7605,"PHASE3":7607,"PHASE4":7609,"NA":7611},{"trials":7602,"activeCount":100},[],{"trials":7604,"activeCount":100},[],{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[],{"trials":7610,"activeCount":100},[],{"trials":7612,"activeCount":100},[7613],{"nctId":7614,"briefTitle":7615,"status":376,"phases":7616,"primaryCompletion":7617,"completion":7618,"start":7619,"enrollment":7620,"conditions":7621,"interventions":7622},"NCT04529720","5-year Follow-up After a Single Dose Acellular Pertussis Vaccination",[],"2020-09-02","2021-11-03","2020-08-24",159,[326],[7599,7623,7624],"Biological\u002FVaccine: Boostagen","Biological\u002FVaccine: Adacel",{"intervention":7623,"totalTrials":139,"cells":7626},{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7633,"PHASE4":7635,"NA":7637},{"trials":7628,"activeCount":100},[],{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[],{"trials":7634,"activeCount":100},[],{"trials":7636,"activeCount":100},[],{"trials":7638,"activeCount":100},[7639],{"nctId":7614,"briefTitle":7615,"status":376,"phases":7640,"primaryCompletion":7617,"completion":7618,"start":7619,"enrollment":7620,"conditions":7641,"interventions":7642},[],[326],[7599,7623,7624],{"intervention":7624,"totalTrials":139,"cells":7644},{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7649,"PHASE3":7651,"PHASE4":7653,"NA":7655},{"trials":7646,"activeCount":100},[],{"trials":7648,"activeCount":100},[],{"trials":7650,"activeCount":100},[],{"trials":7652,"activeCount":100},[],{"trials":7654,"activeCount":100},[],{"trials":7656,"activeCount":100},[7657],{"nctId":7614,"briefTitle":7615,"status":376,"phases":7658,"primaryCompletion":7617,"completion":7618,"start":7619,"enrollment":7620,"conditions":7659,"interventions":7660},[],[326],[7599,7623,7624],{"intervention":7662,"totalTrials":139,"cells":7663},"Procaterol",{"EARLY_PHASE1":7664,"PHASE1":7666,"PHASE2":7668,"PHASE3":7670,"PHASE4":7672,"NA":7674},{"trials":7665,"activeCount":100},[],{"trials":7667,"activeCount":100},[],{"trials":7669,"activeCount":100},[],{"trials":7671,"activeCount":100},[],{"trials":7673,"activeCount":100},[],{"trials":7675,"activeCount":100},[7676],{"nctId":7677,"briefTitle":7678,"status":110,"phases":7679,"primaryCompletion":4377,"completion":2993,"start":1662,"enrollment":7680,"conditions":7681,"interventions":7683},"NCT02349919","Effect of Oral Procaterol on Postinfectious Persistent Cough",[93],74,[7682],"Cough",[7662],{"intervention":7685,"totalTrials":139,"cells":7686},"metoclopramide",{"EARLY_PHASE1":7687,"PHASE1":7689,"PHASE2":7691,"PHASE3":7693,"PHASE4":7695,"NA":7697},{"trials":7688,"activeCount":100},[],{"trials":7690,"activeCount":100},[],{"trials":7692,"activeCount":100},[],{"trials":7694,"activeCount":100},[],{"trials":7696,"activeCount":100},[],{"trials":7698,"activeCount":100},[7699],{"nctId":7700,"briefTitle":7701,"status":376,"phases":7702,"primaryCompletion":1010,"completion":2153,"start":7703,"enrollment":7704,"conditions":7705,"interventions":7707},"NCT01093690","Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin",[93],"2009-04",162,[7706],"Cancer",[7685],{"intervention":7709,"totalTrials":139,"cells":7710},"Inhaled Mometasone\u002Fformoterol",{"EARLY_PHASE1":7711,"PHASE1":7713,"PHASE2":7715,"PHASE3":7717,"PHASE4":7719,"NA":7721},{"trials":7712,"activeCount":100},[],{"trials":7714,"activeCount":100},[],{"trials":7716,"activeCount":100},[],{"trials":7718,"activeCount":100},[],{"trials":7720,"activeCount":100},[],{"trials":7722,"activeCount":100},[7723],{"nctId":7724,"briefTitle":7725,"status":376,"phases":7726,"primaryCompletion":3145,"completion":3145,"start":1796,"enrollment":529,"conditions":7727,"interventions":7728},"NCT02415179","Effect of Inhaled Mometasone\u002FFormoterol Versus Inhaled Fluticasone\u002FSalmeterol in Asthma Patients",[93],[31],[7709,7729],"Inhaled Fluticasone\u002FSalmeterol",{"intervention":7729,"totalTrials":139,"cells":7731},{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7736,"PHASE3":7738,"PHASE4":7740,"NA":7742},{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"trials":7737,"activeCount":100},[],{"trials":7739,"activeCount":100},[],{"trials":7741,"activeCount":100},[],{"trials":7743,"activeCount":100},[7744],{"nctId":7724,"briefTitle":7725,"status":376,"phases":7745,"primaryCompletion":3145,"completion":3145,"start":1796,"enrollment":529,"conditions":7746,"interventions":7747},[93],[31],[7709,7729],{"intervention":7749,"totalTrials":139,"cells":7750},"No-PB-MNC therapy",{"EARLY_PHASE1":7751,"PHASE1":7753,"PHASE2":7755,"PHASE3":7757,"PHASE4":7759,"NA":7761},{"trials":7752,"activeCount":100},[],{"trials":7754,"activeCount":100},[],{"trials":7756,"activeCount":100},[],{"trials":7758,"activeCount":100},[],{"trials":7760,"activeCount":100},[],{"trials":7762,"activeCount":100},[7763],{"nctId":7764,"briefTitle":7765,"status":110,"phases":7766,"primaryCompletion":445,"completion":445,"start":7367,"enrollment":787,"conditions":7767,"interventions":7768},"NCT03686228","Treatment of No-option CLI by G-CSF-mobilized PB-MNC",[93],[7370,4825,7371],[7749],{"intervention":7770,"totalTrials":139,"cells":7771},"Testosterone",{"EARLY_PHASE1":7772,"PHASE1":7774,"PHASE2":7776,"PHASE3":7778,"PHASE4":7780,"NA":7782},{"trials":7773,"activeCount":100},[],{"trials":7775,"activeCount":100},[],{"trials":7777,"activeCount":100},[],{"trials":7779,"activeCount":100},[],{"trials":7781,"activeCount":100},[],{"trials":7783,"activeCount":100},[7784],{"nctId":7785,"briefTitle":7786,"status":376,"phases":7787,"primaryCompletion":7788,"completion":7788,"start":7789,"enrollment":7790,"conditions":7791,"interventions":7794},"NCT06149065","Factors Associated With the Acne Severity Among Transmen Population: a Cross-sectional Study",[],"2023-06-06","2021-06-05",247,[7792,7793],"Acne","Transgenderism",[7770],{"intervention":5374,"totalTrials":139,"cells":7796},{"EARLY_PHASE1":7797,"PHASE1":7799,"PHASE2":7801,"PHASE3":7803,"PHASE4":7805,"NA":7807},{"trials":7798,"activeCount":100},[],{"trials":7800,"activeCount":100},[],{"trials":7802,"activeCount":100},[],{"trials":7804,"activeCount":100},[],{"trials":7806,"activeCount":100},[],{"trials":7808,"activeCount":100},[7809],{"nctId":7810,"briefTitle":7811,"status":376,"phases":7812,"primaryCompletion":1909,"completion":1662,"start":1728,"enrollment":7813,"conditions":7814,"interventions":7818},"NCT01284452","Efficacy of Hydrocortisone in Treatment of Severe Sepsis\u002FSeptic Shock Patients With Acute Lung Injury\u002FAcute Respiratory Distress Syndrome (ARDS)",[93],197,[15,7815,7816,7817],"Severe Sepsis","Acute Lung Injury","Acute Respiratory Distress Syndrome",[5374],{"intervention":7820,"totalTrials":139,"cells":7821},"Early norepinephrine",{"EARLY_PHASE1":7822,"PHASE1":7824,"PHASE2":7826,"PHASE3":7828,"PHASE4":7830,"NA":7832},{"trials":7823,"activeCount":100},[],{"trials":7825,"activeCount":100},[],{"trials":7827,"activeCount":100},[],{"trials":7829,"activeCount":100},[],{"trials":7831,"activeCount":100},[],{"trials":7833,"activeCount":100},[7834],{"nctId":7835,"briefTitle":7836,"status":376,"phases":7837,"primaryCompletion":7838,"completion":7838,"start":7839,"enrollment":7840,"conditions":7841,"interventions":7842},"NCT01945983","Early Use of Norepinephrine in Septic Shock Resuscitation",[93],"2017-08","2013-10-03",310,[15,7815],[7820],{"intervention":7844,"totalTrials":139,"cells":7845},"Gabapentin",{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7847,"activeCount":100},[],{"trials":7849,"activeCount":100},[],{"trials":7851,"activeCount":100},[],{"trials":7853,"activeCount":100},[],{"trials":7855,"activeCount":100},[],{"trials":7857,"activeCount":100},[7858],{"nctId":7859,"briefTitle":7860,"status":376,"phases":7861,"primaryCompletion":7862,"completion":2360,"start":7863,"enrollment":1134,"conditions":7864,"interventions":7866},"NCT04818450","Impact of Gabapentin on Slow Wave Sleep in Adult Critically Ill Patient",[93],"2022-06-25","2021-04-19",[7865,1092],"Sleep Deprivation",[7844],{"intervention":7868,"totalTrials":139,"cells":7869},"Meropenem standard dose",{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7874,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7871,"activeCount":100},[],{"trials":7873,"activeCount":100},[],{"trials":7875,"activeCount":100},[],{"trials":7877,"activeCount":100},[],{"trials":7879,"activeCount":100},[],{"trials":7881,"activeCount":100},[7882],{"nctId":7883,"briefTitle":7884,"status":376,"phases":7885,"primaryCompletion":7886,"completion":1064,"start":7887,"enrollment":7888,"conditions":7889,"interventions":7897},"NCT03344627","Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients",[93],"2018-11-30","2017-11-27",76,[7890,15,28,7891,7892,7893,7894,7895,7896],"Sepsis","Carbapenem","Pharmacokinetic","Pharmacodynamic","Clinical Outcome","Organ Failure, Multiple","Morality",[7868,7898],"Meropenem high dose",{"intervention":7898,"totalTrials":139,"cells":7900},{"EARLY_PHASE1":7901,"PHASE1":7903,"PHASE2":7905,"PHASE3":7907,"PHASE4":7909,"NA":7911},{"trials":7902,"activeCount":100},[],{"trials":7904,"activeCount":100},[],{"trials":7906,"activeCount":100},[],{"trials":7908,"activeCount":100},[],{"trials":7910,"activeCount":100},[],{"trials":7912,"activeCount":100},[7913],{"nctId":7883,"briefTitle":7884,"status":376,"phases":7914,"primaryCompletion":7886,"completion":1064,"start":7887,"enrollment":7888,"conditions":7915,"interventions":7916},[93],[7890,15,28,7891,7892,7893,7894,7895,7896],[7868,7898],{"intervention":7918,"totalTrials":139,"cells":7919},"Influenza vaccine",{"EARLY_PHASE1":7920,"PHASE1":7922,"PHASE2":7924,"PHASE3":7926,"PHASE4":7928,"NA":7930},{"trials":7921,"activeCount":100},[],{"trials":7923,"activeCount":100},[],{"trials":7925,"activeCount":100},[],{"trials":7927,"activeCount":100},[],{"trials":7929,"activeCount":100},[],{"trials":7931,"activeCount":100},[7932],{"nctId":7933,"briefTitle":7934,"status":376,"phases":7935,"primaryCompletion":7936,"completion":7936,"start":7937,"enrollment":1134,"conditions":7938,"interventions":7941},"NCT04122222","Immune Response to Influenza Vaccine in ESRD Patients",[93],"2018-07-20","2016-08-25",[7939,7940],"Immunology","Nephrology",[7918],{"intervention":7943,"totalTrials":139,"cells":7944},"Mosapride",{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7951,"PHASE4":7953,"NA":7955},{"trials":7946,"activeCount":100},[],{"trials":7948,"activeCount":100},[],{"trials":7950,"activeCount":100},[],{"trials":7952,"activeCount":100},[],{"trials":7954,"activeCount":100},[],{"trials":7956,"activeCount":100},[7957],{"nctId":7958,"briefTitle":7959,"status":110,"phases":7960,"primaryCompletion":7961,"completion":2361,"start":7962,"enrollment":4027,"conditions":7963,"interventions":7966},"NCT04905147","Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery",[93],"2023-07-31","2021-07-01",[7964,7965],"Colorectal Cancer","Bowel Ileus",[7943],{"intervention":7968,"totalTrials":139,"cells":7969},"TDF\u002F3TC or FTC\u002FEFV plus Calcium and vitamin D supplement",{"EARLY_PHASE1":7970,"PHASE1":7972,"PHASE2":7974,"PHASE3":7976,"PHASE4":7978,"NA":7980},{"trials":7971,"activeCount":100},[],{"trials":7973,"activeCount":100},[],{"trials":7975,"activeCount":100},[],{"trials":7977,"activeCount":100},[],{"trials":7979,"activeCount":100},[],{"trials":7981,"activeCount":100},[7982],{"nctId":7983,"briefTitle":7984,"status":110,"phases":7985,"primaryCompletion":5805,"completion":6431,"start":2290,"enrollment":447,"conditions":7986,"interventions":7988},"NCT02827643","Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz",[93],[7987],"Bone Density",[7968],{"intervention":7990,"totalTrials":139,"cells":7991},"Bivalent or Quadrivalent HPV vaccines",{"EARLY_PHASE1":7992,"PHASE1":7994,"PHASE2":7996,"PHASE3":7998,"PHASE4":8000,"NA":8002},{"trials":7993,"activeCount":100},[],{"trials":7995,"activeCount":100},[],{"trials":7997,"activeCount":100},[],{"trials":7999,"activeCount":100},[],{"trials":8001,"activeCount":100},[],{"trials":8003,"activeCount":100},[8004],{"nctId":8005,"briefTitle":8006,"status":376,"phases":8007,"primaryCompletion":4636,"completion":4636,"start":5878,"enrollment":8008,"conditions":8009,"interventions":8012},"NCT03763565","Effectiveness of HPV Vaccine in Thai Adult Women",[],993,[8010,8011],"Uterine Cervical Dysplasia","Papillomavirus Vaccines",[7990],{"intervention":8014,"totalTrials":139,"cells":8015},"hydroxypropylmethylcellulose",{"EARLY_PHASE1":8016,"PHASE1":8018,"PHASE2":8020,"PHASE3":8022,"PHASE4":8024,"NA":8026},{"trials":8017,"activeCount":100},[],{"trials":8019,"activeCount":100},[],{"trials":8021,"activeCount":100},[],{"trials":8023,"activeCount":100},[],{"trials":8025,"activeCount":100},[],{"trials":8027,"activeCount":100},[8028],{"nctId":8029,"briefTitle":8030,"status":110,"phases":8031,"primaryCompletion":906,"completion":8032,"start":905,"enrollment":2453,"conditions":8033,"interventions":8036},"NCT01284439","Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma",[93],"2012-02",[8034,8035],"Ocular Surface Disease","Glaucoma",[8014,8037],"sodium hyaluronate",{"intervention":8037,"totalTrials":139,"cells":8039},{"EARLY_PHASE1":8040,"PHASE1":8042,"PHASE2":8044,"PHASE3":8046,"PHASE4":8048,"NA":8050},{"trials":8041,"activeCount":100},[],{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"trials":8049,"activeCount":100},[],{"trials":8051,"activeCount":100},[8052],{"nctId":8029,"briefTitle":8030,"status":110,"phases":8053,"primaryCompletion":906,"completion":8032,"start":905,"enrollment":2453,"conditions":8054,"interventions":8055},[93],[8034,8035],[8014,8037],{"intervention":8057,"totalTrials":139,"cells":8058},"Non vitamin K oral anticoagulants",{"EARLY_PHASE1":8059,"PHASE1":8061,"PHASE2":8063,"PHASE3":8065,"PHASE4":8067,"NA":8069},{"trials":8060,"activeCount":100},[],{"trials":8062,"activeCount":100},[],{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[],{"trials":8068,"activeCount":100},[],{"trials":8070,"activeCount":100},[8071],{"nctId":8072,"briefTitle":8073,"status":376,"phases":8074,"primaryCompletion":8075,"completion":8075,"start":8076,"enrollment":8077,"conditions":8078,"interventions":8079},"NCT04047654","Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation",[],"2019-12-31","2019-04-22",327,[18,6639],[8057],{"intervention":6843,"totalTrials":139,"cells":8081},{"EARLY_PHASE1":8082,"PHASE1":8084,"PHASE2":8086,"PHASE3":8088,"PHASE4":8090,"NA":8092},{"trials":8083,"activeCount":100},[],{"trials":8085,"activeCount":100},[],{"trials":8087,"activeCount":100},[],{"trials":8089,"activeCount":100},[],{"trials":8091,"activeCount":100},[],{"trials":8093,"activeCount":100},[8094],{"nctId":6834,"briefTitle":6835,"status":376,"phases":8095,"primaryCompletion":6837,"completion":6837,"start":6838,"enrollment":6839,"conditions":8096,"interventions":8097},[93],[6841],[6843,6813],{"intervention":8099,"totalTrials":139,"cells":8100},"0.5% marcaine 20ml",{"EARLY_PHASE1":8101,"PHASE1":8103,"PHASE2":8105,"PHASE3":8107,"PHASE4":8109,"NA":8111},{"trials":8102,"activeCount":100},[],{"trials":8104,"activeCount":100},[],{"trials":8106,"activeCount":100},[],{"trials":8108,"activeCount":100},[],{"trials":8110,"activeCount":100},[],{"trials":8112,"activeCount":100},[8113],{"nctId":8114,"briefTitle":8115,"status":376,"phases":8116,"primaryCompletion":1662,"completion":1662,"start":3850,"enrollment":2859,"conditions":8117,"interventions":8119},"NCT02271646","Ultrasound Guided Thoracic Paravertebral Block for Hepatic Tumors Ablation",[93],[8118],"Liver Cancer",[8099],{"intervention":8121,"totalTrials":139,"cells":8122},"Ehedrine Norepineprine",{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8127,"PHASE3":8129,"PHASE4":8131,"NA":8133},{"trials":8124,"activeCount":100},[],{"trials":8126,"activeCount":100},[],{"trials":8128,"activeCount":100},[],{"trials":8130,"activeCount":100},[],{"trials":8132,"activeCount":100},[],{"trials":8134,"activeCount":100},[8135],{"nctId":8136,"briefTitle":8137,"status":376,"phases":8138,"primaryCompletion":8139,"completion":4281,"start":8140,"enrollment":8141,"conditions":8142,"interventions":8144},"NCT05183061","Factors Associated With Post-induction Hypotension in iNPH Patient Undergoing VP and LP Shunt",[],"2021-11-30","2021-06-01",426,[8143],"The iNPH Patients Scheduled for VP or LP Shunt Procedures",[8121],{"intervention":8146,"totalTrials":139,"cells":8147},"topical 0.05% Clobetasol propionate ointment",{"EARLY_PHASE1":8148,"PHASE1":8150,"PHASE2":8152,"PHASE3":8154,"PHASE4":8156,"NA":8158},{"trials":8149,"activeCount":100},[],{"trials":8151,"activeCount":100},[],{"trials":8153,"activeCount":100},[],{"trials":8155,"activeCount":100},[],{"trials":8157,"activeCount":100},[],{"trials":8159,"activeCount":100},[8160],{"nctId":8161,"briefTitle":8162,"status":376,"phases":8163,"primaryCompletion":1318,"completion":1318,"start":6124,"enrollment":6337,"conditions":8164,"interventions":8167},"NCT02492373","Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser",[93],[8165,8166],"Lentigines","Post Inflammatory Hyperpigmentation",[8146],{"intervention":8169,"totalTrials":139,"cells":8170},"topical 2% hydroquinone",{"EARLY_PHASE1":8171,"PHASE1":8173,"PHASE2":8175,"PHASE3":8177,"PHASE4":8179,"NA":8181},{"trials":8172,"activeCount":100},[],{"trials":8174,"activeCount":100},[],{"trials":8176,"activeCount":100},[],{"trials":8178,"activeCount":100},[],{"trials":8180,"activeCount":100},[],{"trials":8182,"activeCount":100},[8183],{"nctId":8184,"briefTitle":8185,"status":110,"phases":8186,"primaryCompletion":8187,"completion":8188,"start":8189,"enrollment":1565,"conditions":8190,"interventions":8192},"NCT04597203","Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial",[93],"2021-01","2021-02","2020-10",[8191],"Melasma",[8169],{"intervention":8194,"totalTrials":139,"cells":8195},"Intraluminal peppermint oil",{"EARLY_PHASE1":8196,"PHASE1":8198,"PHASE2":8200,"PHASE3":8202,"PHASE4":8204,"NA":8206},{"trials":8197,"activeCount":100},[],{"trials":8199,"activeCount":100},[],{"trials":8201,"activeCount":100},[],{"trials":8203,"activeCount":100},[],{"trials":8205,"activeCount":100},[],{"trials":8207,"activeCount":100},[8208],{"nctId":8209,"briefTitle":8210,"status":376,"phases":8211,"primaryCompletion":8212,"completion":1254,"start":3323,"enrollment":8213,"conditions":8214,"interventions":8216},"NCT05559814","Intraluminal Peppermint Oil and Adenoma Detection Rate in Screening Colonoscopy",[93],"2022-05-31",404,[8215],"Colonic Polyp",[8194],{"intervention":6436,"totalTrials":139,"cells":8218},{"EARLY_PHASE1":8219,"PHASE1":8221,"PHASE2":8223,"PHASE3":8225,"PHASE4":8227,"NA":8229},{"trials":8220,"activeCount":100},[],{"trials":8222,"activeCount":100},[],{"trials":8224,"activeCount":100},[],{"trials":8226,"activeCount":100},[],{"trials":8228,"activeCount":100},[],{"trials":8230,"activeCount":100},[8231],{"nctId":6428,"briefTitle":6429,"status":110,"phases":8232,"primaryCompletion":6431,"completion":3211,"start":2661,"enrollment":6432,"conditions":8233,"interventions":8234},[93],[602,6434],[6436,3685],{"intervention":8236,"totalTrials":139,"cells":8237},"Opioids",{"EARLY_PHASE1":8238,"PHASE1":8240,"PHASE2":8242,"PHASE3":8244,"PHASE4":8246,"NA":8248},{"trials":8239,"activeCount":100},[],{"trials":8241,"activeCount":100},[],{"trials":8243,"activeCount":100},[],{"trials":8245,"activeCount":100},[],{"trials":8247,"activeCount":100},[],{"trials":8249,"activeCount":100},[8250],{"nctId":8251,"briefTitle":8252,"status":376,"phases":8253,"primaryCompletion":1498,"completion":8254,"start":8255,"enrollment":8256,"conditions":8257,"interventions":8259},"NCT03374722","Opioid Withdrawal Symptoms in Critically Ill Patients",[],"2018-10-07","2018-01-01",55,[8258,28],"Substance Withdrawal Syndrome",[8236],{"intervention":6444,"totalTrials":139,"cells":8261},{"EARLY_PHASE1":8262,"PHASE1":8264,"PHASE2":8266,"PHASE3":8268,"PHASE4":8270,"NA":8272},{"trials":8263,"activeCount":100},[],{"trials":8265,"activeCount":100},[],{"trials":8267,"activeCount":100},[],{"trials":8269,"activeCount":100},[],{"trials":8271,"activeCount":100},[],{"trials":8273,"activeCount":100},[8274],{"nctId":6438,"briefTitle":6439,"status":376,"phases":8275,"primaryCompletion":2728,"completion":5115,"start":2110,"enrollment":1134,"conditions":8276,"interventions":8277},[93],[6442],[6444,3685],{"intervention":8279,"totalTrials":139,"cells":8280},"Itopride",{"EARLY_PHASE1":8281,"PHASE1":8283,"PHASE2":8285,"PHASE3":8287,"PHASE4":8289,"NA":8291},{"trials":8282,"activeCount":100},[],{"trials":8284,"activeCount":100},[],{"trials":8286,"activeCount":100},[],{"trials":8288,"activeCount":100},[],{"trials":8290,"activeCount":100},[],{"trials":8292,"activeCount":100},[8293],{"nctId":8294,"briefTitle":8295,"status":110,"phases":8296,"primaryCompletion":8297,"completion":8298,"start":8299,"enrollment":8300,"conditions":8301,"interventions":8303},"NCT04104867","Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy",[93],"2022-10-30","2023-02-01","2019-09-16",525,[8302],"Abdominal Pain",[8279,8304],"Domperidone",{"intervention":8304,"totalTrials":139,"cells":8306},{"EARLY_PHASE1":8307,"PHASE1":8309,"PHASE2":8311,"PHASE3":8313,"PHASE4":8315,"NA":8317},{"trials":8308,"activeCount":100},[],{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[],{"trials":8316,"activeCount":100},[],{"trials":8318,"activeCount":100},[8319],{"nctId":8294,"briefTitle":8295,"status":110,"phases":8320,"primaryCompletion":8297,"completion":8298,"start":8299,"enrollment":8300,"conditions":8321,"interventions":8322},[93],[8302],[8279,8304],{"intervention":8324,"totalTrials":139,"cells":8325},"Generic levetiracetam",{"EARLY_PHASE1":8326,"PHASE1":8328,"PHASE2":8330,"PHASE3":8332,"PHASE4":8334,"NA":8336},{"trials":8327,"activeCount":100},[],{"trials":8329,"activeCount":100},[],{"trials":8331,"activeCount":100},[],{"trials":8333,"activeCount":100},[],{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[8338],{"nctId":8339,"briefTitle":8340,"status":376,"phases":8341,"primaryCompletion":8342,"completion":8342,"start":5878,"enrollment":8343,"conditions":8344,"interventions":8346},"NCT04132063","Generic Substitution of Original Levetiracetam in Thai Epilepsy Patients",[],"2019-05-30",75,[8345],"Epilepsy",[8324],{"intervention":8348,"totalTrials":139,"cells":8349},"Mefenamic acid or Hyoscine or placebo",{"EARLY_PHASE1":8350,"PHASE1":8352,"PHASE2":8354,"PHASE3":8356,"PHASE4":8358,"NA":8360},{"trials":8351,"activeCount":100},[],{"trials":8353,"activeCount":100},[],{"trials":8355,"activeCount":100},[],{"trials":8357,"activeCount":100},[],{"trials":8359,"activeCount":100},[],{"trials":8361,"activeCount":100},[8362],{"nctId":8363,"briefTitle":8364,"status":110,"phases":8365,"primaryCompletion":1178,"completion":5115,"start":5092,"enrollment":483,"conditions":8366,"interventions":8368},"NCT01060696","Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women",[93],[8367],"Infertility",[8348],{"intervention":8370,"totalTrials":139,"cells":8371},"Antiviral Agents",{"EARLY_PHASE1":8372,"PHASE1":8374,"PHASE2":8376,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8373,"activeCount":100},[],{"trials":8375,"activeCount":100},[],{"trials":8377,"activeCount":100},[],{"trials":8379,"activeCount":100},[],{"trials":8381,"activeCount":100},[],{"trials":8383,"activeCount":100},[8384],{"nctId":8385,"briefTitle":8386,"status":376,"phases":8387,"primaryCompletion":7122,"completion":8388,"start":8389,"enrollment":8390,"conditions":8391,"interventions":8394},"NCT05317260","Steatohepatitis in Chronic Hepatitis B",[],"2021-12-31","2002-01-01",408,[8392,8393],"Fatty Liver","Chronic Hepatitis b",[8370],{"intervention":8396,"totalTrials":139,"cells":8397},"sodium bicarbonate powders with grain size 65 µm",{"EARLY_PHASE1":8398,"PHASE1":8400,"PHASE2":8402,"PHASE3":8404,"PHASE4":8406,"NA":8408},{"trials":8399,"activeCount":100},[],{"trials":8401,"activeCount":100},[],{"trials":8403,"activeCount":100},[],{"trials":8405,"activeCount":100},[],{"trials":8407,"activeCount":100},[],{"trials":8409,"activeCount":100},[8410],{"nctId":8411,"briefTitle":8412,"status":376,"phases":8413,"primaryCompletion":2660,"completion":2660,"start":1283,"enrollment":2859,"conditions":8414,"interventions":8416},"NCT03140436","Clinical Comparison of the Stain Removal Efficacy of Two Air Polishing Powders",[93],[8415],"Stain Removal Efficacy",[8396,8417],"sodium bicarbonate powders with grain size 40 µm",{"intervention":8417,"totalTrials":139,"cells":8419},{"EARLY_PHASE1":8420,"PHASE1":8422,"PHASE2":8424,"PHASE3":8426,"PHASE4":8428,"NA":8430},{"trials":8421,"activeCount":100},[],{"trials":8423,"activeCount":100},[],{"trials":8425,"activeCount":100},[],{"trials":8427,"activeCount":100},[],{"trials":8429,"activeCount":100},[],{"trials":8431,"activeCount":100},[8432],{"nctId":8411,"briefTitle":8412,"status":376,"phases":8433,"primaryCompletion":2660,"completion":2660,"start":1283,"enrollment":2859,"conditions":8434,"interventions":8435},[93],[8415],[8396,8417],{"intervention":8437,"totalTrials":139,"cells":8438},"4%Chlorhexidine",{"EARLY_PHASE1":8439,"PHASE1":8441,"PHASE2":8443,"PHASE3":8445,"PHASE4":8447,"NA":8449},{"trials":8440,"activeCount":100},[],{"trials":8442,"activeCount":100},[],{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[],{"trials":8450,"activeCount":100},[8451],{"nctId":8452,"briefTitle":8453,"status":110,"phases":8454,"primaryCompletion":8455,"completion":8455,"start":2203,"enrollment":8456,"conditions":8457,"interventions":8460},"NCT04781036","Foot-skin Microbiome and Metabolomics of Pitted Keratolysis",[93],"2024-12-01",250,[8458,8459],"Microbial Disease","Metabolomics",[8437],{"intervention":8462,"totalTrials":139,"cells":8463},"No blood transfusion",{"EARLY_PHASE1":8464,"PHASE1":8466,"PHASE2":8468,"PHASE3":8470,"PHASE4":8472,"NA":8474},{"trials":8465,"activeCount":100},[],{"trials":8467,"activeCount":100},[],{"trials":8469,"activeCount":100},[],{"trials":8471,"activeCount":100},[],{"trials":8473,"activeCount":100},[],{"trials":8475,"activeCount":100},[8476],{"nctId":8477,"briefTitle":8478,"status":376,"phases":8479,"primaryCompletion":8480,"completion":8481,"start":3059,"enrollment":1134,"conditions":8482,"interventions":8486},"NCT02140216","Immunomodulation Effect of Blood Transfusion",[],"2017-06-18","2018-04-10",[8483,8484,8485],"Incompatible Blood Transfusion","Immune Defect","Surgery",[8462,8487,8488],"Day 0 blood transfusion","Day 1 or 2 blood transfusion",{"intervention":8487,"totalTrials":139,"cells":8490},{"EARLY_PHASE1":8491,"PHASE1":8493,"PHASE2":8495,"PHASE3":8497,"PHASE4":8499,"NA":8501},{"trials":8492,"activeCount":100},[],{"trials":8494,"activeCount":100},[],{"trials":8496,"activeCount":100},[],{"trials":8498,"activeCount":100},[],{"trials":8500,"activeCount":100},[],{"trials":8502,"activeCount":100},[8503],{"nctId":8477,"briefTitle":8478,"status":376,"phases":8504,"primaryCompletion":8480,"completion":8481,"start":3059,"enrollment":1134,"conditions":8505,"interventions":8506},[],[8483,8484,8485],[8462,8487,8488],{"intervention":8488,"totalTrials":139,"cells":8508},{"EARLY_PHASE1":8509,"PHASE1":8511,"PHASE2":8513,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8510,"activeCount":100},[],{"trials":8512,"activeCount":100},[],{"trials":8514,"activeCount":100},[],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[8521],{"nctId":8477,"briefTitle":8478,"status":376,"phases":8522,"primaryCompletion":8480,"completion":8481,"start":3059,"enrollment":1134,"conditions":8523,"interventions":8524},[],[8483,8484,8485],[8462,8487,8488],{"intervention":8526,"totalTrials":139,"cells":8527},"curcuminoids, N-acetylcysteine, deferiprone and vitamin E",{"EARLY_PHASE1":8528,"PHASE1":8530,"PHASE2":8532,"PHASE3":8534,"PHASE4":8536,"NA":8538},{"trials":8529,"activeCount":100},[],{"trials":8531,"activeCount":100},[],{"trials":8533,"activeCount":100},[],{"trials":8535,"activeCount":100},[],{"trials":8537,"activeCount":100},[],{"trials":8539,"activeCount":100},[8540],{"nctId":8541,"briefTitle":8542,"status":376,"phases":8543,"primaryCompletion":8544,"completion":8544,"start":2248,"enrollment":1134,"conditions":8545,"interventions":8547},"NCT01597765","Effect of Antioxidant Cocktail in Beta-thalassemia\u002FHb E Patients",[93],"2011-06",[8546],"Thalassemia",[8526,8548],"Curcuminoids and alpha-tocopherol",{"intervention":8548,"totalTrials":139,"cells":8550},{"EARLY_PHASE1":8551,"PHASE1":8553,"PHASE2":8555,"PHASE3":8557,"PHASE4":8559,"NA":8561},{"trials":8552,"activeCount":100},[],{"trials":8554,"activeCount":100},[],{"trials":8556,"activeCount":100},[],{"trials":8558,"activeCount":100},[],{"trials":8560,"activeCount":100},[],{"trials":8562,"activeCount":100},[8563],{"nctId":8541,"briefTitle":8542,"status":376,"phases":8564,"primaryCompletion":8544,"completion":8544,"start":2248,"enrollment":1134,"conditions":8565,"interventions":8566},[93],[8546],[8526,8548],{"intervention":6811,"totalTrials":139,"cells":8568},{"EARLY_PHASE1":8569,"PHASE1":8571,"PHASE2":8573,"PHASE3":8575,"PHASE4":8577,"NA":8579},{"trials":8570,"activeCount":100},[],{"trials":8572,"activeCount":100},[],{"trials":8574,"activeCount":100},[],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[8581],{"nctId":6800,"briefTitle":6801,"status":110,"phases":8582,"primaryCompletion":6803,"completion":6803,"start":6804,"enrollment":6805,"conditions":8583,"interventions":8584},[93],[6807,6808,6809,21],[6772,6811],{"intervention":8586,"totalTrials":139,"cells":8587},"Pollen sensitization",{"EARLY_PHASE1":8588,"PHASE1":8590,"PHASE2":8592,"PHASE3":8594,"PHASE4":8596,"NA":8598},{"trials":8589,"activeCount":100},[],{"trials":8591,"activeCount":100},[],{"trials":8593,"activeCount":100},[],{"trials":8595,"activeCount":100},[],{"trials":8597,"activeCount":100},[],{"trials":8599,"activeCount":100},[8600],{"nctId":8601,"briefTitle":8602,"status":376,"phases":8603,"primaryCompletion":1283,"completion":1283,"start":2661,"enrollment":5023,"conditions":8604,"interventions":8606},"NCT02764827","Comparison of Skin Prick Testing Results of Local and Imported Pollen Allergen Extracts and Specific IgE",[],[8605],"Immediate Type Hypersensitivity",[8586],{"intervention":912,"totalTrials":139,"cells":8608},{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8613,"PHASE3":8615,"PHASE4":8617,"NA":8619},{"trials":8610,"activeCount":100},[],{"trials":8612,"activeCount":100},[],{"trials":8614,"activeCount":100},[],{"trials":8616,"activeCount":100},[],{"trials":8618,"activeCount":100},[],{"trials":8620,"activeCount":100},[8621],{"nctId":902,"briefTitle":903,"status":376,"phases":8622,"primaryCompletion":905,"completion":906,"start":907,"enrollment":908,"conditions":8623,"interventions":8624},[93],[405],[911,912],{"intervention":6543,"totalTrials":139,"cells":8626},{"EARLY_PHASE1":8627,"PHASE1":8629,"PHASE2":8631,"PHASE3":8633,"PHASE4":8635,"NA":8637},{"trials":8628,"activeCount":100},[],{"trials":8630,"activeCount":100},[],{"trials":8632,"activeCount":100},[],{"trials":8634,"activeCount":100},[],{"trials":8636,"activeCount":100},[],{"trials":8638,"activeCount":100},[8639],{"nctId":6537,"briefTitle":6538,"status":376,"phases":8640,"primaryCompletion":3572,"completion":3572,"start":2834,"enrollment":787,"conditions":8641,"interventions":8642},[93],[6541,2501],[6503,6543],{"intervention":8644,"totalTrials":139,"cells":8645},"Seasonal Influenza Vaccine",{"EARLY_PHASE1":8646,"PHASE1":8648,"PHASE2":8650,"PHASE3":8652,"PHASE4":8654,"NA":8656},{"trials":8647,"activeCount":100},[],{"trials":8649,"activeCount":100},[],{"trials":8651,"activeCount":100},[],{"trials":8653,"activeCount":100},[],{"trials":8655,"activeCount":100},[],{"trials":8657,"activeCount":100},[8658],{"nctId":8659,"briefTitle":8660,"status":376,"phases":8661,"primaryCompletion":8662,"completion":402,"start":8663,"enrollment":1134,"conditions":8664,"interventions":8665},"NCT02909842","Effect of Drinking Fermented Milk on Immune Response",[93],"2016-09-01","2016-01-01",[720],[8644],{"intervention":8667,"totalTrials":139,"cells":8668},"Inhalational sedation",{"EARLY_PHASE1":8669,"PHASE1":8671,"PHASE2":8673,"PHASE3":8675,"PHASE4":8677,"NA":8679},{"trials":8670,"activeCount":100},[],{"trials":8672,"activeCount":100},[],{"trials":8674,"activeCount":100},[],{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"trials":8680,"activeCount":100},[8681],{"nctId":8682,"briefTitle":8683,"status":376,"phases":8684,"primaryCompletion":8685,"completion":8686,"start":8687,"enrollment":787,"conditions":8688,"interventions":8694},"NCT05559970","Inhalational Sedation and Mechanical Power",[93],"2023-09-27","2024-04-30","2022-11-15",[8689,8690,8691,8692,8693],"Mechanical Ventilation","Sedation","Mechanical Power","Lung Injury","ICU",[8667,8695],"Convention sedation",{"intervention":8695,"totalTrials":139,"cells":8697},{"EARLY_PHASE1":8698,"PHASE1":8700,"PHASE2":8702,"PHASE3":8704,"PHASE4":8706,"NA":8708},{"trials":8699,"activeCount":100},[],{"trials":8701,"activeCount":100},[],{"trials":8703,"activeCount":100},[],{"trials":8705,"activeCount":100},[],{"trials":8707,"activeCount":100},[],{"trials":8709,"activeCount":100},[8710],{"nctId":8682,"briefTitle":8683,"status":376,"phases":8711,"primaryCompletion":8685,"completion":8686,"start":8687,"enrollment":787,"conditions":8712,"interventions":8713},[93],[8689,8690,8691,8692,8693],[8667,8695],{"intervention":8715,"totalTrials":139,"cells":8716},"Tenofovir\u002FEmtricitabine\u002FRilpivirine",{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8721,"PHASE3":8723,"PHASE4":8725,"NA":8727},{"trials":8718,"activeCount":100},[],{"trials":8720,"activeCount":100},[],{"trials":8722,"activeCount":100},[],{"trials":8724,"activeCount":100},[],{"trials":8726,"activeCount":100},[],{"trials":8728,"activeCount":100},[8729],{"nctId":8730,"briefTitle":8731,"status":376,"phases":8732,"primaryCompletion":8733,"completion":8733,"start":8734,"enrollment":1256,"conditions":8735,"interventions":8740},"NCT03251690","Switching TDF\u002FFTC\u002FEFV to TDF\u002FFTC\u002FRPV VS Continuing TDF\u002FFTC\u002FEFV in HIV Patients With Complete Virological Suppression",[93],"2018-04-30","2016-10-27",[8736,6301,8737,8738,8739,6813],"Anti-Retroviral Agents","HIV-1-infection","Sustained Virologic Response","Dyslipidemias",[8715,8741],"Tenofovir\u002FEmtricitabine\u002FEfavirenz",{"intervention":8741,"totalTrials":139,"cells":8743},{"EARLY_PHASE1":8744,"PHASE1":8746,"PHASE2":8748,"PHASE3":8750,"PHASE4":8752,"NA":8754},{"trials":8745,"activeCount":100},[],{"trials":8747,"activeCount":100},[],{"trials":8749,"activeCount":100},[],{"trials":8751,"activeCount":100},[],{"trials":8753,"activeCount":100},[],{"trials":8755,"activeCount":100},[8756],{"nctId":8730,"briefTitle":8731,"status":376,"phases":8757,"primaryCompletion":8733,"completion":8733,"start":8734,"enrollment":1256,"conditions":8758,"interventions":8759},[93],[8736,6301,8737,8738,8739,6813],[8715,8741],{"intervention":8761,"totalTrials":139,"cells":8762},"isobaric levobupivacaine",{"EARLY_PHASE1":8763,"PHASE1":8765,"PHASE2":8767,"PHASE3":8769,"PHASE4":8771,"NA":8773},{"trials":8764,"activeCount":100},[],{"trials":8766,"activeCount":100},[],{"trials":8768,"activeCount":100},[],{"trials":8770,"activeCount":100},[],{"trials":8772,"activeCount":100},[],{"trials":8774,"activeCount":100},[8775],{"nctId":8776,"briefTitle":8777,"status":376,"phases":8778,"primaryCompletion":1729,"completion":1729,"start":8779,"enrollment":1565,"conditions":8780,"interventions":8783},"NCT01349751","Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution",[93],"2007-01",[8781,8782],"Observation of Neuromuscular Block","Disease (or Disorder); Gynecological",[8761,8784],"hyperbaric levobupivacaine",{"intervention":8784,"totalTrials":139,"cells":8786},{"EARLY_PHASE1":8787,"PHASE1":8789,"PHASE2":8791,"PHASE3":8793,"PHASE4":8795,"NA":8797},{"trials":8788,"activeCount":100},[],{"trials":8790,"activeCount":100},[],{"trials":8792,"activeCount":100},[],{"trials":8794,"activeCount":100},[],{"trials":8796,"activeCount":100},[],{"trials":8798,"activeCount":100},[8799],{"nctId":8776,"briefTitle":8777,"status":376,"phases":8800,"primaryCompletion":1729,"completion":1729,"start":8779,"enrollment":1565,"conditions":8801,"interventions":8802},[93],[8781,8782],[8761,8784]]